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Influenza viruses cause respiratory illnesses which can vary in severity depending on the 
strain of the virus, as well as the age and health condition of the host. Influenza remains a major 
threat to public health due to its nature prone to suffer mutations. As a result, vaccines have to be 
reformulated annually and new strains may cause sporadic global pandemics. Furthermore, the 
recent emergence of resistant strains of the virus against the current standard of care (oseltamivir 
and zanamivir) underlines the need of novel anti-influenza therapeutics.   
The aim of this dissertation work is to contribute to the discovery of new anti-influenza 
inhibitors either by rational drug-design and optimization of oseltamivir structure, or by developing 
screening assays suitable for the discovery of novel inhibitors of the enzymes neuraminidase or 
RNA-polymerase.  
 
Scheme 1. Overview of the strategy used for the development of new anti-influenza therapeutics. The dashed arrows 
indicate the inhibitors that were converted into probes and their corresponding target enzymes  
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 Two main modification points were explored for the improvement of oseltamivir 
properties (Scheme 1); modifications at carbon C-3 aimed to overcome oseltamivir resistance 
caused by common mutations like H274Y, meanwhile modifications at carbon C-5 have been used 
to explore the binding mode of the inhibitors to a cavity adjacent to the catalytic site known as the 
“150-cavity”. 
A second strategy was used in the pursuit of new anti-influenza inhibitors which involved 
the development of novel assays suitable for the screening of novel neuraminidase and RNA-
polymerase inhibitors. Several detection probes based on the structure of known inhibitors 
(tamiphosphor, XV-787 and L-742,001) of the respective proteins were designed, prepared, 
optimized and successfully applied for the development of screening assays based on either 
DIANA or AlphaScreen technology. Two new inhibitors of the PA subunit of RNA-polymerase 
with IC50 in the low micromolar range were found during the first screening campaign using the 
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 Četná onemocnění dýchacích cest jsou způsobena virem chřipky. Jejich závažnost se liší 
v závislosti na kmenu viru a na věku a zdraví hostitele. Chřipka je stále velkou zdravotní hrozbou 
zejména kvůli své přirozené náchylnosti k mutacím. Proto je nezbytné uvádět na trh každý rok 
nové vakcíny účinné proti mutovaným formám viru a snižovat tak riziko pandemií, které by tyto 
formy viru mohly vyvolat. Nedávný výskyt kmenů viru rezistentních vůči současné standardní 
léčbě chřipky (oseltamivir, zanamivir) dokazuje nutnost vývoje nových léčiv. 
 Cílem této disertační práce je přispět k vývoji nových látek účinných proti viru chřipky. 
Toho může být dosaženo racionálním designem a optimalizací stávajících inhibitorů nebo 
prostřednictvím vysokokapacitního testování, které může nalézt strukturně nové inhibitory 
neuraminidasy a RNA-polymerasy. 
  
Schéma 1. Přehled strategie použité pro vývoj nových léčiv účinných proti chřipce. Přerušované šipky spojují 
inhibitory použité pro přípravu sond pro vysokokapacitní testování s enzymy, na které je sondami cíleno. 
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 V rámci optimalizace struktury oseltamiviru byly studovány modifikace v pozicích C-3 a 
C-5. Zatímco změny v pozici C-3 měly za cíl zvýšení aktivity způsobené běžnou mutací H274Y, 
substituce v pozici C-5 byly použity pro studium vazby inhibitoru do dutiny úzce sousedící 
s aktivním místem enzymu. 
 Další strategií byl vývoj metody vysokokapacitního testování pro nalezení nových 
inhibitorů neuraminidasy a RNA-polymerasy. Návrh detekčních sond pro tuto strategii byl 
odvozen od struktur známých inhibitorů těchto enzymů (tamifosfor, XV-787 a L-742,001). 
Navržené sondy byly syntetizovány, optimalizovány a úspěšně použity pro vývoj testovacích 
metod technologiemi DIANA a AlphaScreen. Druhou zmíněnou metodou byly nalezeny dva nové 













1. Introduction  
1.1 Influenza virus  
Influenza is an infection of the upper respiratory tract characterized by sudden onset of 
fever, dry couch, headache, muscle and joint pain, fatigue, sore throat and runny nose. Although 
most people recover from the fever and the other symptoms within a week, in high-risk patients it 
may lead to pneumonia, which can be fatal. According to a recent study (2017) from the World 
Health Organization (WHO)1, 290.000 to 650.000 deaths annually are associated with respiratory 
diseases from seasonal influenza. In the EU/EEA, the number of fatal infections ranges from 
15.000 to 70.000 according to the European Centre for Disease Prevention and Control (ECDC).2 
In addition, influenza has been the cause of 22 pandemics since the 1500s. The most recent ones 
were the Spanish flu (1918), which killed 20 – 50 million worldwide, the Asian flu (1957, 1 – 2 
million casualties) and the Hong Kong flu (1968, 700.000 casualties). 
Influenza viruses belong to the Orthomyxoviridae family which are negative-sense single-
stranded RNA viruses. The viruses are classified into three types (A, B and C) depending on its 
nucleoproteins (NP) and the antigen determinants on its matrix protein (M). Further differentiation 
is found in the genomic RNA segments: influenza A viruses present eight segments that differ in 
size from the eight RNA segments found in B viruses. Influenza C viruses on the other hand, 
present only seven segments.3 Viruses from type A and B are responsible for seasonal influenza, 
type C viruses also cause flu although the symptoms are much less severe. Influenza A viruses 
have attracted much more attention since 
they are accountable for most of the 
occasional pandemic outbreaks. 
Influenza A viruses (Figure 1) 
infect a wide range of avian and 
mammalian hosts, unlike influenza B 
viruses, which infect only humans and 
seals. The influenza A genome is 
composed of eight RNA segments, each 




(formed by PA, PB1 and PB2 subunits) and coiled with nucleoproteins (NP). The viral envelope 
presents two glycoproteins (proteins linked to carbohydrates) on the surface: haemagglutinin (HA) 
and neuraminidase (NA). Also embedded in the lipid membrane is the M2 proton channel. Other 
important proteins are: matrix protein 1 (M1), non-structural protein 1 (NS1) and nuclear export 
protein (NEP). Additional proteins have been identified in different strains in recent years.5, 6 
Influenza A viruses are classified by the antigenic HA and NA subtypes: eighteen HA (H1-
H18) and eleven NA (N1-N11) have been identified so far. All subtypes of influenza viruses have 
been detected in avian species which are considered to be a reservoir of influenza A viruses. 
Additionally, new findings have proved that bats constitute an important reservoir of the virus as 
well.7 On the other hand, influenza B makes up a more homogeneous group with only two different 
subgroups, the Victoria and Yamagata lineages.8  
Antigenic shift and antigenic drift are responsible for the emergence of new strains9 and new 
subtypes of the virus. These two phenomena are the key factors for understanding why influenza 
mutates in some extent every season. Moreover, this also explains why highly pathogenic strains 
could appear suddenly. 
• Antigenic Drift (Figure 2, A): occurs due to the accumulation of small mutations because 
RNA polymerase has no proof-reading mechanism. It’s responsible for flu seasons and the 
reason why the flu vaccine must be reformulated every year. Influenza A and B viruses 
experience antigenic drift. 
• Antigenic Shift (Figure 2, B): occurs when a cell is infected with two or more different 
strains/subtypes of the virus, the viruses combine to form a new subtype with different 
surface antigens. Responsible for occasional pandemics and cross-species transmission of 
the virus, only influenza A viruses undergo an antigenic shift.  
Figure 2. Representation of antigenic drift (left) and antigenic shift (right). 
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Although new vaccines must be reformulated annually, vaccination is still the primary 
method used for influenza prevention. In case of pandemic, long times (6-8 months) are required 
to manufacture enough vaccines to immunize a significant percentage of the population. 
Lamentably, during this extensive period of time, many human lives could have been taken by 
influenza. Therefore, an efficient pharmacotherapy needs to be accessible. Unfortunately, both 
antigenic drift and shift cause resistance of influenza towards recent drugs. The aforementioned 
disadvantages of immunization (vaccination) and drug therapy highlight the need to develop new 
small-molecular-weight inhibitors against crucial influenza enzymes. 
1.1.1 Influenza viral life cycle  
 Influenza A virus presents lipid bilayer envelope 
derived from the previous host cell, within which are eight viral 
ribonucleoproteins, vRNPs (Figure 3). These vRNPs are 
formed by viral RNA (vRNA) genome segments in which the 
5’ and 3’ termini are bound to an RNA polymerase complex, 
and the rest of the vRNA is associated to oligomeric 
nucleoproteins (NP).  
 Hemagglutinin (HA) is by far the most abundant protein in the viral envelope making up to 
eighty percent of all proteins. Neuraminidase (NA) is present in around seventeen percent and M2 
ion channel is a very minor component with only 16-20 molecules per virion. M1 proteins keep the 
vRNPs attached to the inner layer of the envelope.   
 The first step during the infection of the host cell begins with the binding of surface 
glycoprotein hemagglutinin (HA) to sialic acid receptors from the host cell outer membrane10 
(usually cell membranes from the upper respiratory tract rich in sialic residues). After the binding 
to the receptor, the virus is transported into the cell in an endocytic vesicle. The lower pH in the 
endosome triggers two reactions: the fusion of the viral and endosomal membranes and initiates 
the flow of protons into the virus through the M2 ion channel, this results in the dissociation of the 
vRNPs from the M1 protein. Subsequently, nuclear localization sequences (NLSs) on 
nucleoproteins transport the free vRNPs from the cytoplasm to the nucleus.  




Figure 4. Influenza A life cycle according to Fodor et al., Nature Rev Microb 201611 
 Once in the nucleus, RNA-dependent RNA-polymerase initiates viral mRNA synthesis by 
using a 5’-capped RNA fragments from host pre-mRNA as primers, this process will be described 
thoroughly in following chapters. RNA-polymerase is not only responsible for mRNA synthesis; 
it also synthesizes unprimed replicas of vRNAs by making complementary copies of RNA (cRNA) 
that act as templates for replication of vRNAs. The viral mRNAs are transported to the cytoplasm 
for translation into proteins and the surface proteins (HA, NA and M2) are transported to the 
membrane of the host cell. Once formed, the NS1 protein suppresses the production of host mRNA. 
M1–NS2 complexes bound to the newly formed vRNPs transport them to the cytoplasm where 
they can reach the cell membrane to be incorporated in the budding new viruses. NA from the 
buddying viruses cleaves the sialic acid linkages between HA and the host cell, thereby releasing 
the new virions. This process will be described in more detail in upcoming chapters. 
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In the fight against influenza a better understanding of the role of the viral proteins and host 
cellular proteins is essential since they are potential targets for drug development.12 At the time of 
writing, only a few drugs are currently FDA approved (NA inhibitors zanamivir, oseltamivir, 
peramivir and M2 ion channel inhibitors amantadine and rimantadine). The current standard of 
care for influenza cases in the United States is only the NA inhibitors oseltamivir and zanamivir.  
Figure 5 depicts the structure of some of the known anti-influenza drugs. Although it may 
seem that there are enough drugs for the treatment of influenza, several related disadvantages reveal 
the need for new inhibitors. Amantadine and rimantadine were the first drugs to be approved but 
rapid drug resistance and neurotoxic side effects have limited their clinical use. Ribavirin also has 
serious side effects and Arbidol hydrochloride is only approved in Russia and China.  
 
Figure 5. Structure of the available drugs for influenza’s treatment. 
 Neuraminidase inhibitors are the most used antivirals for the treatment of influenza, in 
particular oseltamivir, since it’s the only one that can be administrated orally. Unfortunately, the 
recent emergence of new drug-resistant strains generally caused due to prolonged treatment with 
NA inhibitors13 (mostly oseltamivir), and the appearance of H5N1 viruses that have shown low 




Neuraminidase (NA) (also called sialidase) and Haemagglutinin (HA) are surface 
glycoproteins able to recognize carbohydrates, particularly sialic acid (N-acetylneuraminic acid or 
Neu5Ac) which is associated as the α-linked terminal carbohydrate unit of the upper respiratory 
tract and lung-associated glycoconjugates. The role of neuraminidase is to cleave the glycosidic 
linkage between the terminal sialic acid and the host glycoconjugate. By this process, 
neuraminidase facilitates the movement of the virus through the upper respiratory tract and more 
importantly, releases the budding virions from infected cells in the last step of the viral life cycle.  
Influenzas NA is a mushroom-shaped enzyme attached to the viral membrane made up of 
four identical subunits. Each subunit is made from six β-sheets with a propeller disposition. Eleven 
subtypes of neuraminidase have been identified so far, these subtypes are further classified into 
two phylogenetically distinct groups. Group-1 contains N1, N4, N5 and N8 subtypes whereas 
group-2 contains N2, N3, N6, N7 and N9. These two groups are structurally distinct, the main 
difference being that group-1 has a cavity adjacent to the ligand binding site.15 
 
Figure 6 A. H2N2 influenza virus NA and sialic acid (PDB code: 2bat) B. The eight invariant amino-acid residues 
make direct contact with Neu5Ac, Hui-Ling Yen et al.16 
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The X-Ray structure of NA complex with sialic acid was resolved for the first time in 1983. 
Since then, the crystal structures of neuraminidase from group-1 (N815, N415 and N115) and group-
2 (N717, N617 and N318) have been reported.   
One remarkable feature of neuraminidase is that presents highly conserved amino-acids in 
the active site across all subtypes. These amino-acids can be grouped in three different pockets, 
pocket 1 is formed by E276, E277, R292, N294 and accommodates the glycerol chain of sialic 
acid. The pocket 2 forms a hydrophobic region made of the residues of A246, I222 and R224. The 
third and largest pocket is formed of polar negatively-charged amino-acids E119, E227 and D151. 
 When bound to the active site of neuraminidase, the sialic acid pyran ring flips from the 
most stable chair form to the boat conformation, this is due to the extra stabilization introduced by 
acid-base interactions between C-1 carboxylic acid of 1 and a highly conserved triarginyl cluster 
(Scheme 2). In the boat conformation, the lone pair of the pyran oxygen atom and the glycoside C-
O bond are positioned in antiparallel which allows the overlap between the lone electron pair from 
the pyran oxygen and the σ* orbital of the C-OR bond, as result, the bond is broken and an oxonium 
intermediate 3 is formed, which is then intercepted by water generating a molecule of sialic acid. 
 
Scheme 2. Mechanism of the hydrolysis of the sialic acid residue catalyzed by neuraminidase. 
NA is a very attractive target for drug-development of small-molecular-weight inhibitors 
(less than 1000 Da). All NA inhibitors depicted in Figure 5 bind strongly the active site of NA due 
to their analogous structure to the oxonium intermediate 3, competing directly with sialic acid 
residues and therefore called sialomimetics.  
The recent progress in researching NA inhibitors has been mainly focused on modification 




Figure 7. Structure of covalent inhibitor (4), dimeric zanamivir (5), benzoic acid derivatives (6 and 7) and 
pyrrolidine derivatives (8 and 9). 
Also other types of compounds have been reported as NA inhibitors. Some of them are 
depicted in Figure 7. The irreversible inhibitor 4 is capable to form covalent intermediates with 
amino acids from NA-active site.19 Dimeric zanamivir conjugates (5) were proven to be highly 
potent inhibitors but its deficient application in prophylaxis led to discontinuation of the whole 
project.20 In recent studies was shown that some benzoic acid derivatives21-24 (6 and 7) and 
pyrrolidine-based inhibitors25 (8 and 9) were also effective NA inhibitors. Furthermore, several 
natural products have shown anti-influenza activities,26, 27 but they are outside the scope of this 
work.  
It is also worth to note that numerous compounds (flavonoids) that were described as NA 
inhibitors in the beginning were later on revealed as false-positive hits. Apparently, not only potent 
drugs for the treatment of influenza are required but also reliable and high-throughput screening 
assays are desperately needed. This Thesis described our recent effort to address both issues (vide 
infra).   
1.1.3 150-cavity 
As previously mentioned, NAs were classified into two phylogenetic groups based on 
sequence analysis. Russell et al15 crystallized a series of NA from different subtypes and observed 
that group-1 (N1, N4, N5 and N8) NA feature a cavity near the active-site meanwhile group-2 (N3, 
N6, N7 and N9) did not. Group-1 enzymes presented an unusual conformation in active-site amino-
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acids D151 and E119 which belong to the 150-loop (residues 147-152). As a result, a new cavity 
(150-cavity) of nearly 10 Å long, 5 Å wide and 5 Å deep opens up near the active-site. The 
proximity of the 150-cavity to the catalytic site could allow simultaneous binding of small 
molecules to both sites. 
 However, recent publications have shown that pandemic H1N1 neuraminidase N1 (group-
1 NA) lacks the characteristic 150-cavity.28 Subsequent MS simulations and crystallographic 
studies revealed that a salt bridge between D147-H/R150 controls the cavity formation in group-1 
and group-2 enzymes, both of which are able to adopt flexible loop conformations.29 Furthermore, 
a study reported the crystal structure a group-2 NA (N2) binding with oseltamivir presenting a 
partially open 150-loop,30 which reinforces the assumption that 150-cavity is not a unique 
characteristic of group-1 NA. The fact that group-2 NA could also present the cavity makes it more 
attractive for drug development since new drugs targeting active-site and the 150-cavity could be 
applicable across all subtypes of NA. 
Figure 8 A. Oseltamivir carboxylate bound to the active-site of N1 neuraminidase B. Oseltamivir carboxylate bound 
to 5691the active site of N9 subtype. Figure from Mohan et al.31
 
Several research groups have reported neuraminidase inhibitors that were designed to take 
advantage of the existing cavity-150. The available crystal structures of NA binding to oseltamivir 
indicate that the amino group at the C-5 points towards the 150-cavity. Therefore, atom C-5 has 
been chosen as the modification site in most of the scientific reports.  
A series of NA-inhibitors based on oseltamivir structure which bear a triazole moiety 
instead of  the C-5 amino group showed that the new interactions gained by binding to the 150-
cavity are weaker than the strong hydrogen bonding network that was disrupted by replacing the 
parent amine group by a less basic triazole (compare the Ki of 10, 11 and 12 to oseltamivir in Figure 
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9, tested against virus-like particles that contain an influenza A virus N1 activity).32 The mentioned 
work highlights the importance of having a basic group on C-5 for the inhibition activity. 
Compounds 1333 and 1434 are the most active from all the oseltamivir-based and zanamivir-based 
NA inhibitors designed to target the catalytic site and the 150-cavity so far. 
 
Figure 9. Structure of inhibitors designed to bind the catalytic site as well as the 150-cavity 
Some of the reported inhibitors decorated with “150-cavity binding moieties” showed equal 
inhibition activity against enzymes from group-1 and group-2,34 what implies that inhibitors 












1.1.4 RNA-dependent RNA polymerase (RdRp) 
The influenza RNA polymerase is a heterotrimeric complex formed by three subunits: PA 
(polymerase acidic protein), PB1 and PB2 (polymerase basic protein 1 and 2, respectively). The 
structure of RNA-polymerase complex appears to be highly complex, with all three subunits 
intricately involved in many of the important functional regions (Figure 10).35 The crystal 
structures of the RNA polymerase complex (from bat FluA and human FluB) were firstly reported 
in 2014 by Cusack and co-workers.35,36 The enzymatic complex presents a polymerase core made 
up of PB1, the C-terminal domain of PA and the N-terminal domain of PB2 as well as a flexible 
peripheral appendices formed by the endonuclease part of PA and the PB2 cap-binding, mid-linker, 
627- and NLS domains. These appendices adopt two different conformations that either enable or 
disable cap-snatching, what implies that RdRp exists in several functional states.11 RdRp is capable 
to perform the processes of transcription and replication using the same template of vRNA.  
 
Figure 10. Surface views of the FluA heterotrimer with bound vRNA promoter a) at 0o b) 180 o PB2, PA, PB1 and 
vRNA 5’ and 3’. Figure from Pflug, A. et al35 Nature, 2014. 
Transcription is a primer-dependent process; however, RNA-polymerase does not have 
capping activity and instead uses short capped oligomers from the host pre-mRNA as a primer for 
transcription, this process is called “cap-snatching” (Figure 11). PB2 has a cap binding domain and 
its function is to capture the 5’-cap from host pre-mRNAs (red).37 Subsequently, an endonuclease 
in the amino-terminus of PA subunit (PA-Nter) cleaves the capped RNA 10-13 nucleotides 
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downstream.38 This capped RNA-fragment is used as a primer and vRNA (green) as template by 
the PB1 subunit during the mRNA synthesis. Thus, the produced capped chimeric mRNA is ready 
to be translated into viral proteins in the cytoplasm. 
 
Figure 11. Cap-snatching transcription mechanism of influenza polymerase. Figure extracted from: Boivin et al.39 
Contrary to the transcription process, the replication is primer independent. During this 
process a complementary RNA (cRNA) intermediate is synthesized as an exact, full-length copy 
of the vRNA, the cRNA is then used as a template to synthesize back vRNA. Nascent vRNA are 
immediately packed with nucleoproteins into new vRNPs, transported from the nucleus to the cell 
membrane and incorporated into the new virions.  
Apart from being essential for the processes of transcription and replication, influenza’s 
RNA-polymerase is also responsible for the evolution of the virus. This is due to the absence of a 
proof-reading mechanism in the enzyme which makes it prone to error during the RNA replication, 
the consequence is the production of mutant viral proteins which eventually lead to viruses that are 
better adapted to the host species.  
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RNA-dependent RNA polymerase is highly conserved across all strains and subtypes of 
influenza and it plays a critical role in the life cycle of the virus. Because of these reasons, RNA-
dependent RNA polymerase is an exceptionally promising target for drug development.  
 
1.1.4.1 Polymerase acidic protein (PA) 
PA is a bridged dinuclear metalloenzyme in which the N-terminal (PA-Nter) and the C-
terminal (PA-Cter) region are connected by a long flexible peptide chain. The PA-Nter region 
presents endonuclease activity meanwhile the PA-Cter part forms a “mouth” into which the small 
N-terminal domain of PB1 is inserted. The active-site of the PA-Nter is formed by His41, Lys134 
and a group of the acidic residues Glu80, Asp108 and Glu119 that bind two divalent metal ions 
(Mn2+ or Mg2+). Metal-chelating molecules able to bind these divalent metal ions and occupy the 
PA-Nter active site could work as inhibitors. 
Three main reasons illustrate why the catalytic site of PA endonuclease is a very promising 
target for drug development:  
• Endonuclease activity is essential for the life cycle of the virus. 
• The PA-Nter is highly conserved in all strains and subtypes of the three families of viruses 
(A, B and C) which could lead to a universal inhibitor for influenza.  
• No counterpart of PA-Nter exists in human cells which means that inhibitors have a good 
chance of being selective and non-toxic. 
Although no FDA approved PA inhibitors have been reported till the date (2018), the PA 
inhibitor AL-794 (structures undisclosed) have entered clinical trials and the inhibitor S-033188 
(recently named baloxavir marbotil) has been approved for sale in Japan (February 2018). These 
precedents validate PA-Nter as a target for drug development.  
Many molecules with chelating groups have been reported as inhibitors of PA-Nter, a brief 
compilation of the most relevant is presented in the following lines. These inhibitors could be 
classified in the following groups:  
I. Diketo Acid Derivatives: discovered through a random screening effort,40 further research 
indicated/showed that derivatization of the carboxylic acid in the 2,4-dioxobutanoic side 
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chain is indispensable for the inhibition activity since it’s responsible for the binding to the 
two metal ions (Figure 12). Piperidinyl-diketo acids were reported to be selective inhibitors 
of PA-endonuclease.41 In particular 15 (L-742,001) is one of the most potent inhibitors. 
Compound 15 is able to chelate the two metal ions and at the same time; the two flexible 
benzyl rings (the “wings”) occupy different hydrophobic pockets. It is worth to note that 
the piperidine nitrogen does not participate in hydrogen bonding. The structure of L-
742,001 was used in this work as starting point for the design of a probe suitable for the 
AlphaScreen-based assay (vide infra).  
 
Figure 12. Two possible binding modes of a representative diketo acid and two metal ions, Structure of L-
742,001 (17). 
II. 2,6-Diketopiperazine derivatives: Flutimide (Figure 13, 16) was originally isolated from 
Delitschia confertaspora. This pyrazine derivative exhibits good inhibitory activity (IC50 = 
5.1 µM) against endonuclease without affecting the activities of other polymerases.42 
Additional analogues with substitutions at positions 1, 3, and 5 of 3H-pyrazine-2,6-dione 
have been reported.43 Although some flutimide-derivatives (17 and 18) showed enhanced 
potency in vitro, they also presented high cytotoxicity in cell culture. Other similar 
structures like 19 also showed inhibition activity although the selectivity is unacceptable.  
III. Hydroxylated heterocycles: an extensive series of hydroxypyridines (20 and 21), 
hydroxypyrimidines and hydroxyquinolines have been reported to be not only efficient 
metal chelating agents but also PA inhibitors.44 Compound 22 is a particularly promising 
lead compound suitable for further modification.45  
IV. Catechol derivatives: Natural products containing catechol group have drawn attention 
from researchers in past years (2346 and 2447). Although these structures have not been 
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thoroughly investigated, they could be a promising scaffold for further structural 
optimization. 
V. Others: An extensive list of other small molecules with diverse structures have shown 
binding activity to the PA endonuclease site. For example, 2,3-dihydroxybenzoic acid (25) 
and its bioisosteres (26)48 represent some of them. Compound ANA-0 (27) features a unique 
scaffold and presumably utilizes different mechanism of the action. This compound belongs 
to a group of inhibitors without “textbook” chelating groups.49 
 
Figure 13. Structure of selected PA endonuclease inhibitors. 
The list of possible PA endonuclease inhibitors is quite extensive but it’s important to 
highlight that most of the reported structures were never further investigated after the initial report. 
Therefore, the pursuit of a powerful, selective, orally-available inhibitor of PA endonuclease is still 
a hot topic in medicinal chemistry.  
1.1.4.2 Polymerase basic protein 2 (PB2) 
The role of PB2 as the cap-binding part of the polymerase complex has been known for 
several decades. In 2008 the crystal structure of the PB2 cap-binding domain (PB2-CBD) was 
firstly reported.50 The nature of the cap binding-site was thus unveiled and efficient structure-based 
design of drugs began to appear. The natural ligand of the PB2 domain is the 7-methyl GTP 
(m7GTP) on the 5’ end of the host pre-mRNA; the binding occurs in an independently folded 
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domain of PB2. Although the binding mode is similar to other cap-binding proteins it features 
important differences.50 The binding of m7GTP is shown in Figure 14, the methylated base is 
sandwiched between the residues of Phe404 and His357, and Phe323 stacks also with the ribose. 
The key acidic residue is Glu361 that forms hydrogen bonds with N1 and N2 and at the same time, 
the neighboring Lys376 interacts with O-6. The triphosphate group adopts a bent conformation and 
binds both Arg355 and Asn429.50 
 
Figure 14. Structures of m7GTP and VX-787 and the corresponding X-ray structures with PB2-CBD. Figure from 
Clark, P. M. et al.
51
 
 Clark et al. discovered a series of azaindole-based influenza PB2 inhibitors by phenotypic 
screening effort using cell protection assay. Rational optimization of the hits led to the discovery 
of VX-787 (28), which is an extremely potent, orally available and highly selective inhibitor of 
PB2 cap-binding domain.51 VX-787 is in phase IIIb of clinical trial at the moment (March 2018).  
 The X-ray structure of 28 with PB2 (Figure 14) showed how does the azaindole core 
interact by π-stacking with His357, Phe323 and Phe404 residues. Simultaneously the two nitrogen 
atoms from the heterocycle bind with residues Lys376 and Glu361. The carboxylic acid from the 
[2.2.2]bicyclootane moiety is involved in two water-mediated interactions with the residues of 
His357, Gln406 and Arg355. The fluorine atom attached to the pyrimidine ring points outside the 
cap-binding site into the solvent. 
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Figure 15 shows other cap binding inhibitors. Compound 29 was the first cap-binding 
inhibitor ever reported and was based on the structure of m7GTP.52 Unfortunately due to the 
unfavorable pharmacokinetics the projects associated with compound 29 were discontinued. 
Replacement of the carboxylic acid from 28 by charged and uncharged bioisosteres proved 
that a negatively charged moiety is important for the antiviral potency; unfortunately, none of the 
compounds reported showed superior inhibition activities to 28, but compound 30 showed at least 
similar values.53 Other reported inhibitors are Cap-3 and Cap-7, both exhibited EC50 in the 
micromolar range (Figure 15). 
 
Figure 15. Structures of PB2 cap-binding inhibitors. 
Due to the outstanding inhibition activity of VX-787 (28) and its well-known binding-mode 
to the active-site of PB2, we decided to use its scaffold as the binding part of a detection probe, 
which will be used in the development of a high throughput screening assay for possible PB2 cap-
binding inhibitors.  
 
1.1.4.3 Polymerase basic protein 1 (PB1) 
PB1 is located in the core of the heterotrimeric polymerase complex, bonded to PB2 and 
PA subunits. It’s responsible for the polymerase activity including nucleotide polymerization and 
chain elongation. The polymerase active site is located at the edge of a large central cavity formed 
by PB1 and PB2-Nter.35,36 This central cavity presents several channels that lead to the surface of 
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the protein, some of this channels are formed by amino acids from all three subunits meanwhile 
others, like the NTP entry channel, are made exclusively of residues from PB1 subunit.54 
Very few compounds have been postulated as PB1 inhibitor, the inhibitors 31 and 32 
(Figure 16) were found by high throughput screening assays and the mode-of-action was verified 
by mutation analysis.55,56 
 
Figure 16. Structures of reported PB1 inhibitors. 
Favipiravir (33) is likely the most promising anti-influenza drug in development, in the 
USA has advanced to phase II of clinical trials and in Japan is in phase III. Favipiravir, simple 
pyrazine derivative, was firstly reported in 2002 by Furuta et al.57 Its mechanism of action begins 
with phosphorylation. At first, Favipiravir (also known as T-705) is converted to the 
monophosphate and this metabolite further undergoes phosphorylation by cellular kinases to the 
active triphosphate that are misidentified as a natural purine nucleotide by the virus RNA 
polymerase and is subsequently incorporated to the RNA. Once is introduced into the RNA it 
prevents further extension of the strand. Favipiravir inhibits the virus RNA polymerase but not 
cellular RNA and DNA synthesis since host cells enzymes can differentiate T-705 phosphates from 
the natural nucleotides.58 Favipiravir has been tested against a wide range of influenza strains and 
it has shown high efficiency in nearly all, including strains resistant to neuraminidase and M2 ion 




1.1.4.4 Protein-protein interactions 
Disruption of the heterotrimeric polymerase complex is an alternative strategy for drug 
development against influenza since the protein-protein interactions (PPIs) between PB1, PB2 and 
PA are indispensable for the transcription and replication. Researchers have focused their work on 
the interaction between PA-C terminus and PB1-N terminus and the interaction of PB1-C terminus 
and PB2-N terminus.  
• PPI between PB1 and PB2: The interaction was studied by protein crystallography. The 
contact between these two subunits depends on four salt bridges and eight H-bonds and the 
interface is quite extensive in sequence length what makes it an inappropriate target for 
drug development.59 Despite not being the most promising target in influenza RNA 
polymerase there is some known compounds disrupting PB1-PB2 PPI.60 
• PPI between PA and PB1: Crystallographic studies found that the C-terminal domain of 
PA forms a deep, highly hydrophobic groove formed by several α-helices, meanwhile, the 
N-terminal domain of PB1 forms a compact helix (residues 5-11) that is buried inside PAs  
 
Figure 17. A. Schematic diagram showing PB1-PB2 PPI. The molecular surface of PB1 is colored by charge 
(blue = positive, red = negative). PB2 is shown as a green ribbon. Figure extracted from Sugiyama et al.59 B. 
Crystal structure of PA-Cter (helices = red, strands = yellow, coil = green) bound to PB1-Nter peptide (blue). 
Figure extracted from Obayashi et al.61 
groove.61,62 The two domains interact largely by hydrophobic interactions, although 
hydrogen bonding and van der Waals forces were also detected. Short peptides (15 amino 
acids) derived from PB1-Nter showed inhibition activity not only against FluA polymerase 
but also FluB.63  
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Several small molecules and peptides have been reported as PA-PB1 disrupting 
compounds; benzofurazan derivatives were identified by HTS using ELISA-based 
screening method,64 4,6-diphenylpyridines, cycloheptathiophene-3-carboxamaides and 
triazolopyrimidines were discovered by a combination of virtual screening and ELISA 
assay.65 
So far reported PB1 inhibitors are not meeting the requirement for being considerate as lead 
drug candidates due to a lack of potency or drug-like properties. Nevertheless, the recent 
elucidation of the structure of influenza’s RNA polymerase35 has been a game-changing success 























1.2 Oseltamivir  
In the previous chapters, we described some of influenza enzymes which are being targeted 
for therapeutic intervention. This chapter summarizes the chemistry of the pivotal compound of 
this Thesis, the neuraminidase inhibitor oseltamivir. 
Oseltamivir (34, TamifluTM, GS-4104-02, RO0640796) was firstly synthesized by Kim et 
al66 (Gilead Science). The drug was approved by the FDA and commercially launched in 1999 after 
Gilead Science and F. Hoffmann-La Roche Ltd. signed a co-development contract. Oseltamivir is 
marketed as the phosphonate salt under the trade name of TamifluTM. Tamiflu is an ethyl ester 
prodrug whose active form (oseltamivir carboxylate, 35) is released after hepatic esterases 
hydrolyze the ethyl ester to the free acid.67 Oseltamivir is the most used NA inhibitor at the moment, 
and it is prescribed for treatment and prophylaxis of both influenza A and B infections.  
 
Figure 18. Structure of Oseltamivir, Oseltamivir carboxylate, Dana and Zanamivir. 
The discovery of oseltamivir was the result of intense optimization of the structure of 
DANA (36) and zanamivir (37), which aimed for a less polar molecule with enhanced oral 
bioavailability. Replacing the glycerol moiety by a lipophilic group produced a change in the 
architecture of the active site. Glu276 (which usually interacts with the glycerol moiety in SA) gets 
reoriented and binds Arg224. That leads to the formation of a hydrophobic area where the 
pentyloxy group is accommodated.68 Unlike zanamivir, oseltamivir (34) presents the double bound 
in a position that mimics more closely the oxocarbenium intermediate (Scheme 2), the position of 
the double bound is fundamental for the binding since the other regioisomer of oseltamivir presents 




Figure 19. Intermolecular interactions of oseltamivir carboxylate 35 with 2009 pandemic H1N1 neuraminidase 
(PDB code: 2HUA). Figure from Naumov et al.69 
The binding between oseltamivir carboxylate (35) and the active site of neuraminidase is 
depicted in Figure 19. The negatively charged carboxylate in C-1 binds by acid-base interaction 
with three basic arginine residues from C1 pocket (Arg292, Arg371 and Arg118). The other acid-
base interaction takes place between the positively charged amine at C-5 and the acidic residues 
Glu119, Asp151 and Glu227. The acetamide moiety at C-4 forms a hydrogen bond with Arg152 
meanwhile the pentoxy group binds by hydrophobic interactions with the hydrophobic pocket 
formed by Ile222, Arg224, Ala246 and Glu276. 
Oseltamivir has shown in vitro activity not only against influenza A and B types but also 
across different influenza A subtypes. Furthermore, oseltamivir displays insignificant cross-
reactivity with other sialic acid binding proteins from other viruses, bacteria or human 
microsomes.70 Despite its success, the emergence of oseltamivir-resistant strains and some 




1.2.1 Oseltamivir-Resistant strains 
The original success of oseltamivir is partially based on the fact that the active site of 
neuraminidase is highly conserved among A and B viruses. Mutations leading to viral resistance 
against anti-influenza inhibitors often appears in humans undergoing treatment. Although 
resistance to NA inhibitors is less frequent than resistance to M2 ion channel inhibitors, some 
strains of the virus have shown low sensitivity towards oseltamivir.  
During the 2007-2009 annual influenza epidemics spread a drug-resistant strain of the 
seasonal H1N1 virus containing the mutation H274Y worldwide. Typically, reduced susceptibility 
to neuraminidase inhibitors appears when a mutation alters the size and shape of the NA substrate 
binding site. In the mutation H274Y (Figure 20, A), His274 is replaced by a much bulkier Tyr274 
which pushes Glu276 towards the active site. The new conformation of Glu276 prevents its rotation 
towards Arg224 and therefore the hydrophobic pocket that accommodates the pentyloxy group is 
not formed.71 The H274Y appears in the N1 subtype including in the highly pathogenic H5N1. In 
contrast with oseltamivir, mutation H274Y has little effect in the inhibition of zanamivir, this is 
due to the H-bonding between the glycerol and Glu276 is not disrupted.72 
Figure 20.  A. Effect of mutation H274Y on E276 and oseltamivir in the wild-type N1 NA (yellow) and mutant N1 
NA (green). B. Effect of mutation R294K on E276 and oseltamivir in the wild-type N9 NA and mutant N9 NA. 
Although less common than mutation H274Y, the widespread mutation R294K appears in 
the N2 subtype and markedly reduces the sensitivity towards oseltamivir. X-Ray structural analysis 
showed that a salt bridge formed between the new Lys294 and Glu276 pushes the formed towards 
the pentyloxy group moving the molecule of oseltamivir away from the active site.73 R294K 
confers less resistance towards zanamivir than to oseltamivir.   
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1.2.2 Oseltamivir syntheses   
The first synthesis reported by Kim66 (Scheme 3) used (-)-shikimic acid as starting material 
for the oseltamivir carboxylate synthesis. Shikimic acid as starting material was a reasonable choice 
since it already presents the cyclohexene scaffold and the key carboxylic acid moiety. In addition, 
all carbons have the same oxidation states as in oseltamivir carboxylate.  
 
Scheme 3. Gilead Science’s first synthetic route.66 Reagents and conditions. (i) NaN3, NH4Cl; (ii) MsCl, Et3N; (iii) 
Ph3P, THF/H2O, Et3N; (iv) NaN3, NH4Cl; (v) HCl-MeOH 5%; (vi) TrCl, Et3N; (vii) MsCl, Et3N; (viii) 3-pentanol, 
BF3·OEt2; (ix) Ac2O, py, DMAP; (x) PhP3, THF, H2O; (xi) KOH, THF, H2O. 
The 3-pentoxy moiety is introduced via aziridine-opening reaction at a late stage of the 
synthesis because it could be easily diversified, which is preferable in the drug discovery stage. 
The synthetic route reported by Shi et al74 (Scheme 4) exhibits similar features. With only eight 
steps and 47% overall yield, Shi’s approach is an excellent route for the synthesis of oseltamivir-
derivatives with different moieties in C-3.   
 
Scheme 4. Shi et al synthetic route.
74 Reagents and conditions. (i) SOCl2, EtOH; (ii) MsCl, Et3N, DMAP; (iii) NaN3, 
acetone/water, 0 °C; (iv) Ph3P, THF/water; (v) Ac2O, Et3N; (vi) 3-pentanol, BF3·OEt2; (vii) NaN3, EtOH/water, 
reflux; (viii) Lindlar cat., H2. 
Roche’s current production process relies also on shikimic acid and is suitable for mass 
production.75 More than sixty oseltamivir syntheses have been reported since Kim’s publication in 
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1997, some have been focused on improving the original synthesis by shortening the number of 
steps or increasing the overall yield.76-82 Several reviews have summarized the progress made in 
past twenty years.83-87 
The numerous retrosynthetic approaches towards oseltamivir could be divided into five 
different strategies (Scheme 5):87 
1. Syntheses which use 6-membered rings as a starting material (shikimic acid, quinic acid, 
cyclohexane-1,2-diol, etc.). 
2. Construction of the ring by Diels-Alder reaction using acrylates as dienophile. 
3. Formation of the cyclohexene by ring-closing metathesis reaction. 
4. Assembly of the cyclohexene core via Michael addition to a nitroalkene and subsequent 
Horner−Wadsworth−Emmons. 
5. Approach starting with D-glucal and utilizing Claisen rearrangement.  
 
Scheme 5. Five different retrosynthetic approaches towards oseltamivir synthesis. 
Hudlicky’s approach will be described in more detail here since part of our research was 
based on his work. Hudlicky and coworkers reported a 13-steps synthesis which uses inexpensive 
ethyl benzoate as the starting material with an overall yield of 7%.88 Further optimization lead to 




Scheme 6. Oseltamivir synthesis reported by Hudlicky et al.
89 Reagents and conditions. (i) 1. DMP, TsOH; 2. 
CH3CONOH, NaIO4, MeOH; (ii) Mo(CO)6, MeCN, H2O; (iii) 1. CrO3, Ac2O; 2. NH2OH·HCl, EtOH, py; (iv) 5% 
Rh/Al2O3 60 psi H2, Boc2O; (v) 0.05M EtONa; (vi) Me2PPh, DIAD; (vii) 3-pentanol, Cu(OTf)2; (viii) TFA.  
The synthesis starts with the fermentation of ethyl benzoate 46 with a recombinant strain 
of Escherichia coli JM109 (pDTG601A) to produce the diol 47. The diol was firstly protected as 
the acetonide which underwent an inverse electron-demand Diels-Alder cycloaddition with an acyl 
nitroso species formed in situ. The resulting oxazine 48 was generated as a single isomer. The N-
O bond was then reduced to yield the allylic alcohol 49 which underwent Dauben-Michno oxidative 
transposition under treatment with chromium trioxide. The formed enone was directly converted 
to the oxime 50. Hydrogenation of the oxime under the presence of Boc-anhydride afforded the 
Boc-protected saturated intermediate 51, which after treatment with sodium ethoxide underwent 
elimination of the ether in C-2. The allylic alcohol 52 can’t be directly alkylated and it’s necessary 
to introduce the pentoxy group via aziridine opening; the requested aziridine 53 was formed using 
Mitsunobu conditions. Treatment of aziridine 53 with 3-pentanol in the presence of a Lewis acid 









1.2.3 Tamiphosphor and other bioisosteres 
Design of bioisosteres is a convenient strategy for structural modification in drug design.90 
In particular, phosphonate group is a well-known biosisostere of the carboxylate moiety in 
medicinal chemistry. The phosphonate moiety is able to bind guanidinium cations with stronger 
electrostatic interactions than carboxylate anion, which could be advantageous for the binding to 
NA active side since an arginine triad (Arg292, Arg371 and Arg118) interact with the acidic 
functional group at carbon C-1 of oseltamivir. 
Fang et al reported a synthesis of a phosphonate derivative of oseltamivir (Tamiphosphor, 
55) which showed enhanced potency in the NA inhibition and antiflu assays, high selectivity index 
and no toxicity to the host cell.91 Streicher and coworkers reported a short and efficient approach 
to convert the available azide 56, the precursor of Tamiflu, into tamiphosphor 55 (Scheme 7).92 
 
Scheme 7. Tamiphosphor synthesis reported by Streicher,
92
 possible pathway to monoalkylated tamiphosphor 
derivatives represented in dashed arrows. Reagents and conditions. (i) NaOH 0.5M; (ii) Vilsmeier reagent, N-
hydroxypyridinethione, CF3CH2I, irradiation; (iii) 1. PMe3, THF; 2. Boc2O, THF; (iv) (CH3O)2P(O)H, [Pd(PPh3)4], 
Et3N; (v) NaOH 0.5M; (vi) 1. TMSBr; 2. TFA. 
Moreover, Streicher and co-workers were the first who reported that monoalkylated 
phosphonate derivatives are able to retain a negative charge on C-1 under physiological conditions 
which confers them essentially the same properties than oseltamivir.92 Later, Fang’s group also 
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demonstrated that monoalkylated tamiphosphor and guanidine-tamiphosphor derivatives maintain 
their activity by testing two sets of derivatives in a cell-based assay, the results showed potent anti-
influenza activities for all the monoalkylated derivatives with EC50 in the low nanomolar range.
93  
The guanidine-tamiphosphor analogs tested showed strong potency also against the oseltamivir-
resistant H274Y mutant virus. 
Later on, Streicher reported a solution for the tethering of tamiphosphor without impairing 
its binding potency. In the same publication, he probed that tamiphosphor could be used as a valid 
alternative to oseltamivir in the construction of neuraminidase-binding diagnostic tools (Figure 
21).94 
 
Figure 21. Probes prepared by Streicher based on tamiphosphor bearing  
the reporter groups biotin (left) and fluorescein (right)94 
 
It is worth to mention that other bioisosteres of carboxylic acid, like hydroxamates and acyl 
sulfonamides, have been prepared but none of the reported derivatives showed higher activities 
than oseltamivir.95   
The aforementioned synthetic route (Scheme 7) inspired our approach for the production 
of tamiphosphor-based probes (vide infra). The key intermediate 61 could be easily alkylated and 
regioselectively O-demethylated to afford monoalkylated tamiphosphor derivatives. Thus the 
furnished compound is suitable for the preparation of detection probes in a similar fashion to 










1.3 The Inhibitor Screening Assays. 
An important part of the research presented in this Thesis was dedicated to the synthesis of 
detection probes suitable for the development of different screening assays against several enzymes 
from influenza (vide supra). In the following pages a brief description of the two main assays for 
which the probes are intended will be provided. Both assays have been developed by our 
collaborators from the Department of Proteases of human Pathogens.    
 
1.3.1 DNA-linked Inhibitor Antibody Assay 
A multiwell plate-based DNA-linked Inhibitor Antibody Assay (DIANA) has been reported 
by Konvalinka’s group recently as an ultrasensitive assay suitable for enzyme quantification as 
well as for quantitative screening of enzyme inhibitors with either purified or unpurified enzymes.96 
In DIANA, the wells of the titration plate are coated with immobilized antibodies able to capture 
the target enzyme. Subsequently, the enzyme binds the detection probe, which consists of a known 
inhibitor covalently bound to a reporter DNA oligonucleotide. The DNA is then detected by 
quantitative PCR.96  
 
Figure 22. A. Outline of the assembly of the detection probe. B. Schematic representation of DIANA assay. The 
detection probe binds to the active site of enzyme captured on the solid support of the well after binding to the 
immobilized anti-Strep antibody. The detection probe competes with the tested compound, the amount of detection 
probe binding to the enzyme is determined by quantitative PCR.  
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The selectivity emerges from the dual recognition of the enzyme by the antibody and the 
detection probe meanwhile the high sensitivity is a consequence of the broad linear range of qPCR. 
 
 DIANA has a simple and reliable protocol, doesn’t require the use of purified enzymes, is 
compatible with multiwell plates and has the exceptional ability to calculate the Ki of a compound 
from a single tested concentration. We demonstrate in this work that DIANA assay could be 
successfully used for screening of small-molecule inhibitors against neuraminidase and the PB2-
cap-binding domain of influenza’s RNA-polymerase.   
 
1.3.2 Amplified Luminescent Proximity Homogenous Assay Screen 
 Amplified Luminescent Proximity Homogenous Assay Screen (Known as AlphaScreen) is 
an example of bead-based proximity assay and it was developed from a Luminescent Oxygen 
Channeling Immunoassay reported in 1994.97 AlphaScreen relies on the use of a photoexitable latex 
bead (donor) and a second bead able to produce a chemiluminescent response (acceptor) when is 
placed in close proximity to the donor bead.  
 
Figure 23. Outline of AlphaScreen Assay. Streptavidin-coated donor bead is attached to a biotin-tethered inhibitor of 
PA endonuclease. The acceptor bead is coated with GSH ligated to GST fused to the N-terminal part of PA subunit. 
When there is binding between the inhibitor and the enzyme the two beads are into close proximity and singlet oxygen 
can travel from the donor to the acceptor bead and produce the emission of light. 
 Upon laser excitation, the donor bead produces molecular singlet oxygen which diffuses 
across to react with a chemiluminescer in the acceptor bead which then emits light at 520–620 
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nm.98 Singlet oxygen has a very short half-life (~ 4 µs) and it only reaches the acceptor bead if 
there is co-recognition of the analytes coated on the surface of both beats (in Figure 23 these are 
the biotinylated inhibitor L-742.001 at donor beat and the N-terminal part of subunit PA form 
RNA-polymerase at acceptor bead).   
This technology is used for screening of low-molecular-weight inhibitors that compete with 
the biotin-tethered inhibitor (probe) for the binding to the enzyme. Better binders would displace 
the probe and as a result, the beads would be too distant which produces a detectable change in the 
























2. Objectives of the Thesis 
• Find a convenient synthetic pathway for the introduction of modifications at position C-3 
in oseltamivir’s structure. Adapt and optimize the procedure for a rapid and direct 
production of oseltamivir derivatives designed to overcome oseltamivir-resistant mutations.  
• Design a short and efficient modular synthesis for the production of C-5 derivatives of 
oseltamivir.  
• Synthesize a set of C-5 oseltamivir derivatives designed to explore the binding mode to the 
150-cavity. 
• Prepare tamiphosphor and tamiphosphor-based inhibitors. Explore conditions for the 
decarboxylative halogenation step and for the introduction of phosphonate moiety into the 
cyclohexene ring.  
• Design and synthesize neuraminidase-binding probes containing a sialylmimetic group 
suitable for DIANA assay.  
• Design and prepare from commercially available building blocks probes based on the 
structure of the PB2 inhibitor VX-787. The probes prepared must be suitable for SPR and 
DIANA assay.  
• Design and prepare probes based on the structure of the PA-endonuclease inhibitor L-









3. Results and Discussion 
The herein reported work is subdivided in two main sections; the first part is centered on 
the synthesis of new inhibitor candidates by modification of the structure of oseltamivir. For that, 
we used rational drug design approach to pursuit an improvement in the inhibition activity of the 
molecule. The second part involves the synthesis of molecular tools (also known as probes) suitable 
for the development of assays which final objective is to screen libraries of small molecules for 
new lead inhibitors against influenza’s neuraminidase, PB2 cap-binding domain, and PA 
endonuclease. 
3.1 Synthesis of Oseltamivir derivatives  
As mentioned above, oseltamivir is the most extensively used drug for the treatment and 
prophylaxis of influenza infections. Unfortunately, recent appearance of oseltamivir-resistant 
strains of the virus could compromise its efficiency in the event of future epidemics. In this work, 
we intended to synthesize NA inhibitors capable to overcome oseltamivir-resistance by the 
introduction of polar moieties at position C-3 in oseltamivir (Figure 24).  
The structure of oseltamivir was also used as a template in the synthesis of C-5 derivatives. 
Unlike the C-3 derivatives, C-5 derivatives have the objective to target the 150-cavity adjacent to 
the active site and explore the binding in this region.  
 
Figure 24. Two sets of oseltamivir-derivatives were synthesized by modification of either position C-3 or C-5. 
3.1.1 C-3 Modification of oseltamivir 
Mutations H274Y and R294K which cause oseltamivir resistance were described 
previously. Both mutations cause the blocking the rotation of E276 and therefore the hydrophobic 
pocket cannot be formed. As a result, the binding of oseltamivir to the active site is destabilized. 
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On the other hand, zanamivir, which presents a glycerol group at C-3 instead of a pentoxy group, 
is less sensitive towards these mutations. We hypothesize that replacement of the hydrophobic 
pentoxy moiety by a polar sidechain capable of binding E276 would improve the inhibition activity. 
To demonstrate our hypothesis a set of new oseltamivir derivatives had to be synthesized.  
3.1.1.1 Hudlicky’s approach 
The Hudlicky’s approach to oseltamivir was firstly selected as the synthetic pathway to 
follow for the production of C-3 derivatives of oseltamivir. The advantage of this approach is the 
late stage introduction of the pentoxy moiety via aziridine ring opening with pentan-3-ol (showed 
previously in Scheme 6). In a similar way, the opening of the aziridine 53 with different alcohols 
could potentially be a simple and direct approach towards derivatives with a polar sidechain 
(Scheme 8). 
 
Scheme 8. Outline of the strategy for the synthesis of C-3 derivatives following Hudlicky’s approach 
A second advantage is our direct collaboration with Hudlicky research group which 
provided access to large quantities of the starting material 3-iodocyclohexa-3,5-diene-1,2-diol 62. 
The unstable 3-iododiol was extracted from a buffered solution and protected as the acetonide 
under acid catalyzed conditions (Scheme 9). The resulting product was then directly submitted for 
palladium-catalyzed carbonylation using standard conditions to afford the ethyl ester 63 in 85% 
yield over the two chemical tranformations.99 
 
Scheme 9. Reagents and conditions: (i) TsOH ·HCl, 2,2-dimethoxypropane; (ii) CO (g), Pd(OAc)2, PPh3, Et3N, 
EtOH, 40 °C, 2h, 85% yield. 
The subsequent steps leading to the synthesis of the aziridine 53 follow closely the synthetic 
pathway described in Scheme 6 (page 37). The diene 63 undergoes inverse-electron demand Diels-
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Alder cycloaddition with an acylnitroso dienophile component generated in situ by oxidation of 
hydroxamic acid with sodium periodate, the resulting bicyclic oxazine 48 was obtained as a single 
isomer in 88% yield (Scheme 10).  
 
Scheme 10. Reagents and conditions: (i) NaIO4, acetohydroxamic acid, MeOH, 16h, 88% yield; (ii) Mo(CO)6, 
AcCN/H2O, 85 °C, 4h, 77% yield; (iii) CrO3, Ac2O, 0 °C, 5 min; (iv) NH2OH·HCl, py, NaHCO3, EtOH, 16 h, 71% 
yield; (v) Rh/Al2O3 5%, 60 psi H2, Boc2O, EtOH, 16h, 69% yield; (vi) NaOEt 0.05M, EtOH, 1h, 87% yield; (vii) 
DIAD, PPhMe2, Et3N, -40 °C, 66% yield. 
The N-O bond was then reduced using molybdenum hexacarbonyl under reflux in wet 
acetonitrile. The mechanism of the reduction is represented in Scheme 11; water acts as the source 
of protons and pushes the equilibrium to the right.100 
 




The resulting allylic alcohol 49 was obtained in 77% yield. Compound 49 underwent [3,3] 
oxidative transposition when a solution of chromium trioxide in acetic anhydride was added, the 
formed enone 64 was not isolated and transformed into the stable oxime 50 directly. The overall 
yield from the allylic alcohol 49 to the oxime 50 was around 70%. Special caution should be taken 
when the chromium oxide is being dissolved in acetic anhydride since the solution needs to be 
heated up to 80 °C and it tends to bubble vigorously upon addition of the chromium oxide. The 
unsaturated oxime 53 is then hydrogenated using a Parr shaker apparatus with a hydrogen pressure 
of 60 psi overnight period. The reduction is done in the presence of Boc-anhydride to yield the 
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protected amine 51 in a 69% yield. The acetonide 51 collapses under treatment with sodium 
ethoxide to produce the allylic alcohol 52 via E1cB elimination in 87% yield. The suggested 
mechanism is depicted in Scheme 12. 
 
Scheme 12. Proposed mechanism for the elimination of the acetonide. 
 Direct alkylation of the allyl alcohol 52 has been reported to be inefficient with yields lower 
than 10 %.89 Therefore, the introduction of the ether functional group at C-3 had to be done 
indirectly via opening of aziridine. The aziridine 53 was formed by intramolecular Mitsunobu 
reaction following the conditions reported by Shibasaki.101 Despite the fact that the conditions 
applied were optimized to minimize the formation of the oxazoline 65 I always observed the 
formation of a non-negligible amount of by-product 65 which lowered the yield of the reaction to 
60-65% in the best cases (Scheme 13).  
  
Scheme 13. Reagents and conditions: (i) DIAD, Me2PPh, Et3N, -40 °C, 10 min. 
 Once the aziridine 53 was obtained, I attempted its opening with a set of relatively complex 
alcohols (Table 1). Two Lewis acids were used; Cu(OTf)2 in catalytic amounts inspired by Corey’s 
conditions102 and stoichiometric excess of BF3·OEt2 following Shibasaki’s method.
101 
 





Alcohol N° Run Eq. Alc. Lewis A. Eq. LA T (°C) t (h) Yield 
 1 60 BF3 ·OEt2 1.5 -20 0.25 - 
 2 10 Cu(OTf)2 0.16 -20 16 - 
 
3 1.5 BF3 ·OEt2 0.16 -20 16 - 
 
4 2 BF3 ·OEt2 2 -20 0.5 8% 
 
5 5 Cu(OTf)2 0.16 -20 16 34% 
 
6 5 BF3 ·OEt2 2 -10 1 34% 
 
7 4.5 Cu(OTf)2 0.16 -20 16 - 
 
8 3.4 Cu(OTf)2 0.16 -20 16 - 
Table 1. The columns represent (from left to right); structure of the alcohols, number of the run, equivalents of the 
alcohol, Lewis acid used, equivalents of the Lewis acid, temperature, time and yield. All reactions were carried out in 
DCM under inert atmosphere. 
 2-(Methylthio)ethanol (run 1 and 2) and its derivative 2-hydroxyethyl methyl sulfoxide (3) 
were the first alcohols used for the opening of the aziridine. Condition 1 used the alcohol as a co-
solvent meanwhile conditions 2 and 3 used it in large and small excess respectively. Unfortunately, 
no formation of product was observed for either of these conditions. In the runs 4, 5 and 6 I used 
the same alcohol but with different amount of equivalents and reaction times. In these runs, I 
obtained similar yields of the product by using either Cu(OTf)2 or BF3·OEt2 as Lewis acid. Higher 
yields were actually obtained when the alcohol was used in larger excess. Disappointingly, when I 





Scheme 15. Reagents and conditions: (i) NaOH 0.5 M, 1,4-dioxane; (ii) neat TFA, 1h 
 Despite the low yields, enough of the ether 66 was obtained to finish up the synthesis. The 
following step involved the hydrolysis of the ethyl ester and Boc-deprotection of the two amines 
by treatment with neat TFA. Compound 67 has a similar structure to oseltamivir but featured a 
secondary amine in the sidechain introduced at C-3 position. The reason to have an amine group 
in this position is to attempt binding of the basic moiety with the acidic Glu276 in a similar way as 
zanamivir does.  
 Compound 67 should be tested for inhibition of the neuraminidase activity of an H1N1 
virus in collaboration with Konvalinka’s group at the Institute of Organic Chemistry and 
Biochemistry of the CAS. 
3.1.1.2 Conclusions from Hudlicky’s approach 
1. I was able to follow and repeat the synthetic approach reported by Hudlicky. 
2. I investigated the key aziridine-opening step with different alcohols and under catalytic 
and stoichiometric conditions. 
3. A new oseltamivir derivative was synthesized and purified, the compound is 
undergoing testing. 
 Although I was able to complete the synthesis and prepare a promising new oseltamivir 
derivative we decided to abandon this approach due to the complexity of the reactions involved. 
Other important reasons that led to the discontinuation of this pursue were the low overall yield 
(19% from the 3-iododiol 62 to the aziridine 53), the limited scope of alcohols that were 




3.1.1.3 Shi’s approach  
 The second synthetic strategy used for the preparation of C-3 modified oseltamivir 
derivatives followed closely the approach reported by Shi et al. depicted in Scheme 3.74 The 
advantages of this approach stem from the simple chemical transformations that are utilized and 
the use of commercially available (-)-shikimic acid as a starting material. Another positive aspect 
is the rapid formation of key aziridine (only four steps from the starting material) and the 
introduction of the ether moiety at C-3 in the late stage of the synthesis. 
 The first three steps of the synthesis are identical to the ones described previously in 
Scheme 4 (page 35). Esterification of (-)-shikimic 38 acid under acidic conditions with ethanol 
yielded the ethyl shikimate 39 in 86% yield.103 The three hydroxyl groups were mesylated 
simultaneously using an excess of methanesulfonyl chloride and trimethylamine, the mesylated 
product 40 was obtained in quantitative yields (97%). Highly regioselective nucleophilic 
substitution at the allylic position by azido moiety can be achieved by carefully adding an aqueous 
solution of sodium azide to the mesylate meanwhile keeping the temperature always below 5 °C, 
the reaction gives the corresponding azide 41 with the (S)-configuration at C-3 in an 89% yield.  
 
 Scheme 16.  Compound 44 was transformed into 46 without isolation of the intermediates. Reagents and conditions. 
(i) SOCl2, EtOH; (ii) MsCl, Et3N, DMAP; (iii) NaN3, acetone/water, 0 °C; (iv) Ph3P, THF; (v) H2O, Et3N; (vi) Ac2O, 
Et3N, 51% overall yield. 
 Staudinger reduction of the azide 41 gave the free amine which in the presence of 
triethylamine undergoes nucleophilic attack at C-4 and closes the aziridine ring in situ. Aziridine 
42 was difficult to separate from the triphenylphosphine oxide by column chromatography. Shi and 
co-workers solved this problem by diluting the aziridine 42 in an acidic aqueous solution and 
extracting the triphenylphosphine oxide into the organic layer, the pH of the aqueous solution was 
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then set up to basic and the neutral aziridine was extracted to the organic layer. Low yields were 
always obtained by using this purification method hence I decided to submit the crude aziridine 
mixture for the acetylation step and purify it afterwards. By this method I was able to transform 
the azide 41 into the N-acetyl aziridine 43 in a 51% yield over the three chemical steps which is 
considerably higher than the yield obtained when the aziridine 42 was isolated. 
  
Scheme 17. The opening of the aziridine, alcohols used are depicted in table 2  
Alcohol N° Run Eq. Alc Lewis A. Eq. LA T (°C) t (h) Yield 
 1 10 BF3 ·OEt2 2 -40 16* - 
 
2 8 Cu(OTf)2 0.1 0 16* >10% 
 
3 10 BF3 ·OEt2 1.5 -40 1 60% 
 4 10 BF3 ·OEt2 1.5 -40 1 58% 
 5 10 BF3 ·OEt2 1.5 -40 1 64% 
 
6 10 BF3 ·OEt2 1.5 -40 16* - 
 
7 7 BF3 ·OEt2 2.5 -40 16* - 
Table 2. The columns represent (from left to right); structure of the alcohols, number of the run, equivalents of the 
alcohol, Lewis acid used, equivalents of the Lewis acid, temperature, time and yield. All reactions were carried out in 
DCM under inert atmosphere, BF3·OEt2 was used as 1.65 M in DCM. *The reaction was monitored for 1 h but no 
product was observed, therefore reaction was left overnight at r.t.  
 Once I had the key aziridine 43 in hands, I attempted the opening with 2-
(methylthio)ethanol (run 1). Unfortunately, as it happened for the previous aziridine 53, the 
reaction was unsuccessful. The reaction using a more complex alcohol (run 2) resulted in the 
formation of product but only in negligible quantities. On the other hand, when much simpler 
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alcohols were used (run 3, 4 and 5) I obtained the corresponding ether in fair yields. Increasing the 
complexity of the alcohols used led always to unsuccessful results as runs 6 and 7 demonstrate.  
 Due to the narrow range of alcohols that were suitable for the aziridine opening, we decided 
to change slightly our strategy and open the aziridine only with Boc-protected ethanolamine, 
propargyl alcohol, and allyl alcohol (runs 3, 4 and 5). The corresponding products (68, 79 and 81 
respectively) were supposed to be used as branching points for introduction of more complex 
moieties and will be described in the following paragraphs. 
 The ether 68 resulting from opening the aziridine with Boc-protected ethanolamine, was 
transformed into the corresponding azide 69 by nucleophilic substitution of the mesyl group in C-
5 with sodium azide, this second substitution was performed by refluxing in aqueous ethanol 
overnight in contrast with the C-3 substitution that needed low temperature and short reaction times 
to enhance the regioselectivity.  
 
 Scheme 18. Reagents and conditions. (i) NaN3, EtOH/H2O 5:1, reflux 24h, 81% yield; (ii) TFA/DCM 1:5, 1h; (iii) 
Ac2O, Et3N, 3h, r.t., 88% yield; (iv) nicotinoyl chloride hydrochloride, Et3N, 4h, 71% yield; (v) divinyl sulfone, 
Et3N, 3h, 60 °C, 89% yield; (vi) Boc-L-alanine, TBTU, Et3N, 16h, 58% yield. 
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 The amine of 69 was then de-protected by treatment with TFA, the free amine was used as 
a vector for introduction of several groups for the coverage of a broader chemical space. Namely, 
the free amine was treated with acid anhydrides, acyl chlorides, Michael acceptors and activated 
amino acids (Scheme 18). These reactions afforded the products 70-73. This “proof of concept” set 
of compounds showed that introduction of ethanolamine could be a viable and flexible vector for 
further derivatization at the C-3 position. 
 
Scheme 19. Reagents and conditions. (i) Lindlar catalyst (60 w%), 1 atm H2, EtOH, 3h r.t.; 
 (ii) NaOH 0.5M, 1,4-dioxane; (iii) neat TFA, 1h. 
 
 The furnished azides 70-73 were reduced by hydrogenation using Lindlar catalyst to 
prevent the hydrogenation of the C1=C2 double bond. The last step was the hydrolysis of the ethyl 
ester moiety by treatment with sodium hydroxide solution and further Boc-deprotection with TFA 
if needed (Scheme 19). Purification using preparative HPLC furnished five oseltamivir derivatives 
bearing polar sidechains at C-3 (Figure 25).  
 
Figure 25. Structure of five new oseltamivir derivatives. 
 On the other hand, the ether intermediate 79 obtained by opening the aziridine with 
propargyl alcohol was designed to be used for introduction of different sidechains via CuAAC 
(Scheme 20). In this case, the click reaction had to be done prior to the azide introduction at C-5. 
The reduction of the azide and hydrolysis of the ester steps were identical to the conditions 




Scheme 20. Reagents and conditions. (i) [Cu(CH3CN)4]PF6, TBTA, THF, 24 h, r.t., 77% yield; (ii) NaN3, EtOH/H2O 
5:1, reflux 24h, 37% yield; (iii) Lindlar catalyst (60 w%), 1 atm H2, EtOH, 3h r.t., 85% yield; (iv) NaOH 0.5M, 1,4-
dioxane, 57% yield. 
 Only one compound was synthesized following the CuAAC approach due to changes in the 
priority of the research. This method became the central work of one of my co-workers and further 
research is being done solely by him.  
 Lastly, the introduction of the allyl alcohol in C-3 position allowed us to perform 
asymmetric dihydroxylation of the double bound (Scheme 21). AD-mix-α was used for the 
dihydroxylation of olefin 82; the oxidized intermediate 83 was obtained in 61% yield. 
Unfortunately, when I attempted to reduce the azido moiety I have observed rapid hydrogenation 
of the double bond despite the fact that Lindlar catalyst was used. This could happen due to the 
presence of two vicinal hydroxyl groups which could bind tightly the catalyst and direct it towards 
C1=C2 double bond.   
  
Scheme 21. Reagents and conditions. (i) NaN3, EtOH/H2O 5:1, reflux 24h, 37% yield; (ii) AD-mix-α, t-BuOH/H2O 
1:1, 0 °C, 24h, 61% yield; (iii) Lindlar catalyst; (60 w%), 1 atm H2, EtOH, 3h r.t., 95% yield. 
 Due to time restriction and the project moving on, I had no time to improve the 
aforementioned approach utilizing allyl alcohol. The problems encountered with the reduction of 
the azide could apparently be solved by using Staudinger reduction instead of catalytic 
hydrogenation. 
 
3.1.1.4 Conclusions from Shi’s approach.  
1. I was able to follow and replicate the synthetic approach reported by Shi et al. 
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2. The yield of the aziridine formation step has been improved.  
3. Several alcohols were screened for the aziridine-opening reaction. 
4. Boc-protected ethanolamine, propargyl alcohol and allyl alcohol were proven to be suitable 
for the opening of the aziridine, further derivatization could be done allowing us to explore 
a broad chemical space. 
5. Six new C-3 modified oseltamivir derivatives were prepared, the compounds are 
undergoing testing at IOCB.  
The aforementioned approach represents a simple and efficient way for the synthesis of 
broad number of oseltamivir derivatives. Unfortunately, due to time restriction and the project 
moving on, a large library of oseltamivir derivatives has not been prepared. 
 
3.1.2 C-5 Modifications of oseltamivir 
 As described in the chapter discussing the 150-cavity, recent studies showed that the 150-
cavity is not only present in group A but also in group B neuraminidases. The so-called 150-loop 
is flexible and allows the cavity to adopts “open” and “closed” conformations.30 Molecules capable 
of binding the active site of NA and simultaneously interact with the aminoacids forming the 150-
cavity could feature better affinity towards particular subtypes of neuraminidases.  
 Modifications at position C-5 of oseltamivir have the objective of exploring the binding 
mode of new inhibitors to the 150-cavity without compromising the interactions with the NA 
catalytic site. The amine group located at C-5 in the oseltamivir structure is directed towards the 
cavity and therefore has been used as the modification site (Figure 8).  
3.1.2.1 1,2,3-Triazole derivatives 
 With the objective of preparing a set of C-5 modified oseltamivir derivatives in a short 
period of time, I designed a fast and efficient modular approach which relies on the introduction of 
several moieties via copper(I)-catalyzed alkyne-azide cycloaddition (CuAAC). Previous research 
highlighted the importance of having a basic group at carbon C-5. Hence I prepared the first set of 
C-5 oseltamivir derivatives that conserve the basic amine in this position. We postulated that direct 
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alkylation of the amine group with propargyl alcohol followed CuAAC reaction with a collection 
of azides could be a rapid way to achieve a broad number of derivatives. 
 Direct alkylation of amines usually leads to a mixture of products because the generated 
secondary amine retains its nucleophilicity and usually react rapidly with a second equivalent of 
alkylating agent. After a short screening of conditions for the alkylation of oseltamivir phosphate 
(Table 3), I was able to obtain the mono-propargylated oseltamivir 85 in reasonable yields 
minimizing the formation of side-products.    
 
Scheme 22. Alkylation of oseltamivir phosphate 
Table 3. *DMF was mixed with powdered molecular sieves 4 Å. **1.2 equivalents of propargyl bromide were used, 
the reaction was stirred 24h at r.t. followed by addition of 0.1 eq. of propargyl bromide and heating to 50 °C for 4 h. 
 Propargylated oseltamivir 85 was combined with a series of azide-containing fragments by 
CuAAC. For this click reaction, I used an excess of copper(II) sulfate pentahydrate which was 
reduced in situ to Cu(I) by sodium L-ascorbate. The resulting crude triazole intermediates were 
directly hydrolyzed and after purification by preparative HPLC, the desired set of C-5 oseltamivir 
derivatives was obtained.  
  
Scheme 23. Reagents and conditions. (i) CuSO4·5H2O, (+)-sodium L-ascorbate, THF/H2O 2:1, 45 °C, 2h; (ii) NaOH 
0.5 M, 1,4-dioxane, 2h, r.t. 
Base Base Eq. Reagent Eq. Solvent Temp. (°C) Time (h) Yield 
K2CO3 3 1 CH3CN r.t. 24 40 % 
K3PO4 3 1 CH3CN r.t. 24 24 % 
K2CO3 5 1 CH3CN r.t. 24 63 % 
LiOH 3 1.2 DMF* r.t. 24 33 % 
K2CO3 5 1.2 + 0.1** CH3CN r.t. then 50 °C 24 + 4 65 % 
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1 1.2 2 5 55% 
 
2 1.2 2 5 21% 
 
3 1.2 2 5 48% 
 
4 1.2 2 5 45% 
 
5 1.2 2 5 30% 
 
6 1.2 2 5 12%** 
Table 4. Azides and conditions used for the CuAAC reaction. *Yields after hydrolysis of the ester moiety and 
preparative HPLC purification. **The yield corresponds to the free acid formed by hydrolysis of the amide.  
 The employed azide-containing synthons possess either hydrogen bonding donor or 
hydrogen bonding acceptor moieties. All the CuAAC reactions generated the desired products 
(showed in Figure 26). Unfortunately, during the hydrolysis of the ester in run 6 I observed the 
hydrolysis of the amide from the morpholine ring. The unexpected free carboxylic acid 91 was 
identified, isolated and submitted for testing with the other derivatives since it could also be a valid 
inhibitor candidate. 
 Compounds 86 and 87 (Figure 26) differ in their ability to participate in hydrogen bonding 
with the residues from the cavity. Compounds 88 and 91 present the same short chain but differ in 
the oxidation state of the terminal functional group. Finally, compounds 89 and 90 bear much 
bulkier substituents which could fit tighter into the cavity helping to delimitate the size of it. We 
intended to use these derivatives to shed light on the mode of binding to the 150-cavity. These 
compounds are undergoing testing at Konvalinka’s group in IOCB, the results will be soon 




Figure 26. Structures of the C-5 oseltamivir derivatives synthesized using the CuAAC approach. 
 The other possible approach, in which the oseltamivir core bears the azido moiety and the 
fragment introduced contains the triple bond was also attempted. Although the binding activity 
could be impaired by replacing the basic amine group with a triazole moiety, we decided to 
synthesize some of these derivatives and observe how this modification affects the binding. The 
first step was to transform oseltamivir phosphate into the azide 92 by treatment with diazo-transfer 
reagents. Imidazole-1-sulfonyl azide hydrochloride and 2-azido-1,3-dimethylimidazolinium 
hexafluorophosphate were prepared according to the literature and successfully used for the 
synthesis of 92 (Scheme 24).104,105 
 






Scheme 25. Reagents and conditions. (i) CuI, DIPEA, toluene, 2h, 91% yield; 
(ii) NaOH 0.5M, 1,4-dioxane, 24 h, r.t., 85% yield. 
 After CuAAC with propargyl alcohol I obtained the triazole 93 in quantitative yields, 
further hydrolysis of the ethyl ester group to the acid furnished the new neuraminidase inhibitor 94 
(Scheme 25). Although the inhibition potency of 94 was nearly 20 times worse than oseltamivir, 
the crystal structure of the inhibitor binding to the catalytic site of neuraminidase was obtained 
(Figure 27). This crystal structure as well as the binding activities of the inhibitors designed to bind 
the 150-cavity will be published in the form of a research publication.  
 
Figure 27. Crystal structure of the 94 (shown as a stick model) binding to the active site of neuraminidase 
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3.1.2.2 Alkylation at the C-5 amine 
 The amine at carbon C-5 is the most nucleophilic moiety present in the oseltamivir 
structure. Therefore, it could be selectively used to produce a broad number of oseltamivir 
derivatives in a direct and straightforward way. Unsurprisingly this approach has been extensively 
studied in the past and many C-5 derivatives have been reported,106-110 nevertheless in this section 
we describe the synthesis of some new C-5 derivatives that were prepared. The prepared inhibitors 
were intended to be used to demonstrate the validity of DIANA assay as a screening method. 
Moreover, a set of well-known inhibitors of neuraminidase had to be prepared to compare the 
inhibition values obtained from our assay with the previously published data based on fluorometric 
enzyme (MUNANA) assay.   
 
Scheme 26. Reagents and conditions. (i) Ethyl 2-bromopropionate, NaHCO3, 73% yield; (ii) 0.5 M NaOH, 1,4-
dioxane; (iii) 4-nitrobenzoyl chloride, Et3N, 36% yield; (iv) NaHCO3, dimethyl maleate, 75% yield; (v) 2-[2-(2-
methoxyethoxy)-ethoxy]acetic acid, TBTU, Et3N, DMF, 93% yield; (vi) 0.5 M NaOH, 1,4-dioxane, 70% yield. 
 Treatment of oseltamivir phosphate with ethyl 2-bromopropionate under basic conditions 
produced a mixture of the two diastereomers 95 and 96. After their separation from each other 
followed by saponification of the ester, the diastereomers 97 and 98 were obtained in 38% and 34% 
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yields respectively. In order to determine the absolute configuration of the diastereomers I 
attempted several crystallization experiments. Unfortunately, no suitable monocrystal of 
compound 98 for X-ray analysis has been obtained. We decided to solve this issue by introducing 
a group that facilitates the crystallization. Hence compound 99 was prepared, which eventually 
yielded a suitable monocrystal whose X-ray structure (depicted in Figure 28) revealed the absolute 
configuration. 
 
Figure 28. Crystal structure of compound 99. The stereogenic center is depicted in yellow color (R). 
 When oseltamivir phosphate was alkylated with dimethyl maleate I obtained 100 as an 
inseparable mixture of diastereomers, after hydrolysis of the ester the free acid 101 was obtained 
and used as a diastereomeric mixture.  
 In the case of the next inhibitor, we intentionally decreased the basicity at C-5 by forming 
an amide at carbon C-5. This poor inhibitor was prepared to demonstrate the viability of DIANA 
assay on a broader range of Ki values. In this case, oseltamivir phosphate was submitted to standard 
amide coupling with 2-[2-(2-methoxyethoxy)ethoxy]acetic acid using TBTU as the coupling agent, 
subsequent hydrolysis of the ester gave the compound 103 in 65% overall yield.   
 The last inhibitor that was prepared by C-5 modification was the oseltamivir analogue 105 
which is a well-known and potent neuraminidase inhibitor firstly prepared by Gilead Science in 
2000 (Scheme 27).111 Compound 105 was prepared to provide a comparison between the inhibition 





Scheme 27. Reagents and conditions. (i) N,N’-di-(tert-butoxycarbonyl)thiourea, HgCl, Et3N, DMF, 24 h, 89% yield; 
(ii) NaOH 0.5 M, 1,4-dioxane, 24 h, 48% yield; (iii) TFA, 1h, r.t., 43% yield. 
 The binding constants of the inhibitors reported in this section will be discussed in the 
upcoming chapter covering the synthesis of detection probe suitable for DIANA assay. 
3.1.3 C-1 Modifications (Tamiphosphor) 
 Tamiphosphor is a well-known bioisostere of oseltamivir which presents enhanced potency 
and high selectivity. Oseltamivir derivatives bearing other bioisosteres of carboxylic acid at C-1 
have been reported but none showed better binding activities than tamiphophor (Figure 29).95  
 




 Tamiphosphor plays a pivotal role in this Thesis since it was used as a cornerstone 
compound to prepare particular neuraminidase inhibitors as well as to prepare the detection probes 
for the development of DIANA assay. Moreover, a tamiphosphor derivative was also used for the 
construction of a polymeric material that could be used in the treatment of patient in life-treating 
condition. This side-project is not cover by the Thesis since we do not want to disclose our findings 
at this time. 
 The first synthetic approach that I empoyed for preparation of tamiphosphor 55 was 
inspired by the work reported by Streicher (see Scheme 7, page 38). Even though Streicher’s 
procedure (which features a decarboxylative halogenation of the azide intermediate 57) was quite 
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optimal, a more convenient synthesis could be done by using commercially available oseltamivir 
phosphate 34 as the starting material instead of the azide intermediate 56 used by Streicher. 
 Tamiphosphor 55 was prepared in my case from commercially available oseltamivir 
phosphate 34. The synthesis starts with free basing of oseltamivir followed by protection of the 
amine at carbon C-5 with Boc-anhydride. The ethyl ester 106 was then hydrolyzed to form the 
corresponding free acid 107 in quantitative yields (Scheme 28). 
 
Scheme 28. Reagents and conditions. (i) NaHCO3/H2O; (ii) Boc2O, Et3N, 98% yield; 
 (iii) 0.5 M NaOH, 1,4-dioxane, 95% yield. 
 
 The following step is the decarboxylation of 107; the conditions used by Streicher92 
(Vilsmeier reagent and N-hydroxypyridinethione) were initially attempted but gave low yields. An 
alternative approach described by Gunasekera was subsequently explored.112 In this case, the 
decarboxylative halogenation was done via formation of a standard Barton ester intermediate 
(Scheme 29). Although the reaction was successful I decided to optimize and simplify the 
procedure.  
 The conditions used for the Barton decarboxylation are summarized in Table 5, in all cases 
the Barton thioester was formed by activating the acid with coupling agents. Once formed, the 
Barton thioester undergoes radical decarboxylation upon irradiation with a flood lamp which 
produces a vinyl radical. This free radical could be trapped with a halide from the solvent to yield 
the corresponding vinyl bromide or vinyl iodide (110 and 111).  
Mercaptopyridine N-oxide was firstly used for the Barton ester formation with different 
coupling reagent. The coupling with propylphosphonic anhydride and HBTU were unsuccessful 
(run 1 and 3) meanwhile TBTU gave low yields (run 2). When 2-mercapto-4-methylthiazole 3-
oxide was used instead of 2-mercaptopyridine (run 4) a significant improvement in the yield was 
observed. S-(1-Oxido-2-pyridyl)-N,N,N′,N′-tetramethyl-thiuronium hexafluorophosphate (also 
known as HOTT) is a coupling reagent which contains the 2-mercaptopyridine N-oxide part and 
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could be used to form the Barton ester in a much straightforward way. After a short optimization 
(runs 5, 6, and 7) I was able to obtain the desired vinyl bromide 110 and vinyl iodide 111 by using 
CBrCl3 or 2,2,2-trifluoroiodoethane as radical trapping agents, respectively. Higher yields were 
obtained when the decarboxylation step was performed without the presence of the radical initiator 
AIBN and using CBrCl3 as radical trapping agent (run 7). 
 
Scheme 29. A. Formation of the Barton ester of oseltamivir B. Radical decarboxylation step.     
Table 5.  Conditions for the Barton ester formation A and for the radical decarboxylation B. Yields over two steps 
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 The carbon-phosphorous bond was introduced via palladium-catalyzed Hirao coupling of 
the bromide 110 with dimethyl phosphite, which afforded the dimethyl phosphonate 60 in very 
good yield (Scheme 30). Vinyl iodide 111 was also successfully used for Hirao coupling with 
comparable efficiency to the bromide.  When 0.15 equivalents of palladium catalyst were used 
erratic yields were observed, this problem was solved by increasing the catalyst loading to 0.3 
equivalents that gave consistently yields around 80%.  
 
Scheme 30. Reagents and conditions. (i) Dimethyl phosphite, Pd(PPh3)4, Et3N, 80 °C, 90 min, 86% yield.  
 
 The dimethyl ester 60 was selectively mono-O-demethylated by treatment with sodium 
hydroxide solution in 1,4-dioxane. This mild reaction afforded compound 61 in quantitative yields. 
Intermediate 61 could be either further demethylated and deprotected to yield tamiphosphor 55 or 
just Boc-deprotected to yield O-methoxytamiphosphor 114 (Scheme 31).  
 
   
Scheme 31. Reagents and conditions. (i) TFA; (ii) N,N’-di-Boc-1H-pyrazole-1-carboxamidine, Et3N, 47% yield; (iii) 
TMSBr, DCM, 21% yield; (iv) NaOH 0.5M, 1,4-dioxane, 18h r.t., 91% yield; (v) TFA/H2O, 43% yield of compound 
114; (vi) TMSBr, 2,6-lutidine; (vii) TFA/H2O. 
 The parental compound 60 was also used to produce the known inhibitor 113. One pot 
deprotection of the amine followed by installation of the guanidium moiety furnished 112 which 
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was treated with trimethylsilyl bromide to afford fully deprotected compound with the guanidinium 
moiety. Naturally, all prepared compounds were purified by preparative HPLC and submitted for 
biochemical tests. 
 Kinetic analysis of the binding between the compounds depicted in Figure 30 and pandemic 
A/California/07/2009 (H1N1) influenza virus (NA2009wt) was done by Dr. Milan Kožíšek from 
Konvalinka’s group. The results show that oseltamivir carboxylate 34 and tamiphosphor 55 had 
equal affinity for NA2009wt. It also proved that a negative charge at carbon C-1 is fundamental as 
the low Ki value of ethyl ester 34 indicates. From the inhibitory potency of 114, we could extract 
that introduction of methoxy group as replacement of one hydroxyl from the phosphonic acid has 
a negligible effect on the binding activity which is in full agreement with Streicher and Fang 
findings. Replacement of the amine at C-5 by guanidine moiety did not produce an improvement 
in the inhibition.  
 
Figure 30. Oseltamivir derivatives (A) and tamiphosphos derivatives (B). The inhibition constants were determined 
by fluorimetric assay 
 The first crystal structure of tamiphosphor with the catalytic domain of neuraminidase 
(NA2009wt) was resolved by our collaborators Dr. Milan Kožíšek and Dr. Pavlína Maloy 
Řezáčová at 1.8 Å resolution (Figure 31). They used for his pioneering work tamiphosphor 
prepared by me. 
 The synthesis of the compounds showed in Figure 30 as well as their binding activities were 
published by us in 2016. The publication also included the crystal structure of tamiphosphor and 
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neuraminidase complex (Figure 31) as well as the first thermodynamic characterization (ITC) of 
the binding mode of oseltamivir carboxylate and tamiphosphor to neuraminidase.  
Albiñana, C. B.; Machara, A.; Řezáčová, P.; Pachl, P.; Konvalinka, J.; Kožišek, M. Kinetic, 
thermodynamic and structural analysis of tamiphosphor binding to neuraminidase of H1N1 (2009) 
pandemic influenza. European Journal of Medicinal Chemistry. 2016, 121, 100-109.113  
https://doi.org/10.1016/j.ejmech.2016.05.016 
 
Figure 31. A) Detail of the crystal structure of tamiphosphor in complex with NA2009wt; all residues interacting with 
the inhibitor are shown. The 2Fo-Fc electron density map for the inhibitor contoured at 1.0 σ is shown. B) Hydrogen 
bonding comparison between tamiphosphor and oseltamivir carboxylate (from PDB entry 3TI6, in black).  
 
 The crystal structure of tamiphosphor binding to the catalytic site of neuraminidase showed 
that tamiphosphor and oseltamivir carboxylate have comparable interactions with the active site 
which is in concordance with the almost identical binding constants. Only one significant 
difference was found; the third oxygen of the phosphonate, which is exposed to the solvent, forms 
a water-mediated contact with Asp151 side chain. The structural information obtained for the 
interaction of tamiphosphor with NA was used in the design of second-generation inhibitors as 






3.2 Design and synthesis of the Probes  
 The second part of this Thesis is focused on the synthesis of probes suitable for the 
development of several screening assays. At first, let us define what is a probe; according to 
Arrowsmith and co-workers: “probes are small-molecule modulators of a protein’s function that 
allow the user to ask mechanistic and phenotypic questions about its molecular target”.114 The 
probes are indispensable tools for medicinal as well as biological chemists since they enable 
visualization, advanced imaging, identification and quantification of the enzymes based on their 
specific activity in vivo and in situ. Furthermore, they could be used for efficient and high-
throughput inhibitor testing. 
The probes described in this work share the same general structure (Figure 32); a binding 
head based on the structure of a well-known inhibitor (ligand), a spacer usually made of 
polyethylene glycol linkers and an anchor group, usually a bioorthogonal functional group (azide) 
or a small molecule able to conjugate proteins (biotin). These probes have been used for the 
development of different assays for testing the activity of small molecules against influenza’s 
neuraminidase, PA-endonuclease and PB2 cap-binding domain. 
 
 Figure 32. General structure of the detection probes prepared 
3.2.1 Oseltamivir-based probes for DIANA assay 
 One of the fundamental requisites for the design of probes suitable for DIANA assay is that 
requires separation of the tethered sialylmimetic (the enzyme binding site) from the oligonucleotide 
part by a linker of sufficient length. The linker should end up with a bioorthogonal functional group 
capable of ligation to the oligonucleotide. Since the ligation reaction is done by strain-promoted 
alkyne-azide cycloaddition (SPAAC) the functional group required is an azide (Figure 22).  
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 Oseltamivir was firstly selected as the sialylmimetic part of the detection probe since the 
nitrogen atom at carbon C-5 of oseltamivir is a highly convenient exit vector. This primary amine 
could be easily alkylated as we showed in the chapter dealing with C-5 oseltamivir derivatives. 
For the synthesis of our first probe, we used commercially available oseltamivir 
phosphonate as starting material. Standard alkylation with N3-PEG4-I agent (Scheme 32) under 
basic conditions gave the compound 115. The linker was prepared in our lab from tetraethylene 
glycol following reported procedures. After saponification of the ester functional group, the probe 
116 was obtained in moderate yields.  
 
Scheme 32. Reagents and conditions. (i) NaHCO3; (ii) 1-azido-2-(2-(2-(2-iodoethoxyl)ethoxy)ethoxy)ethane, Et3N, 
24h, 60% yield; (iii) NaOH 0.5M, 1,4-dioxane, 24 h, 83% yield. 
 Compound 116 was tested for its use in DIANA assay but provided a deficient sensitivity 
not suitable for the assay, this could be because the amine at C-5 points towards the 150-cavity and 
not into the solvent and therefore no space is available to accommodate the tethered 
oligonucleotide.    
3.2.2 Tamiphosphor-based probes for DIANA assay 
 Using the amine at the carbon C-5 of oseltamivir structure as an exit vector for installation 
of the linker gave unsatisfactory results. Consequently, we decided to change our strategy for the 
synthesis of probes suitable to DIANA assay. Our previously reported crystal structure of the 
tamiphosphor complex with neuraminidase showed that the third oxygen atom of the phosphonate 
functionality is heading out of the enzymatic site and is not engaged in any direct interactions with 
protein residues.113 We postulated that tamiphosphor could be used as a valid sialylmimetic for the 
construction of the probe, the phosphonate group would allow us to simultaneously introduce the 
connection of the linker at position C-1 and keep the fundamental negative charge. 
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  As I described in the introduction and as I noted in previous chapters, a negative charge at 
carbon C-1 is indispensable for the inhibition activity. Streicher and co-workers firstly reported 
that monoalkyl phosphonates retain inhibitory potency comparable to oseltamivir.92 Later on, he 
reported a solution for tethering of tamiphosphor without impairing its binding potency.94 The 
compound synthesized by Streicher was ω-hexylazido tamiphosphor 117.  We decided that there 
was no need to introduce changes in its structure since it meets all the requirements to be a valid 
recognition probe for DIANA. 
3.2.2.1 Design and synthesis of ω-hexylazido tamiphosphor 
 For the preparation of ω-hexylazido tamiphosphor I initially used the key mono-
demethylated intermediate 61, which was prepared in the synthesis of tamiphosphor (see the 
chapter about tamiphosphor) from oseltamivir phosphate (Scheme 33). 
 
Scheme 33. Strategy for the synthesis of a tamiphosphor-based detection probe for DIANA.   
 In an effort to obtain the dimethyl phosphonate 60 in a more efficient manner I 
experimented with the direct conversion of the Barton thioester into the phosphonate. Photo-
Arbuzov reactions were firstly reported back in 1966; aryl iodides were used as starting material 
which upon irradiation form an aryl radical that can be trapped with a phosphite which after 




Scheme 34. A. Old route for the conversion of carboxylate 107 into phosphonate 60 via vinyl bromide formation and 
palladium catalyzed C-P bond formation; B. New one-pot conversion of Barton’s thioester into phosphonate via photo-
Arbuzov reaction. The proposed mechanism is depicted inside the dashed box.  
 We postulated that by irradiation of the Barton thioester we would form a vinyl radical via 
homolytic cleavage of the thioester and radical decarboxylation. The vinyl radial could be then 
directly trapped with trimethyl phosphite to form the phosphonate 60 (Scheme 34). This would be 
an important shortcut in the synthesis of tamiphosphor and would avoid the palladium catalyzed 
C-P bond formation. Following this approach, we could be able to transform the unsaturated 
carboxylic acid 107 into the unsaturated phosphonate 60 in one-pot procedure. Only one method 
has been published so far for this specific transformation which uses nickel catalyst for the 
decarboxylation and C-P cross-coupling step.116 A recent publication reported a transition-metal-
free C-P bond formation using several phosphine oxides but failed to introduce diethyl phosphonate 
moiety.117  
 The Barton thioester was prepared in situ from the free acid 107 using the highest yielding 
condition developed during my synthesis of tamiphosphor (Scheme 35). The solvent was then 
evaporated and four different sets of conditions were attempted for the radical decarboxylation and 
photo-Arbuzov reaction (Table 6). The desired product was formed under all four conditions but 
in unimpressive yields. Use of radical initiator AIBN and tris(trimethylsilyl)silane did not lead to 
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a substantial improvement of the yield (run 2 and 4). Slightly higher yields were obtained when 
triethylphosphite was used although still were in 30 – 40 % range.  
 
Scheme 35. The thioester was formed as previously described. Conditions for the radical decarboxylation and photo-
Arbuzov descrived in Table 6. Reagents and conditions. (i) HOTT, Et3N, THF, 1 h, r.t.; (ii) see Table 6. 
Table 6. Trimethyphosphite and triethylphosphite were used as radical trapping agents. The importance of using 
radical initiator AIBN and tris(trimethylsilyl)silane was explored (compare 1 and 2, 3 and 4).   
 Although the reaction produced the desired product and shortened the synthesis in one step, 
due to the project moving on I could not carry on with the optimization. Although the best yield 
obtained for the photo-Arbuzov reaction (run 4) was slightly inferior in comparison to the previous 
approach (decarboxylation followed by Pd-catalyzed C-P bond formation) proper optimization of 
the reaction conditions could lead to a novel and straighforward method for synthesis of unsaturated 
dialkyl phosphonates.  
 The key intermediate O-methyl tamiphosphor 61 (Boc-OMT) was prepared again from 
derivative 60. Direct alkylation of the phosphonate 61 always gave 119 in underwhelming yields. 
More extensive examination of the reaction showed that the alkylated product lacking the methyl 
ester moiety 120 was formed as a side-product (Scheme 36). This was an exciting surprise since 
any increasing of the side-product 120 formation would shorten the synthesis in one step and would 
avoid the use of thiophenol for the second O-demethylation step, which is problematic due to its 
pungent odor. 
N° Run Phosphite 
Eq. 
Phosphite 
Eq. AIBN Eq. TTMSS Solvent Yield 
1 P(OMe)3 15 - - Tol/DCM 28 % 
2 P(OMe)3 15 0.15 1.3 Tol/DCM 29 % 
3 P(OEt)3 15 - - Tol/DCM 32 % 




Scheme 36. Reagents and conditions. (i) 1-azido-6-bromohexane, Et3N, DMF, 40 °C, 25% yield; (ii) PhSH, Et3N, 3 
days; (iii) KOTMS, Et2O, 16 h, 77% yield; (iv) 1-azido-6-bromohexane, NaI, Et3N, DMF, 60 °C, 56% yield; (v) 
TFA, 1h. 
 We hypothesized that under the applied conditions the desired alkylation was followed with 
O-demethylation by the action of the free bromide anion coming from 1-azido-6-bromohexane. 
We expected that using catalytic amounts of sodium iodide would facilitate this transformation 
since iodide is a better leaving group than bromide and has comparable nucleophilicity. Increased 
temperature and longer reaction times also favored the formation of 120 but O-demethylation of 
119 has never reached full completion. Although I was able to obtain 120 in around 50 % yields 
from 61 the reaction was not thoroughly optimized due to lack of time.    
 The selective second O-demethylation of 119 was firstly accomplished by treatment with 
thiophenolate but underwhelming yields were obtained. Besides, thiophenol is an uncomfortable 
reagent to work with.  Potassium trimethylsilanolate has been reported as a mild and selective O-
demethylating reagent for phosphonates.118 When potassium trimethylsilanolate was employed the 
desired phosphonate 120 was obtained in excellent yield and the reaction set-up was substantially 
simplified.  
 After Boc-deprotection of 120 by treatment with trifuoroacetic acid (TFA), a mixture of the 
diastereomeric monoalkyl esters of 117 was obtained. This is because the phosphorus atom 
represents an additional stereogenic center. Separation of the diastereomers was not observed on 
analytical HPLC and therefore they were used as such. 
 
3.2.2.2 Results obtained from ω-hexylazido tamiphosphor 
 In our previous work we reported the crystal structure of the catalytic domain of NA2009wt 
with tamiphosphor (Figure 31),113 this work will be extended in an upcoming publication where 
we reveal the crystal structures of methyl- (114) and ω-hexylazido tamiphosphor (117) with the 
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catalytic domain of neuraminidase (Figure 34). Analysis of the complex of 114 with NA showed 
that the methyl ester moiety points outside from the active site which is also the case for the more 
sophisticated compound 117 in which the ligand extension leads directly into the solvent. This 
could explain the almost identical inhibitory potency obtained for the two compounds.  
 
 Figure 33. Structure of the inhibitors that were co-crystallized with the catalytic domain of NA2009wt 
 In the following-up publication, we demonstrate that DIANA assay employing compound 
117 is a new, reliable and rapid screening method for candidate inhibitors of influenza 
neuraminidase. The preparation of the detection probe ω-hexylazido tamiphosphor was reported in 
this publication as well as the crystal structures shown in Figure 34. Furthermore, a comparison of 
the binding constant for various inhibitors tested by DIANA assay with results from the standard 
fluorometric assay (which uses MUNANA as a substrate) was also reported (Table 7). 
Kožíšek, M.; Navrátil, V.; Rojíková, K.; Pokorná, J.; Albiñana, B.C.; Pachl, P.; Zemanová, J.; Machara, A.; 
Hudlický, J.; Císařová, I.; Řezáčová, P.; Konvalinka, J. DNA-linked Inhibitor Antibody Assay (DIANA) as a new 




Figure 34. Crystal structure of NA2009wt in complex with compound 114 (A) and compound 117 (B, C). Compounds 
are shown as stick models and carbon atoms are yellow, oxygen atoms are red, nitrogen atoms are blue, and phosphorus 
atoms are orange. In panel A, tamiphosphor molecule from the previous paper is overlaid and colored black.119 In panel 




Table 7. Results of inhibition constants determined by enzyme kinetics and DIANA assay. Fold Ki parameter 
represents the ratio Ki (DIANA; pH 7.4)/Ki (enzyme kinetics; pH 6.15).  
Compound Chemical formula 
Ki (enzyme kinetics) 
(pH 6.15) [nM] 
Ki (DIANA) 





24 ± 5 33 ± 8 1.4 
55 
 
26 ± 4 52 ± 9 2.0 
114 
 
39 ± 1 100 ± 20 2.6 
35 
 
24 ± 4 31 ± 6 1.3 
34 
 
2 100 ± 200 2 000 ± 500 1.0 
113 
 
140 ± 30 570 ± 180 4.1 
105 
 
46 ± 12 570 ± 200 12 
97 
 
15 ± 2 170 ± 70 11 
98 
 
250 ± 40 960 ± 260 3.8 
101 
 
13 000 ± 1 000 16 000 ± 5 000 1.3 
103 
 
43 000 ± 11 000 210 000 ± 110 000 5 
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 Here a brief summary of the conclusions we extract from the binding potency of the tested 
compounds is provided: tamiphosphor 55, methyl tamiphosphor 114 and ω-hexylazido 
tamiphosphor 117 have comparable potency to oseltamivir carboxylate 34, which validates our 
decision of using the phosphonate moiety of tamiphosphor as a way to introduce the linker without 
disrupting the binding affinity. Contrary to previously published data,120,109 replacement of the 
amine at C-5 by a guanidine group did not cause an improvement in the binding affinity. The S 
diastereomer 97 is significantly more potent than the R diastereomer 98, and it’s the only inhibitor 
prepared by us which presents superior inhibition values than oseltamivir carboxylate 35. The much 
bulkier substituent in 101 is not well tolerated and obstructs the binding. Unsurprisingly, the 
presence of a non-basic moiety at C-5 in 103 impaired the binding activity of the inhibitor. The 
reason behind the synthesis of compound 103 was to validate the DIANA assay for a very weak 
inhibitor, we observed that even in the micromolar Ki range the data obtained by DIANA fits well 
with the data provided by standard MUNANA assay. The observed deviation in the Ki data 
provided by both assays could be explained by the different pH used in both methods.  
3.2.2.3 Elongated ω-hexylazido tamiphosphor 
 Inspired by the promising results obtained with ω-hexylazido tamiphosphor, we decided to 
extend the application of this probe and use it in a different side-project.  
 In short, the aim was to decorate a polymeric material with a neuraminidase inhibitor. The 
inhibitor-containing polymer is supposed to enhance the pharmacological properties of the 
bounded tamiphospor and the material is intended to be administrated to patients in life-treating 
stages of influenza’s infection.  
 ω-Hexylazido tamiphosphor was firstly used to coat the polymeric material. Unfortunately, 
its antiviral activity was unsatisfactory presumably due to the insufficient length of the linker. 
Likely, the tethered inhibitors remained in close proximity to the polymer which hinders the 
binding to neuraminidase. Therefore, elongation of the linker was needed for a better antiviral 
activity. Thus, a facile one-pot elongation of Boc-protected ω-hexylazido tamiphosphor 120 was 





Scheme 37. Reagents and conditions. (i) Lindlar catalyst, H2 (1 atm), MeOH, 5 h, r.t.; (ii) NHS-PEG6-N3, Et3N, 
DMF, 24 r.t.; (iii) TFA, 1h, r.t., 42% yield. 
 The synthesis begins with the reduction of the azido moiety in 120 to form the free amine. 
Catalytic hydrogenation was selected as the right reduction method because it allowed us to 
produce the free amine without the need for further purification. Lindlar catalyst was used to avoid 
possible hydrogenation of the cyclohexene ring. Once the reaction was completed, the catalyst was 
filtered out and the solvent was evaporated. The crude product was dissolved in DMF and treated 
with the commercially available linker N3-PEG6-NHS ester. Finally, the reaction mixture was 
treated with an excess of trifluoroacetic acid to deprotect the amine. Purification via preparative 
HPLC afforded the tamiphosphor with the long linker 121 in 41% overall yield (from 120).  
 Compound 121 was then used for the design of potential anti influenza compounds based 
on active small molecules conjugated to a polymeric scaffold. Preliminary tests of the prepared 
drug candidates tested on influenza infectivity showed promising antiviral activity.  
 
3.2.3 VX-787-based probe for DIANA assay 
 Turning a well-known neuraminidase inhibitor into a probe allowed us to develop a simple 
and reliable assay for screening of low-molecular-weight inhibitor (sialylmimetics). Encouraged 
by the results obtained from the neuraminidase project, we decided to use the same approach to 
develop a DIANA assay that allows us to screen low-molecular-weight inhibitors of a different 
vital enzyme of influenza.  
 We realized that only limited number of compounds that interact with the cap-binding 
domain of PB2 in RNA-polymerase have been reported so far. Therefore, we decided to broaden 
the knowledge in this topic by developing an assay for screening of new inhibitors of the cap-
binding domain of PB2. One of the reported inhibitors (VX-787, 28) showed extreme potency and 
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high selectivity for PB2 cap-binding domain. Its outstanding properties51 makes VX-787 (28) a 
perfect candidate for conversion into a detection probe. 
  Moreover, the crystal structure of 28 binding to the active site of PB2 has been characterized 
(Figure 14, page 27)51. This fact allowed us to meticulously study its binding mode and determinate 
a suitable position for attachment of the linker (exit vector) without compromising the inhibitory 
activity. The fluorine atom at the pyrimidine ring points directly outside of the catalytic site of PB2, 
thus we hypothesized that attachment of the linker at this position would not interfere with the 
binding potency (Figure 35). 
  
Figure 35. Structure of the VX-787 (on the left) and proposed exit vector 
 for the design of the probe (on the right). 
 
 Unlike in the synthesis of ω-hexylazido tamiphosphor, where I started from a commercially 
available inhibitor and systematically modified its structure, for the conversion of VX-787 to the 
desired probe I had to synthesize the inhibitor/probe from few commercially available building-
blocks. 
 Not one, but actually two similar probes which differ only in the anchor group at the end of 
the linker had to be prepared for the development of the assay. One probe had to possess a biotin 
group which makes it suitable for SPR assay (Surface Plasmon Resonance). The other had to bear 
a linker ending with an azido moiety required for the ligation to the oligonucleotide. The first probe 
will be used for testing the binding activity of the molecule to the catalytic site of PB2 and shall 
confirm that the affinity for the enzyme was not disrupted. The second probe will be used as the 
actual detection probe in the DIANA assay.  
In Figure 36 we proposed a modular synthesis for 122 in which synthons A, B and D were 
prepared in parallel and then were sequentially introduced to the core fragment C, which is 
commercially available. To sum it up, compound 122 was selected as our target molecule, it was 
 
80 
intended to function as a common intermediate that can be directly converted into both probes in 
the last step of the synthesis. 
 
 
Figure 36. Brief retrosynthetic analysis. On the left, structure of the target molecule 122 showing how the connection 
of the synthons could be done. On the right, depiction of the structures of the four key synthons needed for the 
construction of compound 122. Note, alphabetical descriptors of each synthon.  
  
3.2.3.1 Preparation of synthon A 
 For the synthesis of synthon A (123), I loosely followed a patented procedure developed 
by Vertex Pharmaceuticals for the large-scale preparation of VX-787.121 The procedure had to be 
adapted to the milligram-gram scale with notable differences introduced.  
 2-Amino-3-bromo-5-fluoropyridine 127 was chosen as the starting material. The synthesis 
begins with formation of the 7-azaindole derivative 130 (Scheme 38). Two pathways were 
investigated to get 130; in both of them a Pd-catalyzed reactions were involved. The Heck pathway 
starts with one-pot condensation of the aminopyridine 127 with acetaldehyde to form the respective 
enamine which under the applied conditions and in the presence of a palladium pre-catalyst, 
undergoes intramolecular Heck reaction to furnish the azaindole 128. The catalyst and ligand used 
in the patent, bis(dibenzylideneacetone)palladium(0) and tri-tert-butyl phosphine, were not 
convenient for small scale synthesis. Thus, I decided to replace it by Buchwald precatalysts. 
Reaction with tBuXPhos Pd G1 complex gave 128 in 25 % yield. When the catalyst was changed 
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to tBuXPhos Pd G3 complex the yields rose to 61 %. The azaindole was then tosylated under basic 
conditions to form compound 130 in a 54 % overall yield for the two steps.  
 
Scheme 38. Reagents and conditions. (i) tBuXPhos Pd G3, DABCO, TBAB, DMSO/EtOAc, 75 °C, 24h, 63% yield; 
(ii) NaH, TsCl, 1h, 88% yield; (iii) Ethynyltrimethylsilane, CuI, Pd(dppf)2Cl2, DCM, 55 °C, 24 h, 83% yield; (iv) 
tBuOK, NMP, 70 °C, 2h; (v) TsCl, NMP, 0 °C, 1h, 31% yield. 
 A second pathway was explored as an attempt to improve the formation of intermediate 
130. Sonogashira coupling of the bromopyridine 127 with ethynyltrimethylsilane gave the desired 
compound 129 in excellent yields. The following step was ring-closing reaction under basic 
conditions to produce the azaindole heterocycle. This ring-closing reaction belongs to the 5-endo-
dig type and therefore is favored according to Baldwin’s rules. Subsequent in situ protection of the 
pyrrole nitrogen with tosyl chloride afforded product 130 in a low yield (31%). Although the 
Sonogashira reaction was more efficient than the intramolecular Heck reaction, the low yields 
associated with the ring-closing reaction made the Sonogashira pathway significantly inferior than 
the Heck approach.   
 
Scheme 39. Reagents and conditions. (i) NBS, DCM, 24 h, 68% yield; (ii) Pd(OAc)2, PPh3, KOAc,  
1,4-dioxane, 100 °C, 15 min, 76% yield. 
 
 The following step was bromination of the annulated pyrrole by treatment with N-
bromosuccinimide as the source of electrophilic bromine (Scheme 39). Azaindole 130 reactivity is 
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analogous to indole and accordingly, the most reactive position for electrophilic aromatic 
substitution is carbon C-3. A single regioisomer was obtained from the bromination reaction in fair 
yields (68%). The bromoazaindole 131 had to be then converted into the coupling partner for 
Suzuki reaction. Miyaura borylation reaction with bis(pinacolato)diboron catalyzed with palladium 
acetate gave the boronic ester 123 in high yields. Thus, synthesis of synthon A was accomplished. 
This key compound 123 was introduced to the pyrimidine core via Suzuki coupling reaction (vide 
infra).   
3.2.3.2 Preparation of synthon B 
 Preparation of synthon B was synthetically more challenging since it involved several key 
steps that needed to be addresed by a rational design of the synthetic pathway. The construction of 
the bicyclo[2.2.2]octane amino acid moiety and the resolution of its racemate were the major 
obstacles to overcome.   
 The formation of the bicyclo[2.2.2]octane was done in the first step via Diels-Alder reaction 
between 1,3-cyclohexadiene and freshly submiled maleic anhydride (Scheme 40). The patented 
conditions used for this reaction gave me exclusively the endo product 134 in excellent yields.122  
 
Scheme 40. Reagents and conditions. (i) DCM, 0 °C, 24 h, 85% yield; (ii) NH4Cl 6%, 0 °C, 30 min; (iii). NaOH 2 
M, 0 °C, 30 min; (iv) NaClO 1 M, 10 min, 75 °C; (v) NH4Cl 28%, THF, 5h, r.t., 94% yield; (vi) PIDA, 
EtOAc/AcCN/H2O, 24h, r.t., 90% yield. 
 The following step was opening of the anhydride using ammonia as nucleophile to form 
the amide 134 which after Hofmann rearrangement would give a racemate of the desired amino 
acid 133. A one-pot procedure was attempted in which the anhydride was firstly opened with an 
ammonia hydroxide solution, strongly basic conditions were subsequently applied. Addition of 
sodium hypochlorite would chlorinate the amide and after a short refluxing period the amino acid 
 
83 
133 should be formed. Unfortunately, only small amounts of product were generated under these 
conditions. As an effort to understand why the reaction didn’t work, I isolated the amide 134 and 
experimented with different reagents to perform the Hoffman rearrangement. Sodium hypochlorite 
and [bis(trifluoroacetoxy)iodo]benzene always produced unsatisfactory results. On the other hand, 
when the amide was treated with (diacetoxyiodo)benzene (PIDA) the reaction proceeded smoothly 
affording the amine 133 as a racemate in high yields. 
 To separate the two enantiomers from each other, I used an approach never attempted in 
the synthesis of VX-787. Firstly, esterification of the carboxylic acid was necessary for a successful 
resolution of the enantiomers (Scheme 41).123 The racemate 135 was then treated with half 
equivalent of the resolving agent (-)-dibenzoyl-L-tartaric acid monohydride [also known as (-)-
DBTA] which precipitated the desired enantiomer out of the solution as the corresponding 
diastereomeric salt 136. The diastereomeric salt was then recrystallized several times to increase 
the diastereomeric excess, although the yield was reduced. To determine the efficiency of the 
resolution, an aliquot of 136 was acetylated and the sample was submitted for chiral gas 
chromatography. The measurement showed that the desired enantiomer was present in a 
satisfactory 95% enantiomeric excess.   
 
Scheme 41. Reagents and conditions. (i) SOCl2, EtOH, 24 h, r.t., 5 h, reflux, 73% yield; (ii) (-)-DBTA (0.5 eq.), 
EtOH, 75 °C, 5 min, 25% yield; (iii) Ac2O, DMAP, Py; (iv) NaHCO3; (v) NaOEt, EtOH, 2h, reflux, 32% yield; (vi) 
H2 (1 atm), Pd/C 10%, EtOH, 24 h, r.t., 95% yield. 
 The free base of 136 was treated with sodium ethoxide to epimerize at the alfa carbon 
related to the ester group. This transformation gave the trans stereoisomer 137. The reaction 
proceeded in low yields although the unreacted starting material could be recovered. The last step 
 
84 
in the preparation of synthon B was hydrogenation of the double bound which afforded key synthon 
B (124) in quantitative yields.  
3.2.3.3 Construction of the Probe based on VX-787  
 The linker used for tethering the probe, named as synthon D (126), was prepared from 
tetraethylene glycol following procedures developed in our group in 52 % overall yield. A key step 
involving the selective mono-reduction in a Staudinger-like fashion of tetraethylene bis(azide) 140 
was used to break the symmetry in the linker. Compared to standard Staudinger condition, this 
transformation was done in a two-phase system composed of an acidic aqueous layer and a 
diethylether layer. The aqueous layer immediately collects the product of the monoreduction and 
thus prevents compound 141 from overreduction which would happen under standard conditions 
(one-phase system). The synthesis of synthon D is depicted in Scheme 42. 
    
Scheme 42. Reagents and conditions. (i) TsCl, KOH, DCM, 3 h, 0 °C, 98% yield; (ii) NaN3, DMF, 60 °C, 24 h, 82% 
yield; (iii) PPh3, Et2O, HCl 5%, 24 h, r.t., 81% yield; (iv) Boc2O, Et3N, THF, 5h, r.t., 89% yield; (v) PPh3, THF, 24 h, 
r.t., water, 60 °C, 2h, 90% yield. 
 The required synthon C is commercially available and was purchased from a supplier. 
Synthon C represents the core of the target molecule where the other synthons would be attached. 
The order in reactivity of the different sites at the pyrimidine derivative (synthon C) defined the 
order in which the synthons should be introduced. The most reactive site should be the acyl 
chloride, followed by the carbon C-4 of the pyrimidine ring and carbon C-2 (Figure 37). 
 
Figure 37. Order of reactivity in Synthon C. 
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Accordingly, the introduction of the linker (synthon D, 126) should be done in the first step 
of the assembly of the probe. In the first experiment, one equivalent of the linker 126 was added to 
an ice-cold DCM solution of synthon C (125) in the presence of DIPEA. After 90 min the reaction 
was quenched and the worked-up reaction mixture was separated by column chromatography. 
Surprisingly I observed also substitution at position C-4 with a second equivalent of 126 giving a 
mixture of products (Scheme 43). Position C-4 in pyrimidines is known for being highly reactive 
towards nucleophilic aromatic substitution especially in pyrimidines bearing electron-withdrawing 
groups. Lowering the reaction temperature to -78 °C and slowing down the rate of addition of the 
linker led to a higher regioselectivity of the reaction. The formation of side-product was thus 
suppressed.  
  
Scheme 43. Reagents and conditions. DIPEA, DCM, 90 min. Effect of the temperature on the regioselectivity of the 
reaction. The reaction conducted at -78 °C gave the desired product in 56% yield.  
 The high reactivity of position C-4 in the pyrimidine ring turned to be an advantage during 
the introduction of synthon B, which was done via nucleophilic aromatic substitution of the 
chlorine atom by the free amine of 124 (Scheme 44). The desired intermediate 144 was obtained 
in high yield and perfect regioselectivity (no substitution at C-2 was observed).  
 
Scheme 44. Reagents and conditions. (i) DIPEA, i-PrOH, 24 h, r.t., 84% yield.   
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 The last step in the construction of the probe turns to be tricky. The introduction of the 
synthon A (123) to intermediate 144 is in fact a carbon-carbon bond formation reaction between 
the pyrimidine and the azaindole heterocycles. Therefore, it requires a combination of coupling 
partners suitable for Suzuki-Miyaura reaction (Scheme 45).  
 
 Scheme 45. Conditions showed in Table 8. Azaindole used either as the boronic ester or the trifluoroborate salt.  
 Table 8. Conditions screened for Suzuki coupling; no optimization was done. The boronic ester was transformed into 
the trifluoroborate salt by treatment with potassium hydrogenflourid. Buchwald pre-catalyst SPhos Pd G3 gave the 
best results.  
 The conditions screened for the reaction are summarized in Table 8. The coupling of the 
boronic ester 123 with the pyrimidine derivative 144 was attempted four times (runs 1, 2, 3 and 4) 
but only one set of conditions (run 4) furnished the product in fair yields. Disappointed by the 
results obtained with the boronic ester I decided to transform the borate 123 into the potassium 
trifuoroborate salt. These salts are known to be less prone to protodeboronation that usually 
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complicates Suzuki-Miyaura reactions. Unfortunately, I did not observe an improvement by using 
the trifluoroborate salts (runs 5 and 6).  
 Although the yield obtained by applying conditions 4 for the Suzuki coupling was not 
spectacular, it represents a viable route to intermediate 145. In few experiments carried in the same 
manner like in run 4, I got enough material to finish the synthesis of the probe. Therefore, no further 
optimization of the Suzuki-Miyaura reactions was performed.  
 Treatment of 145 with a solution of lithium hydroxide resulted in the hydrolysis of the ethyl 
ester moiety and simultaneous removal of the tosyl group (Scheme 46). The solvent was then 
evaporated and the crude mixture was dissolved in a solution of DCM/TFA to deprotect the Boc-
amine. The key intermediate 122 was isolated after preparative HPLC purification in 69 % yield 
over the two steps. 
  
Scheme 46. Reagents and conditions. (i) LiOH 2M, 45 °C, 4 days; (ii) TFA/DCM 1:1, 40 min, r.t., 69% yield; (iii) 
Biotin-PEG6-NHS ester, Et3N, AcCN/DMF, 24 h, r.t., 43% yield; (iv) azido-PEG6-NHS ester, Et3N, AcCN/DMF, 
24 h, r.t., 51% yield. 
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 The intermediate 122 presents most of the necessary features of a probe: the inhibitor part 
is already constructed and is tethered by the linker. Compound 122 was designed to act as a “pre-
probe” that would allow us to easily transform it into different probes suitable for SPR and DIANA 
assay. The free amine group at the linker allows us to introduce different anchor groups in one 
simple step without having to modify or repeat the synthesis of the probe.  
 The first probe that I prepared was used to validate the binding of the molecule to the cap-
binding domain of the PB2. The method used was Surface Plasmon Resonance (SPR) and this 
method required a probe linked to a biotin group. The preparation of this probe was done by 
treatment of 122 with the commercially available biotin-PEG6-NHS ester under the presence of 
triethylamine. The primary amine is without any doubts more reactive than the sterically hindered 
amino-pyrimidine group and thus and gave the desired probe 146 in moderate yields (Scheme 46). 
The probe was then purified by preparative HPLC.  
Once the binding of the probe 146 to PB2 was corroborated by SPR, I had to prepare a 
second probe this time suitable for DIANA assay. We postulated that by separating the binding 
head and the anchor group with a linker of enough length we could minimize the possible effect in 
the binding that different anchor groups could have. Therefore, we assumed that the binding 
activity of probe 146 must be analogous to 147. Treatment of 122 with azido-PEG6-NHS ester 
using the previously described conditions afforded the desired probe 147 in moderate yields.  
 The flexible and modular approach used for the preparation of VX-787-based probes not 
only allowed us to produce a common intermediate 122 that can be transformed into different 
detection probes, but also works as a backup plan in the case that further elongation of the linker 
was needed. Probe 147 was used to develop and optimize a DIANA technology-based screening 
assay, at the time writing the assay is ready for screening IOCB’s vast library of nucleoside-like 
compounds. Promising results are expected to come since the natural ligand of the cap-binding 





3.2.4 L-742,001-based probe suitable for AlphaScreen assay  
 As I described in the introduction chapter, PA-endonuclease domain is an exceptionally 
promising therapeutic target for the development of new inhibitors since it’s essential for the life 
cycle of the virus. Additionally, the enzyme is highly conserved among all three families of 
influenza and has no counterpart in human cells.  
 This last chapter is dedicated to the preparation of chemical tools, specifically to the 
preparation of probes required for development of an assay suitable for screening low-molecular-
weight compounds against the PA-endonuclease. Unfortunately, in this case DIANA technology 
could not be used to develop the assay due to the endonuclease activity of the enzyme, which would 
cleave the reporter oligonucleotide part of the detection probe. AlphaScreen technology, which 
methodology has been described previously in the introduction, was used as a valid alternative 
method for the development of the screening assay.  
 From all the reported inhibitors of PA-endonuclease catalytic site, L-742,001 (15) stands 
out as the molecule with the highest potency (IC50 = 0.43 µM) and also in vitro activity.
41 In 
addition, L-742,001 has been successfully converted into a fluorescent probe previously, therefore 
the optimal position where structural modifications could be introduced has been already disclosed 
(Figure 38).124 
 
Figure 38. Structure of L-742,001 (left), fluorescent probe reported by Baughman et al. (center),
124 
and the early 
design of our probe (right) which was partially based on the structure of the fluorescent probe.  
 We proposed that if the substitution of the N-benzyl group of L-742,001 by fluorescein did 
not compromise the binding ability of the molecule, replacement of the fluorescein group by the 
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much more flexible linker would not have an adverse effect either. Scrupulous study of the reported 
structure of 2009 H1N1 PA endonuclease in complex with L-742,001 (Figure 39) supported our 
assumption. 
 
Figure 39. Structure of L-742,001 (left), the green arrow points to the future modification point. Co-crystal structure 
of L-742,001 (in red) with the catalytic site of PA (right). PDB 5CGV 
 The structure of the firstly designed probe is depicted in Figure 40. Three synthons can be 
readily disconnected, synthon A would form the binding head of the probe since it contains the β-
diketo acid group, synthon B would mimic the second benzyl “wing” of L-742,001 and at the same 
time introduce the tetraethylene glycol linker which would be attached to biotin in the latest stage 
of the synthesis. Synthon A and B were prepared from the commercially available ethyl 
isonipecotate 149 and dimethyl 4-hydroxyisophthalate 150, respectively. 
 Synthon A and B were prepared in parallel and the construction of the probe was done in a 




Figure 40. Structure of the first probe synthesized. The disconnection between synthon A, synthon B and biotin is 
represented, as well as the disconnection between the linker and the aromatic part of synthon B. The structure of the 
starting compounds used for the preparation of the two synthons is depicted as well.  
  
3.2.4.1 Preparation of Synthon A 
 For the preparation of synthon A (156) I followed a reported procedure for the synthesis of 
L-742,001.125 However, several modifications had to be introduced (Scheme 47). The synthesis 
begins with Boc-protection of the piperidine nitrogen atom in ethyl isonipecotate 149 followed by 
formation of the enolate by treatment with a strong base. Subsequent alkylation of the enolate with 
4-chlorobenzyl chloride formed the first “wing” of the inhibitor. The ethyl ester group of 152 was 
hydrolyzed and the acid 153 was transformed to methyl ketone 155 via formation of the Weinreb 
amide 154 and its subsequent reaction with methylmagnesium chloride. Addition of one equivalent 
of the organometallic reagent to the Weinreb amide produces a tetrahedral intermediate that is 
stabilized and does not collapse to ketone under reaction conditions. The last step involves the 
formation of the key β-diketo acid moiety which was done via Claisen condensation of the ketone 
155 with di-tert-butyl oxalate. Although di-tert-butyl oxalate could be less reactive than other 
oxalates due to the steric hindrance, the introduction of the tert-butyl ester was the most sensate 




Scheme 47. Reagents and conditions. (i) Boc2O, Et3N, DCM, 16 h, r.t., 97% yield; (ii) NaHMDS 0.6M, THF, 4-
chlorobenzyl chloride, -78 °C, 3h, 80% yield; (iii) KOH, MeOH/Dioxane, reflux, 48 h, 98%; (iv) EDC·HCl, THF, 15 
min, r.t. then N,O-dimethylhydroxylamine hydrochloride, 48 h, r.t., 66% yield; (v) MeMgBr 3.0 M, THF, reflux, 40 
min, 94% yield; (vi) NaHMDS 0.6 M, THF, -78 °C, 20 min; (vii) di-tert-butyl oxalate, 24 h, r.t., 78% yield. 
3.2.4.2 Preparation of Synthon B 
The preparation of synthon B (depicted in Scheme 48) commits with the regioselective hydrolysis 
of the ortho ester moiety on dimethyl 4-hydroxyisophthalate 150 using a reported set of 
conditions.126 The resulting acid 157 was converted into a tert-butyl ester 158 and then the phenol 
was alkylated with the linker. The azide-PEG4-Ts linker was prepared from tetraethylene glycol  
 
Scheme 48. Reagents and conditions. (i) py, reflux, 20 h, 93% yield; (ii) t-BuOH, MgSO4, H2SO4, DCM, 48 h, 53% 
yield; (iii) azide-PEG4-Ts, K2CO3, DMF, 60 °C, 24 h, 94% yield; (iv) NaOH 0.5 M, 1,4-dioxane, 24 h, r.t., 97% yield; 
(v) TBTU, THF, Et3N, N-hydroxysuccinimide, 24 h, r.t., 87% yield. 
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by bis-tosylation of both hydroxyl groups followed by SN2 reaction with one equivalent of sodium 
azide. The last two steps involved the hydrolysis of the methyl ester in para position and formation 
of the N-hydroxysuccinimide ester (NHS) using TBTU coupling agent.  
3.2.4.3 Construction of the probe based on L-742,001 
 The assembly of the probe is depicted in Scheme 49 and starts with the Boc-deprotection 
of the piperidine of synthon A. Treatment of intermediate 156 with a DCM solution of TFA at 0 
°C gave me the expected free amine. Surprisingly when the reaction times were shorter than 1 hour 
I did not observe the cleavage of the tert-butyl ester. Once the deprotection was completed, the 
solvent was evaporated and the crude mixture re-dissolved in DCM, an excess of triethylamine was 
added to quench the residual TFA followed by addition of synthon B in dichloromethane. The 
coupled intermediate 162 had to be attached to the anchor group N-(but-3-ynyl)biotinamide 163 
via CuAAC reaction. Compound 163 was prepared from commercially available biotin through the 
corresponding NHS ester and then the activated ester was treated with 1-amino-3-butyne. The first 
attempt for the CuAAC reaction used tetrakis(acetonitrile)copper(I) hexafluorophosphate as 
catalyst and tris(benzyltriazolyl-methyl)amine. Unfortunately, no formation of product was 
observed under these conditions. On the other hand, when copper(II) sulfate pentahydrate and 
sodium L-ascorbate were used instead, the desired product was formed in fair yields. The solvent 
was then removed and the crude mixture treated with a DCM solution of TFA to cleave the two 
remaining tert-butyl esters. The desired probe 148 was isolated after purification by preparative 
HPLC. 
 
Scheme 49. Reagents and conditions. (i) TFA/DCM (1:1), 0 °C, 1 h. (ii) Synthon B, Et3N, DCM, 24 h, r.t., 30% 
yield; (iii) 163, CuSO4·5H2O, sodium L-ascorbate, EtOH/water/THF (2:2:1), 1 h, r.t.; (iv) TFA/DCM (1:1), 1 h, r.t. 
 
94 
 The results measured by SPR for this first probe 148 showed high binding activity towards 
PA endonuclease (Kd < 7.3 nM), but unfortunately the binding was non-stoichiometric which is 
fundamental for the AlphaScreen assay. Dr. Milan Kožíšek who worked on the development of the 
assay pointed two possible causes for the non-stoichiometric binding; either the triazole connection 
is affecting the binding between biotin and Streptavidin or the linker has an insufficient length to 
separate the donor bead and the PA endonuclease domain.  
 In the case of the second probe, we decided to test if the triazole group is responsible for 
the unusual binding. Thus, I replaced the triazole connection (between the biotin and the linker) by 
an amidic bond and study how this modification affects the binding activity of the probe.  
 To accomplish the synthesis of this second probe only a minor modification in the 
preparation of synthon B was needed (Scheme 50). The azido moiety from intermediate 160 had 
to be reduced via catalytic hydrogenation to form the free amine, the catalyst was then filtered out 
and the solvent evaporated. The resulting crude mixture was treated with a solution containing the 
NHS ester of biotin, which was prepared from biotin and N-hydroxysuccinimide. The biotinylated 
product 164 was isolated and converted to the activated NHS ester 165. 
 
Scheme 50. Reagents and conditions. (i) Lindlar catalyst, H2 (1 atm), MeOH, 90 min, r.t.; (ii) NHS-biotin, Et3N, 
DMF, 46 h, r.t., 39% yield; (iii) N-hydroxysuccinimide, TBTU, Et3N, DMF, 24 h, r.t., 70% yield. 
 The connection between synthon A and the new synthon B (165) was done in an identical 
fashion as in the case of the first probe (Scheme 49, page 92). However, in this case, the crude 
coupled product was directly treated with TFA for the deprotection of the tert-butyl esters. 




Scheme 51. Reagents and conditions. (i) TFA/DCM (1:1), 0 °C, 30 min; (ii) 165, Et3N, DCM, 24 h, r.t.; (iii) 
TFA/DCM (2:1) 2 h, r.t., 27% yield. 
 Although the binding activity was similar to probe 1 (148), the change in the construction 
of the probe did not fix the non-stoichiometric binding observed when the probe is used in the 
AlphaScreen assay. We decided to prepare a third probe in which the spacer between the binding 
head and the biotin group has been substantially elongated.  
 To simplify the synthesis, we decided to introduce a biotinylated linker in the latest step of 
the preparation. As a consequence of this change, I had to transform the azide intermediate 160 
into the protected amine 167 via one-pot procedure in which the azido moiety of 160 was firstly 
reduced and the resulting amine was Boc-protected.  
 
Scheme 52. Reagents and conditions. (i) TFA/DCM (1:5), 15 min, r.t.; (ii) 167, Et3N, DCM, 24 h, r.t., 68% yield; (iii) 
TFA/DCM (1:5), 15 min, r.t.; (iv) Biotin-PEG6-NHS ester, Et3N, DCM, 24 h, r.t., 15% yield. 
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 The construction of the probe was performed in a modular fashion by a sequence of Boc-
amine deprotection and amide formation reactions (Scheme 52). Synthon A was firstly Boc-
deprotected and the free amine coupled with the activated ester 167 in one-pot procedure. The 
resulting product 168 contains also a protected amine that was submitted for the same deprotection-
coupling procedure, but this time using Biotin-PEG6-NHS ester. Purification by preparative HPLC 
afforded the desired third probe (169) with the elongated linker. 
 
3.2.3.4 Results obtained from the AlphaScreen assay 
 The third probe (169) showed comparable binding activities (Kd < 9.3 nM) to the first and 
second probe (148 and 166) but in this case we observed a stoichiometric binding with a classic 
Hook effect as well as much higher sensitivity in the AlphaScreen assay (Figure 41). The results 
obtained verified the assumption that the short length of the linker was compromising the binding 
between the bead caring the probe and the bead attached to the PA endonuclease domain. These 
steric effects were minimized by the introduction of a much longer spacer. 
Figure 41. Comparison between the Alpha counts obtained by using 1st Probe (148, left) and 3rd Probe (169, right), an 
acute increment in the response of the assay can be easily appreciated for the 3rd Probe as well as a classic Hook effect. 
  The developed AlphaScreen assay was used to screen a first batch of fifty compounds for 
binding activity against PA endonuclease. Two integrase inhibitors were found to bind to PA 
endonuclease, both of them showing IC50 in the low micromolar range. Further screening will be 
done using the described probe.  
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4. Conclusion and outlook 
During my research, I was able to reproduce Shi’s and Hudlicky’s syntheses of oseltamivir 
and adapt them for the production of C-3 modified derivatives of oseltamivir. The issues 
encountered during the key aziridine-formation and aziridine-opening steps were solved and 
several alcohols were screened for the aziridine opening step. The first set of compounds were 
prepared, and the results obtained will be published soon. The developed strategy allows a simple 
and direct preparation of an uncountable number of C-3 modified oseltamivir derivatives from (-)-
shikimic acid. This part of my Thesis became the central work of one of my colleagues and further 
research is being carried out solely by him.  
With regards to the modification at C-5 of oseltamivir, a short and effective synthetic 
strategy was proposed and the first set of derivatives were prepared following this method. A 
manuscript is being drafted at the time of this writing which will show the activities of the C-5 
modified derivatives prepared, as well as the crystal structure of 94 with the catalytic site of 
neuraminidase. The objective of this publication is to shed light on the binding mode of these 
inhibitors to the 150-cavity adjacent to the NA catalytic site.  
The reported synthesis of tamiphosphor was simplified and shortened, and tamiphosphor 
and its congeners were prepared. Furthermore, a novel radical-decarboxylation/photo-Arbuzov 
approach was explored for the conversion of vinyl carboxylic acids to vinyl phosphates in one step. 
To the best of our knowledge, only one similar reaction has been reported for this transformation. 
The synthesis and the activities of the prepared inhibitors, as well as the crystal structure of 
tamiphosphor binding to the neuraminidase active site have been published in the European Journal 
of Medicinal Chemistry.  
In the second part of my Thesis, I pursued the preparation of chemical tools/probes which 
are required for the development of novel screening assays.   
Several detection probes suitable for DIANA assay containing sialylmimetic groups were 
prepared. In particular, a highly active tamiphosphor-based detection probe was prepared and the 
crystal structure of the probe binding the catalytic site was furnished. The prepared inhibitors were 
used to validate DIANA assay as an efficient and reliable screening method and these findings are 
currently being prepared for publication.  
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A second tamiphosphor-based probe was also synthesized; this much longer probe was used 
for the preparation of a polymeric material which presents enhanced pharmacological properties. 
The polymer is intended to be administrated to patients in life-treating stages of influenza’s 
infection. Unfortunately, due to the possibility of a future patent application, the findings could 
only be partially disclosed.  
We also designed and prepared two detection probes based on the structure of the PB2 
inhibitor VX-787. The synthesis had to be highly modified and optimized for the successful 
preparation of the probes from commercially available building blocks. The synthesized probes 
present strong binding affinities and are being used to develop a screening assay which aims to find 
novel inhibitors of PB2 cap-binding domain.  
Lastly, a similar strategy was used to design and prepare several probes based on the 
structure of the PA endonuclease inhibitor L-742,001. The issues associated with the low 
sensitivity of the first probe were solved and the final probe was used to develop a screening assay 
based on AlphaScreen technology that has already discovered new inhibitors of PA endonuclease.  
All of the detection probes could be used for an extensive period of time in multiple 
screening campaigns. Therefore, my research will contribute to the discovery of future drug 
candidates at IOCB against neuraminidase, PB2 cap-binding domain and PA endonuclease by the 











5. Experimental Section 
General: Unless otherwise noted, all reactions were carried out under argon in oven-dried 
glassware. The solvents used for reactions were distilled from the corresponding drying agents 
indicated and were transferred under argon: THF (Na/benzophenone); toluene (Na); DCM (CaH2). 
Chromatography was performed either classical or using HPFC Biotage Isolera One system, using 
Fluka silica gel 60 (0.040 - 0.063mm) or Merck silica gel 60 RP-18 F254 –coated aluminium sheets 
were used. The spots were detected both in UV and by the solution of Ce(SO4)2·4H2O (1%) and 
H3P(Mo3O10)4 (2%) in 10% sulfuric acid (10%). All starting materials were used as purchased 
(Sigma Aldrich, Alfa Aesar, Strem Chemicals, Santiago, TCI), unless otherwise indicated. 
Oseltamivir phosphate was purchased from Santiago. All tested inhibitors were purified using 
preparative HPLC of Jasco brand (flow rate 10 mL/min; gradient 2-100 % ACN in 50 minutes), 
with column Waters SunFire C18 OBD Prep Column, 5 μm, 19 x 150 mm. The purity of 
compounds was tested on analytical Jasco PU-1580 HPLC (flow rate 1 mL/min, invariable gradient 
2-100 % ACN in 30 minutes) with column Watrex C18 Analytical Column, 5 μm, 250x5 mm. The 
final inhibitors were all at least of 95 % purity. The 1H-NMR spectra were measured at 400.13 or 
600.13 MHz, the 13C-NMR spectra at 100.61 or 150.90 MHz in CDCl3, MeOH-d4, D2O or 
(CD3)2SO, with tetramethylsilane or solvent peaks as an internal standard. The chemical shifts are 
given in δ-scale, coupling constants J are given in Hz. The EI mass spectra were determined at an 
ionizing voltage of 70 eV, the m/z values are given alone with their relative intensities (%). The 
ESI mass spectra were recorded using ZQ micromass mass spectrometer (Waters) equipped with 











General procedure for saponification of the ethyl esters. 
To a solution of the desired ethyl ester (1 equivalent) in 1,4-dioxane (0.14 M) was added an aqueous 
solution of NaOH (2 equivalents, 0.5 M), the reaction mixture was stirred from 2 h to 24 h at room 
temperature. The consumption of the starting material was monitored by TLC. Once the reaction 
was complete, the pH of the reaction was adjusted to neutral by addition of amberlite IR 120. The 
amberlite was filtered out and the beads rinsed with MeOH several times, the filtrate was then 
evaporated to dryness and the remaining product was purified either by preparative HPLC or flash 
chromatography to afford the desired free acid.  
 
Ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate  
To a solution of oseltamivir phosphate (1.0 g, 2.43 mmol) in water (30 mL) 
was added a saturated solution of sodium bicarbonate (10 mL). The reaction 
mixture was stirred for 5 min at room temperature. The mixture was extracted 
with DCM/MeOH mixture (3:1; 4x10 mL). The combined organic phase was 
washed with brine, dried over anhydrous Na2SO4 and concentrated under 
reduced pressure to furnish the free base of oseltamivir (0.75 g, 98% yield). 
The product was used without further purification.  
1H NMR (300 MHz, Chloroform-d3) δ 6.78 (t, J = 2.1 Hz, 1H), 6.26 (d, J = 8.3 Hz, 1H), 4.34 – 
4.10 (m, 3H), 3.55 (dt, J = 10.3, 8.4 Hz, 1H), 3.37 (dd, J = 17.7, 12.0 Hz, 1H), 3.26 – 3.08 (m, 1H), 
2.76 (dd, J = 17.7, 5.1 Hz, 1H), 2.26 – 2.08 (m, 1H), 2.04 (s, 3H), 1.58 (s, 2H), 1.55 – 1.44 (m, 
4H), 1.29 (t, J = 7.1 Hz, 3H), 0.90 (td, J = 7.4, 3.8 Hz, 6H). 13C NMR (75 MHz, Chloroform-d3) δ 
171.1, 166.4, 137.8, 129.5, 81.7, 77.6, 77.2, 76.7, 75.0., 60.8, 58.9, 49.3, 33.7, 26.2, 25.7, 23.6, 
14.2, 9.6, 9.3. HR-ESI-MS calculated for C16H29O4N2 (M+H
+) 313.2122, found 313.2122. 
 
Oseltamivir carboxylate  
 The conditions used are described in the general procedure for the 
saponification of ethyl esters. Purified by preparative HPLC (0.12 g, 88% 
yield). 
 1H NMR (400 MHz, Methanol-d4) δ 6.64 (s, 1H), 4.11 (d, J = 8.5 Hz, 1H), 
3.83 (dd, J = 11.4, 8.7 Hz, 1H), 3.40 (td, J = 10.8, 5.5 Hz, 1H), 3.34 – 3.22 
 
101 
(m, 1H), 3.16 (dt, J = 3.3, 1.6 Hz, 1H), 2.80 (dd, J = 17.3, 5.1 Hz, 1H), 2.38 – 2.18 (m, 1H), 1.91 
(s, 3H), 1.47 – 1.28 (m, 4H), 0.75 (dt, J = 12.6, 7.4 Hz, 6H). 13C NMR (101 MHz, Methanol-d4) δ 
174.9, 169.6, 138.4, 129.8, 83.7, 76.0, 54.5, 50.5, 30.0, 27.2, 26.6, 23.4, 9.8, 9.6. HR-ESI-MS 
calculated for C14H23O4N2 (M-H
+) 283.1663, found 283.1656. 
 
Ethyl (3aR,7aS)-2,2-dimethyl-3a,7a-dihydrobenzo[d][1,3]dioxole-4-carboxylate 
(3aS,7aS)-4-Iodo-2,2-dimethyl-3a,7a-dihydro-1,3-benzodioxole (3.5 g, 12.6 
mmol) was dissolved in 2,2-dimethoxypropane (10 mL) and p-toluenesulfonic acid 
monohydrate (0.17 g, 5 w%) was added, the reaction mixture was stirred for 5 min, 
after which the consumption of the starting material was checked by TLC 
(hexanes/EtOAc 4:1). The reaction was quenched by addition of a saturated solution of sodium 
bicarbonate (10 mL) and the aqueous phase was extracted with EtOAc (3x 15 mL), the combined 
organic layers were evaporated under reduced pressure at 20 ºC. The resulting product was 
dissolved in EtOH (200 mL) followed by addition of triethylamine (3.5 mL, 25.2 mmol), the 
reaction mixture was purged with carbon monoxide for 15 min. Triphenylphosphine (0.66 g, 2.53 
mmol) and palladium(II) acetate (0.28 g, 1.26 mmol) were subsequently added, the reaction 
mixture was heated to 40 ºC for 2 h under constant bubbling of carbon monoxide through the 
solution. The solvent was evaporated under reduced pressure and the resulting mixture was purified 
by flash chromatography (Hexanes/EtOAc 4:1) to yield the desired ethyl ester (2.4 g, 85%). The 
product was immediately used for the next reaction due to the low stability of the compound. 
 
3-Acetyl-1-ethoxycarbonyl-5,6-O-isopropylidine-2-oxa-3-azabicyclo[2.2.2]oct-7-ene- 5,6-diol 
Sodium periodate (1.5 g, 7.06 mmol) was added portion wise to a solution of 
ethyl (3aR,7aS)-2,2-dimethyl-3a,7a-dihydrobenzo[d][1,3]dioxole-4-
carboxylate (0.79 g, 3.53 mmol) in aqueous methanol (80 mL, MeOH/water 
3:1) at 0 ºC. A solution of acetohydroxamic acid (0.53 g, 7.06 mmol) in 
methanol (20 mL) was added dropwise to the reaction mixture at 0 ºC and the 
resulting solution was stirred overnight at room temperature. The reaction mixture was quenched 
by addition of a saturated solution of sodium bicarbonate (10 mL), the precipitate was filtered out 
and the filtrate was concentrated down under reduced pressure.  The resulting aqueous phase was 
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extracted with EtOAc (4x 25 ml), the combined organic phases were washed with a saturated 
solution of sodium bicarbonate (20 mL) and evaporated down. The resulting mixture was purified 
by flash chromatography (Hexanes/EtOAc 3:1) to yield the cycloaddition product (0.9 g, 88%). 
1H NMR (300 MHz, Chloroform-d3) δ 6.66 – 6.54 (m, 2H), 5.47 (s, 1H), 4.70 (dd, J = 6.9, 0.8 Hz, 
1H), 4.54 (ddd, J = 6.9, 4.2, 0.8 Hz, 1H), 4.37 (q, J = 7.1 Hz, 2H), 1.99 (s, 3H), 1.36 (t, J = 7.1 Hz, 
3H), 1.31 (s, 3H), 1.29 (s, 3H). 13C NMR (75 MHz, Chloroform-d3) δ 174.0, 166.6, 132.5, 128.5, 




Molybdenum hexacarbonyl (0.92 g, 3.48 mmol) was added to a solution of 3-
acetyl-1-ethoxycarbonyl-5,6-O-isopropylidine-2-oxa-3-azabicyclo[2.2.2]oct-
7-ene-5,6-diol (0.5 g, 1.74 mmol) in aqueous acetonitrile (9 mL, CH3CN/water 
15:1) and the reaction was heated up to 85 ºC for 4 h. The reaction was cooled 
down to room temperature and the resulting slurry was filtered through a pad 
of celite, rinsed several times with EtOAc and the combined organic phases were evaporated down 
under reduced pressure. The resulting mixture was purified by flash chromatography (EtOAc) to 
afford the reduced alcohol (0.40 g, 77%). 
1H NMR (300 MHz, Chloroform-d3) δ 6.12 (d, J = 8.8 Hz, 1H), 6.06 – 5.91 (m, 2H), 4.81 (dtd, J 
= 8.8, 3.8, 1.3 Hz, 1H), 4.40 – 4.33 (m, 2H), 4.27 (qd, J = 7.2, 1.4 Hz, 2H), 4.00 (s, 1H), 1.99 (s, 
3H), 1.36 (s, 3H), 1.33 (t, J = 7.2 Hz, 3H), 1.29 (s, 3H). 13C NMR (75 MHz, Chloroform-d3) δ 




Chromium(VI) oxide (0.8 g, 8.0 mmol) was carefully added to a solution of 
acetic anhydride (2 mL) at 80 ºC, the solution was stirred for 5 min until all 
the chromium oxide was dissolved. The solution was allowed to cool down 
to room temperature, the mixture was diluted in DCM (6 mL) and further 
cooled down to 0 ºC on an ice bath. In a separate flask was prepared a 
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solution of the alcohol (0.96 g, 3.2 mmol) in DCM (20 mL) and the solution was cooled down to 0 
ºC in an ice bath, the chromium oxide solution was added dropwise to the solution of the alcohol 
and the reaction was stirred for 5 min, the complete consumption of starting material was checked 
by TLC (EtOAc). The reaction was cooled down to 0 ºC again followed by addition of EtOH (7.5 
mL), sodium bicarbonate (1.9 g), pyridine (0.35 mL) and hydroxylamine hydrochloride (2.2 g, 32.0 
mmol), the resulting reaction mixture was stirred for 16 h at room temperature. The reaction was 
carefully quenched by addition of a saturated solution of sodium bicarbonate (10 mL) and the two 
phases were separated, the aqueous solution was extracted with EtOAc (3x 15 mL). The combined 
organic layers were evaporated under reduced pressure and the remaining mixture was purified by 
column chromatography (EtOAc) to furnish the desired oxime (0.71 g, 71%). 
1H NMR (300 MHz, Chloroform-d3) δ 9.56 (s, 1H), 7.75 (s, 1H), 6.00 (d, J = 8.6 Hz, 1H), 5.09 – 
4.89 (m, 2H), 4.42 – 4.19 (m, 3H), 2.04 (s, 3H), 1.49 (s, 3H), 1.43 (s, 3H), 1.34 (t, J = 7.2 Hz, 3H). 
13C NMR (75 MHz, Chloroform-d3) δ 171.2, 165.5, 149.1, 132.6, 124.9, 111.3, 76.2, 70.8, 61.9, 
50.1, 28.0, 26.6, 23.5, 14.3. 
 
(3aR,6S,7R,7aS)-7-Acetylamino-6-tert-butoxycarbonylamino-2,2-dimethyl-3a,6,7,7a-
tetrahydro-benzo[1,3]dioxole-4-carboxylic acid ethyl ester 
A suspension of ethyl (3aR,7R,7aS)-7-acetamido-6-(hydroxyimino)-2,2-
dimethyl-3a,6,7,7a-tetrahydrobenzo-[d][1,3]dioxole-4-carboxylate (0.43 g, 
1.38 mmol), di-tert-butyl dicarbonate (1.04 g, 3.17 mmol) and Rh/Al2O3 5% 
(0.17 g, 40 wt%) in aqueous ethanol (10 mL, EtOH/water 100:1) was 
thoroughly purged with hydrogen followed by hydrogenation in a Parr 
apparatus (60 pound/inch2). After 16 h the reaction was filtered, the catalyst 
was rinsed with ethanol several times and the combined ethanolic phases were concentrated down, 
the resulting mixture was purified by column chromatography (Hexanes/EtOAc 1:1) to yield the 
hydrogenated Boc-protected amine (0.38 g, 69%) as a white solid. 
1H NMR (300 MHz, Chloroform-d3) δ 5.67 (d, J = 9.3 Hz, 1H), 4.98 (d, J = 8.8 Hz, 1H), 4.54 (t, J 
= 4.1 Hz, 1H), 4.31 – 4.04 (m, 2H), 3.97 (dt, J = 11.4, 9.2 Hz, 1H), 3.84 (dd, J = 8.9, 4.4 Hz, 1H), 
3.35 (tdd, J = 11.9, 8.8, 3.2 Hz, 1H), 2.80 (dt, J = 13.0, 4.3 Hz, 1H), 2.14 – 2.04 (m, 1H), 1.98 (s, 
3H), 1.99 – 1.84 (m, 1H), 1.54 (s, 3H), 1.40 (s, 9H), 1.33 (s, 3H), 1.25 (t, J = 7.1 Hz, 3H). 13C NMR 
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(75 MHz, Chloroform-d3) δ 171.3, 170.5, 156.3, 110.0, 79.8, 78.8, 73.9, 61.1, 55.3, 51.0, 41.5, 28.5 
(x4), 28.1, 26.3, 23.5, 14.3. 
 
(3R,4R,5S)-4-Acetylamino-5-tert-butoxycarbonylamino-3-hydroxy-cyclohex-1-enecarboxylic 
acid ethyl ester 
A solution of sodium ethoxide in ethanol (6.4 mL, 0.05 M) was added to a 
flask containing a solution of the (3aR,6S,7R,7aS)-7-acetylamino-6-tert-
butoxycarbonylamino-2,2-dimethyl-3a,6,7,7a-tetrahydro-benzo[1,3]-di-
oxole-4-carboxylic acid ethyl ester (0.33 g, 0.83 mmol) in absolute ethanol 
(7.7 mL) and the reaction was stirred for 1 h at room temperature. The 
mixture was quenched by addition of water (10 mL) and an aqueous solution 
of citric acid (0.5 mL, 5 w%). The aqueous solution was extracted with EtOAc (3x 10 mL), the 
combined organic layers were washed with brine (5 mL) and concentrated under reduced pressure. 
The resulting mixture was purified by column chromatography (DCM/MeOH 20:1) to yield the 
elimination product (0.247 g, 87%). 
1H NMR (300 MHz, Chloroform-d3) δ 7.35 (d, J = 5.9 Hz, 1H), 6.81 (t, J = 2.4 Hz, 1H), 5.02 
(broad s, 1H), 4.82 (d, J = 7.8 Hz, 1H), 4.31 (dq, J = 5.8, 1.9 Hz, 1H), 4.20 (qd, J = 7.1, 1.7 Hz, 
2H), 3.81 (ddd, J = 10.7, 7.7, 5.4 Hz, 1H), 3.72 (ddd, J = 11.6, 8.0, 5.9 Hz, 1H), 2.91 – 2.75 (m, 
1H), 2.27 – 2.09 (m, 1H), 2.01 (s, 3H), 1.46 (s, 9H), 1.28 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, 





Diisopropyl azodicarboxylate (0.14 g, 0.69 mmol) was added dropwise to a 
solution of dimethylphenylphosphine (0.09 g, 0.69 mmol) in DCM (1.3 mL) 
at -40 ºC under inert atmosphere. In a separated flask was prepared a solution 
of (3R,4R,5S)-4-acetylamino-5-tert-butoxycarbonylamino-3-hydroxy-
cyclohex-1-enecarboxylic acid ethyl ester (0.11 g, 0.32 mmol) and 
triethylamine (9 µL) in DCM (1.3 mL) under inert atmosphere. The solution of the substrate was 
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cooled down to 0 ºC and then it was added dropwise to the solution of the phosphine at -40 ºC. The 
reaction was stirred for 10 min allowing it to gradually warm up to 0 ºC. The solvents were 
evaporated under reduced pressure and the resulting mixture was purified by column 
chromatography (hexanes/EtOAc 3:1) to yield the aziridine (0.07 g, 66%). 
1H NMR (300 MHz, Chloroform-d3) δ 7.19 (dd, J = 4.3, 3.3 Hz, 1H), 4.55 (m, 1H), 4.44 (m, 1H), 
4.21 (q, J = 7.1 Hz, 2H), 3.18 – 3.05 (m, 2H), 2.75 (dt, J = 17.2, 1.9 Hz, 1H), 2.42 – 2.26 (m, 1H), 
2.15 (s, 3H), 1.44 (s, 9H), 1.36 – 1.24 (t, J = 7.2 Hz, 3H). 13C NMR (75 MHz, Chloroform-d3) δ 
165.6, 155.1, 133.6, 130.3, 80.0, 61.2, 42.1, 41.2, 32.0, 28.5 (3x), 28.2, 26.9, 22.8, 14.3. 
 
2-Ethyl-2-[(tert-butoxycarbonylmethylamino)methyl]butan-1-ol 
Di-tert-butyl dicarbonate (0.94 g, 4.3 mmol) was added to a solution of 2-
ethyl-2-[(methylamino)methyl]butan-1-ol (0.5 g, 3.4 mmol) and 
triethylamine (1.05 mL, 7.5 mmol) in methanol (10 mL) and the reaction was 
stirred at room temperature. After 6 h the reaction mixture was concentrated under reduced pressure 
and the remaining oil was purified by column chromatography (DCM/MeOH 20:1) to afford the 
protected amine (0.79 g, 95%).  
1H NMR (300 MHz, Chloroform-d3) δ 4.55 (t, J = 7.6 Hz, 1H), 3.15 (d, J = 7.6 Hz, 2H), 3.05 (s, 
2H), 2.89 (s, 3H), 1.46 (s, 9H), 1.28 (dt, J = 15.0, 7.4 Hz, 2H), 1.14 (dt, J = 14.3, 7.3 Hz, 2H), 0.83 
(t, J = 7.5 Hz, 6H). 13C NMR (75 MHz, Chloroform-d3) δ 155.2, 80.5, 64.3, 52.6, 43.0, 38.1, 28.5 




An oven-dried flask was charged with a solution of ethyl 
(1S,5S,6R)- 7-acetyl-5-(tert-butoxycarbonylamino)-7-azabi-
cyclo[4.1.0]hept-2-ene-3-carboxylate (42 mg, 0.13 mmol) and 
2-ethyl-2-[(tert-butoxycarbonylmethylamino)methyl]-butan-1-
ol (158 mg, 0.64 mmol) in DCM (1 mL), the flask was purged 
with argon and the solution was cooled to -40 ºC. Boron 
trifluoride diethyl etherate (36 mg, 0.26 mmol) was added dropwise to the solution of the aziridine 
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and the reaction mixture was gradually warmed to 0 ºC. After 1 h stirring at 0 ºC, the solvent was 
removed under reduced pressure and the resulting mixture was purified by column chromatography 
(hexanes/EtOAc 1:1) to yield the desired ether (25 mg, 34%).  
1H NMR (600 MHz, Chloroform-d3) δ 7.83 – 7.61 (m, 1H), 6.87 (s, 1H), 6.05 (d, J = 7.3 Hz, 1H), 
4.21 (qd, J = 7.2, 4.1 Hz, 2H), 3.97 – 3.84 (m, 2H), 3.80 – 3.71 (m, 1H), 3.65 (m, 1H), 3.47 (d, J = 
8.8 Hz, 1H), 3.01 – 2.91 (m, 2H), 2.88 (s, 3H), 2.46 (d, J = 14.3 Hz, 1H), 2.23 – 2.14 (m, 1H), 1.98 
(s, 3H), 1.46 (s, 9H), 1.43 (s, 9H), 1.29 (m, 7H), 0.85 (t, J = 7.4 Hz, 3H), 0.76 (t, J = 7.5 Hz, 3H). 
13C NMR (151 MHz, Chloroform-d3) δ 173.5, 166.4, 157.1, 156.4, 134.9, 130.0, 79.9, 79.2, 78.0, 
71.2, 61.1, 54.2, 52.5, 51.9, 42.6, 38.3, 32.4, 28.6 (6x), 23.4, 23.1, 22.2, 14.4, 7.6, 7.1. HR-ESI-MS 
calculated for C29H51O8N3Na (M+Na)




The conditions used are described in the general procedure for the 
saponification of ethyl esters. The solvent was removed under 
reduced pressure and the remaining solid was dissolved in TFA (3 
mL, 100%), the reaction was stirred for 1 h at room temperature. The 
acid was removed under reduced pressure and the resulting solid was 
purified by preparative HPLC to yield the desired amino acid.  
1H NMR (400 MHz, D2O) δ 7.00 (t, J = 2.1 Hz, 1H), 4.35 – 4.14 (m, 2H), 3.77 (d, J = 9.5 Hz, 1H), 
3.63 (td, J = 10.7, 5.7 Hz, 1H), 3.48 (d, J = 9.5 Hz, 1H), 3.05 (s, 2H), 3.03 – 2.94 (m, 1H), 2.72 (s, 
3H), 2.59 – 2.47 (m, 1H), 2.12 (s, 3H), 1.48 – 1.30 (m, 4H), 0.85 (td, J = 7.5, 5.6 Hz, 6H). 13C NMR 
(101 MHz, D2O) δ 175.4, 168.9, 136.1, 128.3, 77.8, 74.3, 55.9, 51.3, 48.6, 39.1, 34.3, 28.4, 23.5, 
23.1, 22.3, 6.3, 6.2. HR-ESI-MS calculated for C17H32O4N3 (M+H)





(-)-Shikimic acid (1 g, 5.7 mmol) was dissolved in absolute EtOH (10 mL) and 
thionyl chloride (0.21 mL, 2.8 mmol) was added dropwise to reaction mixture. 
The solution was then refluxed for 3 h under inert atmosphere. The solvent was 
evaporated under reduced pressure and the remaining residue was triturated with 
refluxing tert-butyl methyl ether (20 mL). The solution was slowly cooled to 0 
ºC and the formed precipitate was filtered and dried under reduced pressure, the desired ethyl ester 
was obtained as a white solid (1 g, 86%), mp 97.7 - 99.3 ºC (tert-butyl methyl ether). 
1H NMR (300 MHz, DMSO-d6) δ 6.60 (s, 1H), 4.22 (d, J = 2.3 Hz, 1H), 4.11 (q, J = 7.1 Hz, 2H), 
3.85 (dt, J = 6.1, 4.1 Hz, 1H), 3.65 – 3.54 (m, 1H), 2.46 – 2.35 (m, 1H), 2.13 – 1.98 (m, 1H), 1.21 
(t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, DMSO-d6) δ 166.3, 139.6, 127.7, 70.1, 66.9, 65.5, 60.1, 
29.7, 14.2.  
 
Ethyl (3R,4S,5R)-3,4,5-trimethanesulfonyl-1-cyclohexenecarboxylate  
To a vigorously stirred solution of ethyl (3R,4S,5R)-(−)-3,4,5-trihydroxy-1-
cyclohexenecarboxylate (1.34 g, 6.62 mmol) in EtOAc (17 mL) at 0 ºC was 
added dropwise methanesulfonyl chloride (2.3 mL, 29.8 mmol) and 4-
dimethylaminopyridine (0.24 g, 1.98 mmol). Triethylamine (4.6 mL, 33.1 
mmol) was subsequently added over a period of 30 min and the resulting solution was stirred for a 
further hour at 0 ºC. The reaction mixture was quenched by addition of aqueous HCl 1M (11.5 mL) 
and the organic phase was separated, washed with an aqueous solution of K2CO3, dried over 
MgSO4 anhydrous and evaporated down. The resulting oil was triturated with aqueous MeOH 
(MeOH/water 8:2) and the formed precipitate was filtered, rinsed with aqueous MeOH and dried 
under reduced pressure to afford the mesylated compound as a white solid (2.45 g, 97%). 
1H NMR (300 MHz, Chloroform-d3) δ 6.89 – 6.78 (m, 1H), 5.50 (t, J = 4.4 Hz, 1H), 5.13 (ddd, J 
= 9.2, 7.2, 5.9 Hz, 1H), 5.04 – 4.93 (m, 1H), 4.25 (q, J = 7.1 Hz, 2H), 3.28 – 3.22 (m, 1H), 3.19 (s, 
3H), 3.17 (s, 3H), 3.13 (s, 3H), 2.68 (dddd, J = 18.8, 7.3, 2.5, 1.1 Hz, 1H), 1.31 (t, J = 7.1 Hz, 3H). 
13C NMR (75 MHz, Chloroform-d3) δ 164.4, 133.2, 130.1, 74.6, 72.9, 72.8, 62.0, 39.1 (x2), 39.0, 
30.7, 14.2. 
 
Ethyl (3S,4S,5R)-3-azido-4,5-dimethanesulfonyl-1-cyclohexenecarboxylate  
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A double neck flask equipped with an internal thermometer was charged with 
ethyl (3R,4S,5R)-3,4,5-O-trimethanesulfonyl-1-cyclohexenecarboxylate (0.5 g, 
1.14 mmol) and acetone (4 mL), the solution was cooled down to 0ºC in an ice 
bath and a solution of sodium azide (0.29 g, 4.5 mmol) in water (0.8 mL) was 
added dropwise over a period of 10 min, keeping the reaction mixture always 
under 5 ºC, the reaction was left stirring for 4 h more at 0 ºC. The reaction mixture was diluted in 
toluene (10 mL) and quenched by water (2.5 mL). The organic phase was separated and washed 
successively with water (10 mL) and brine (5 mL). The organic phase was dried over anhydrous 
MgSO4, and the solvents were evaporated under reduced pressure. The crude product was then 
purified by flash chromatography (Hexanes/EtOAc 1:1) to furnish azide compound (89%). 
1H NMR (300 MHz, Chloroform-d3) δ 6.73 (td, J = 3.5, 2.8, 0.8 Hz, 1H), 4.87 (td, J = 9.6, 6.1 Hz, 
1H), 4.74 (dd, J = 10.0, 7.9 Hz, 1H), 4.33 (dq, J = 8.0, 1.9 Hz, 1H), 4.22 (q, J = 7.1 Hz, 2H), 3.21 
– 3.15 (m, 1H), 3.20 (s, 3H), 3.13 (s, 3H), 2.77 – 2.52 (m, 1H), 1.29 (t, J = 7.1 Hz, 3H). 13C NMR 




To a solution of ethyl (3R,4S,5R)-3-azido-4,5-dimethanesulfonyl-1-
cyclohexenecarboxylate (0.8 g, 2.1 mmol) in THF (20 mL) was added 
triphenylphosphine (0.6 g, 2.3 mmol) in portions, the reaction was stirred for 
30 min at room temperature. Triethylamine (0.86 mL, 6.3 mmol) and water 
(1.6 mL) were added and the reaction mixture was allowed to stir overnight at 
room temperature. After addition of water (3 mL) the solution was extracted with EtOAc (3x 20 
mL), the combined organic layers were washed with brine (5 mL) and evaporated to dryness. The 
remaining oil was dissolved in EtOAc (28 mL) and cooled down in an ice bath, triethylamine (0.83 
mL, 6.3 mmol) was added followed by dropwise addition of acetic anhydride (0.38 mL, 4.2 mmol) 
over a 10 min period, the reaction mixture was stirred 30 min more. The reaction mixture was 
quenched by addition of a solution of K2CO3 (15 w%, 6 mL), the organic layer was then washed 
with water (5 mL) and brine (5 mL). The combined organic layers were evaporated to dryness and 
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the remaining residue was purified by flash chromatography (Hexanes/EtOAc 1:1) to yield the 
acetylated aziridine (0.32 g, 51%). 
1H NMR (400 MHz, Chloroform-d3) δ 7.09 (dd, J = 4.6, 3.4 Hz, 1H), 5.01 (ddd, J = 10.2, 6.6, 2.3 
Hz, 1H), 4.21 (q, J = 7.1 Hz, 2H), 3.37 (dt, J = 6.1, 2.1 Hz, 1H), 3.23 (dd, J = 6.1, 4.6 Hz, 1H), 
3.16 (s, 3H), 3.07 (ddd, J = 16.2, 6.6, 1.9 Hz, 1H), 2.38 (ddd, J = 16.2, 10.2, 3.5 Hz, 1H), 2.20 (s, 
3H), 1.29 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, Chloroform-d3) δ 181.8, 165.0, 132.7, 131.2, 





[4.1.0]-hept-2-ene-3-carboxylate (0.13 g, 0.43 mmol) and N-(tert-
Butoxycarbonyl)ethanolamine (0.7 g, 1.3 mmol) were dissolved in 
DCM (1 mL) and the resulting solution was cooled to -40 ºC. Boron 
trifluoride diethyl etherate 1.65 M in DCM (0.39 mL, 0.64 mmol) 
was slowly added dropwise and the reaction mixture was gradually 
warmed up to room temperature. After 1 h at room temperature, the reaction was quenched by 
addition of water (2 mL), the pH was adjusted to neutral by addition of a saturated solution of 
sodium bicarbonate. The aqueous phase was extracted with EtOAc (4x 5 mL), the combined 
organic layers were washed with brine (3 mL) and evaporated down. The residue was purified by 
flash chromatography (hexanes/EtOAc 1:1) to afford the desired ether (0.12 g, 60%). 
1H NMR (300 MHz, Chloroform-d3) δ 6.90 (q, J = 1.9 Hz, 1H), 6.41 (d, J = 7.2 Hz, 1H), 5.23 (td, 
J = 3.4, 2.0 Hz, 1H), 4.99 (s, 1H), 4.32 – 4.12 (m, 4H), 3.77 – 3.65 (m, 1H), 3.51 (ddd, J = 9.8, 6.8, 
3.7 Hz, 1H), 3.35 – 3.23 (m, 2H), 3.03 (s, 3H), 2.79 (dt, J = 4.1, 2.0 Hz, 2H), 2.04 (s, 3H), 1.43 (s, 
9H), 1.30 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, Chloroform-d3) δ 171.2, 165.6, 156.2, 135.8, 
132.2, 79.6, 78.3, 74.6, 68.5, 61.4, 60.5, 51.0, 38.5, 30.5, 28.5 (3x), 23.3, 14.3. HR-ESI-MS 
calculated for C19H33O9N2S (M+H)






Sodium azide (0.08 g, 1.2 mmol) was added to a solution of the ethyl 
(3R,4S,5R)-4-acetamido-3-(2-((tert-butoxycarbonyl)amino)ethoxy)-
5-((methylsulfonyl)oxy)cyclohex-1-ene-1-carboxylate (0.14 g, 0.30 
mmol) in aqueous EtOH (1,5 mL, EtOH/water 5:1) and the reaction 
was heated to reflux for 24h. The solvent was evaporated under 
reduced pressur, the residue was dissolved in EtOAc (5 mL) and the organic phase was washed 
with water (1.5 mL) and brine (1 mL). The organic layer was evaporated down and the residue was 
purified by column chromatography (EtOAc) to furnish the desired azide (0.1 g, 81%). 
1H NMR (300 MHz, Chloroform-d3) δ 6.81 (t, J = 2.6 Hz, 1H), 6.05 (d, J = 8.0 Hz, 1H), 4.96 (s, 
1H), 4.38 (s, 1H), 4.29 – 4.15 (q, J = 7.1, 2H), 4.07 – 3.88 (m, 1H), 3.79 – 3.61 (m, 2H), 3.52 (td, 
J = 6.7, 3.5 Hz, 1H), 3.30 (m, 2H), 2.88 (ddd, J = 18.5, 5.9, 1.4 Hz, 1H), 2.43 – 2.18 (m, 1H), 2.07 
(s, 3H), 1.44 (s, 9H), 1.30 (t, J = 7.1, 3H). 13C NMR (75 MHz, Chloroform-d3) δ 171.46, 165.6, 
156.1, 136.3, 132.1, 79.8, 78.4, 68.7, 61.4, 57.7, 55.6, 40.8, 30.6, 28.5 (x3), 23.6, 14.3. HR-ESI-
MS calculated for C18H29O6N5Na (M+Na)




Lindlar catalyst (45 mg, 60 w%) was added to a solution of the ethyl 
(3R,4R,5S)-4-acetamido-5-azido-3-(2-((tert-butoxycarbonyl)amino)-
ethoxy)cyclohex-1-ene-1-carboxylate (73 mg, 0.17 mmol) in absolute 
EtOH (2.5 mL) the flask was sealed and purged with hydrogen, the 
reaction was left stirring overnight at room temperature under 1 
atmosphere of hydrogen. The catalyst was filtered out and rinsed several times with EtOH, the 
filtrate was evaporated to dryness to yield the amine (67 mg, 98%). The product was used in the 
next step without further purification. HR-ESI-MS calculated for C18H32O6N3 (M+H)
+ 386.2286,  
found 386.2286. 
 
 (3R,4R,5S)-4-Acetamido-5-amino-3-(2-aminoethoxy)cyclohex-1-ene-1-carboxylic acid 
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 The conditions used are described in the general procedure for the 
saponification of ethyl esters. The solvent was evaporated under 
reduced pressure and the remaining crude mixture was dissolved in 
TFA (1 mL, 100%), the reaction was stirred for 30 min at room 
temperature. The TFA was removed by evaporation under reduced 
pressure and the remaining solid was purified by preparative HPLC to 
afford the desired amino acid (30 mg, 34%). 
1H NMR (401 MHz, Methanol-d4) δ 6.87 (t, J = 2.5 Hz, 1H), 4.26 (ddt, J = 8.8, 3.8, 1.8 Hz, 1H), 
4.04 (dd, J = 11.1, 8.7 Hz, 1H), 3.87 (ddd, J = 10.6, 6.2, 4.4 Hz, 1H), 3.81 – 3.60 (m, 2H), 3.11 (t, 
J = 4.7 Hz, 2H), 3.00 – 2.81 (m, 1H), 2.35 – 2.15 (m, 1H), 2.05 (s, 3H). 13C NMR (101 MHz, 
Methanol-d4) δ 174.3, 168.6, 136.9, 131.6, 79.2, 65.5, 59.8, 54.9, 40.9, 31.3, 23.0. HR-ESI-MS 
calculated for C11H20O4N3 (M+H)




amino)ethoxy)cyclohex-1-ene-1-carboxylate (0.08 g, 0.19 mmol) was 
dissolved in DCM (1mL) followed by addition of TFA (0.25 mL), the 
reaction was stirred for 1 h at room temperature. The solvents were 
removed under reduced pressure and the dry residue was dissolved in 
EtOAc (1.5 mL). Triethylamine (0.17 mL, 0.76 mmol) was 
subsequently added followed by acetic anhydride (0.04 ml, 0.38 mmol) and the reaction was stirred 
for 3 h at room temperature. The mixture was diluted in EtOAc (15 mL) and the organic phase was 
washed with diluted solution of potassium carbonate (2 mL) and brine (2 mL). The organic layer 
was evaporated to dryness and the crude residue purified by flash chromatography (DCM/MeOH 
10:1) to yield the acetamide (0.06 g, 88%).  
1H NMR (300 MHz, Chloroform-d3) δ 6.87 – 6.71 (m, 2H), 6.54 (t, J = 5.3 Hz, 1H), 4.21 (m, 3H), 
3.95 (dt, J = 11.1, 8.5 Hz, 1H), 3.85 – 3.66 (m, 2H), 3.55 (ddd, J = 12.1, 5.6, 2.9 Hz, 1H), 3.50 – 
3.40 (m, 1H), 3.29 (ddt, J = 14.0, 6.3, 3.7 Hz, 1H), 2.97 – 2.78 (m, 1H), 2.30 (ddt, J = 17.7, 10.1, 
3.2 Hz, 1H), 2.06 (s, 3H), 2.00 (s, 3H), 1.29 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, Chloroform-
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d3) δ 171.7, 170.9, 165.5, 136.1, 129.6, 77.6, 67.7, 61.4, 58.1, 54.2, 39.6, 30.4, 23.6, 23.2, 14.3. 
HR-ESI-MS calculated for C15H24O5N5 (M+H)
+ 354.1772,  found 354.1773. 
 
Ethyl (3R,4R,5S)-4-acetamido-3-(2-acetamidoethoxy)-5-aminocyclohex-1-ene-1-carboxylate 
Lindlar catalyst (34 mg, 60 w%) was added to a solution of ethyl 
(3R,4R,5S)-4-acetamido-3-(2-acetamidoethoxy)-5-azidocyclohex-1-
ene-1-carboxylate (57 mg, 0.16 mmol) in absolute ethanol (2.5 mL), 
the flask was purged with hydrogen twice and the reaction was left 
stirring at room temperature for 3 h under hydrogen (1 atm) 
atmosphere. The catalyst was filtered and rinsed several times with ethanol, the filtrate was 
evaporated to dryness under reduced pressure. The resulting amine (47 mg, 90%) was used in the 
following step without further purification.  
1H NMR (400 MHz, Chloroform-d3) δ 6.79 (d, J = 2.6 Hz, 1H), 6.68 (t, J = 5.3 Hz, 1H), 6.53 (d, J 
= 8.8 Hz, 1H), 4.20 (q, J = 7.0 Hz, 2H), 4.13 – 4.01 (m, 1H), 3.89 (dt, J = 10.6, 8.8 Hz, 1H), 3.78 
– 3.65 (m, 2H), 3.59 – 3.40 (m, 2H), 3.28 (ddd, J = 13.4, 7.0, 3.2 Hz, 1H), 3.08 – 2.85 (m, 1H), 
2.89 – 2.72 (m, 1H), 2.21 (broad s, 2H), 2.06 (s, 3H), 2.00 (s, 3H), 1.29 (t, J = 7.1 Hz, 3H). 13C 
NMR (101 MHz, Chloroform-d3) δ 172.1, 170.9, 166.0, 136.0, 130.8, 78.4, 67.4, 61.2, 56.0, 49.7, 
39.6, 33.9, 23.7, 23.2, 14.3. HR-ESI-MS calculated for C15H25O5N3Na (M+Na)




The conditions used are described in the general procedure for the 
saponification of ethyl esters. The product was purified by preparative 
HPLC to afford the desired amino acid (35 mg, 82%). 
1H NMR (400 MHz, D2O) δ 6.95 (s, 1H), 4.36 – 4.28 (m, 1H), 4.18 
(dd, J = 11.3, 8.7 Hz, 1H), 3.80 (ddd, J = 10.3, 6.0, 4.5 Hz, 1H), 3.72 
– 3.57 (m, 2H), 3.36 (td, J = 6.7, 6.3, 4.2 Hz, 2H), 3.01 – 2.88 (m, 
1H), 2.54 (ddt, J = 16.8, 10.3, 3.1 Hz, 1H), 2.09 (s, 3H), 2.00 (s, 3H). 13C NMR (101 MHz, D2O) δ 
175.2, 174.2, 168.8, 136.7, 128.4, 76.6, 67.8, 51.2, 48.8, 39.4, 28.0, 22.2, 21.8. HR-ESI-MS 
calculated for C13H22O5N3 (M+H)







carbonyl)amino)ethoxy)cyclohex-1-ene-1-carboxylate (0.08 g, 
0.19 mmol) was dissolved in DCM (1mL) followed by addition 
of TFA (0.25 mL), the reaction was stirred for 1 h at room 
temperature. The solvents were removed under reduced pressure, 
the dry residue was dissolved in DCM (2 mL) and the solution 
was cooled to 0 ºC in an ice-bath. Triethylamine (0.13 mL, 0.95 mmol) was added followed by a 
solution of nicotinoyl chloride hydrochloride (0.053 g, 0.28 mmol) and the reaction was stirred for 
4h at room temperature. The solution was diluted in EtOAc (10 mL) and the organic phase was 
washed with water (2 mL) and brine (1.5 mL), the organic layer was dried under reduced pressure 
and the remaining mixture purified by chromatography (DCM/MeOH 10:1) to yield the desired 
amide (0.057 g, 71%). 
1H NMR (400 MHz, Chloroform-d3) δ 9.07 (d, J = 2.3 Hz, 1H), 8.63 (dd, J = 4.9, 1.6 Hz, 1H), 8.21 
(dt, J = 7.9, 2.0 Hz, 1H), 7.76 (t, J = 5.1 Hz, 1H), 7.43 – 7.28 (m, 2H), 6.78 (s, 1H), 4.26 (dt, J = 
9.0, 1.9 Hz, 1H), 4.17 (q, J = 7.0 Hz, 2H), 3.98 (dt, J = 11.2, 8.7 Hz, 1H), 3.84 (ddd, J = 9.6, 7.2, 
3.4 Hz, 1H), 3.77 – 3.60 (m, 3H), 3.57 – 3.46 (m, 1H), 2.92 – 2.80 (m, 1H), 2.26 (ddq, J = 17.2, 
10.3, 3.0 Hz, 1H), 1.83 (s, 3H), 1.25 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, Chloroform-d3) δ 
171.9, 166.1, 165.4, 151.9, 148.6, 136.1, 135.5, 130.1, 129.6, 123.5, 77.6, 66.9, 61.4, 58.2, 53.8, 
40.3, 30.4, 23.2, 14.2. HR-ESI-MS calculated for C19H25O5N6 (M+H)




Lindlar catalyst (34 mg, 60 w%) was added to a solution of ethyl 
(3R,4R,5S)-4-acetamido-5-azido-3-(2-(nicotinamido)ethoxy)-
cyclo-hex-1-ene-1-carboxylate (57 mg, 0.16 mmol) in absolute 
ethanol (2.5 mL), the flask was purged with hydrogen twice and 
the reaction was left stirring at room temperature for 3 h under 
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hydrogen (1 atm) atmosphere. The catalyst was filtered and rinsed several times with ethanol, the 
filtrate was evaporated to dryness under reduced pressure. The resulting amine (45 mg, 89%) was 
used in the following step without further purification. A solution of NaOH 0.5 M (0.55 mL, 0.23 
mmol) was added to a solution of the ethyl ester (45 mg, 0.12 mmol) in 1,4-dioxane (0.55 mL), the 
reaction mixture was stirred at room temperature for 4 h. The solvent was evaporated under reduced 
pressure and the remaining solid was purified by preparative HPLC to afford the desired amino 
acid (34 mg, 79%).  
1H NMR (400 MHz, D2O) δ 9.20 (dd, J = 2.0, 0.8 Hz, 1H), 8.97 (ddt, J = 5.9, 1.4, 0.7 Hz, 1H), 
8.96 – 8.88 (m, 1H), 8.20 (dddd, J = 6.7, 5.8, 1.6, 0.8 Hz, 1H), 6.93 (s, 1H), 4.40 – 4.32 (m, 1H), 
4.21 (dd, J = 11.4, 8.7 Hz, 1H), 3.93 (dt, J = 10.4, 5.2 Hz, 1H), 3.83 (dt, J = 10.3, 5.0 Hz, 1H), 3.69 
– 3.58 (m, 3H), 3.01 – 2.87 (m, 1H), 2.53 (ddt, J = 17.4, 10.2, 3.1 Hz, 1H), 1.99 (s, 3H). 13C NMR 
(101 MHz, D2O) δ 175.1, 168.8, 166.0, 144.5, 143.9, 141.3, 136.5, 133.2, 128.7, 127.4, 76.7, 67.5, 
51.1, 48.8, 40.3, 28.0, 22.1. HR-ESI-MS calculated for C17H23O5N4 (M+H)






carbonyl)-amino)ethoxy)cyclohex-1-ene-1-carboxylate (0.066 g, 
0.16 mmol) was dissolved in DCM (1mL) followed by addition of 
TFA (0.25 mL), the reaction was stirred for 1 h at room 
temperature. The solvents were removed under reduced pressure, 
the dry residue was dissolved in propan-2-ol (1mL) followed by 
addition of triethylamine (0.11 mL, 0.8 mmol) and divinyl sulfone (0.022 g, 0.19 mmol), the 
reaction mixture was then heated to 60 ºC for 3 h. The solvent was evaporated under reduced 
pressure and the remaining mixture was directly purified by flash chromatography (DCM/MeOH 
10:1) to yield the conjugated addition product (0.061 g, 89%).  
1H NMR (300 MHz, Chloroform-d3) δ 6.82 (s, 1H), 6.04 (d, J = 8.2 Hz, 1H), 4.43 (dt, J = 8.7, 2.0 
Hz, 1H), 4.22 (q, J = 7.1 Hz, 2H), 3.98 (td, J = 10.4, 5.7 Hz, 1H), 3.80 – 3.52 (m, 3H), 3.16 – 2.98 
(m, 8H), 2.88 (ddd, J = 17.2, 6.2, 3.3 Hz, 1H), 2.81 – 2.65 (m, 2H), 2.39 – 2.19 (m, 1H), 2.06 (s, 
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3H), 1.29 (t, J = 7.1 Hz, 3H). 13C NMR (75 MHz, Chloroform-d3) δ 171.2, 165.5, 136.5, 129.7, 
76.5, 66.6, 61.4, 57.8, 56.6, 55.0, 51.5, 51.0, 30.5, 23.7, 14.3. HR-ESI-MS calculated for 
C17H28O6N5S (M+H)




Lindlar catalyst (36 mg, 60 w%) was added to a solution of ethyl 
(3R,4R,5S)-4-acetamido-5-azido-3-(2-(1,1-dioxidothio-
morpholino)-ethoxy)cyclohex-1-ene-1-carboxylate (60 mg, 0.16 
mmol) in absolute ethanol (2.5 mL), the flask was purged with 
hydrogen twice and the reaction was left stirring at room 
temperature for 3 h under hydrogen (1 atm) atmosphere. The catalyst was filtered and rinsed several 
times with ethanol, the filtrate was evaporated to dryness under reduced pressure. The resulting 
amine (52 mg, 93%) was used in the following step without further purification. A solution of 
NaOH 0.5 M (0.56 mL, 0.28 mmol) was added to a solution of the ethyl ester (45 mg, 0.14 mmol) 
in 1,4-dioxane (0.56 mL), the reaction mixture was stirred at room temperature for 4 h. The solvent 
was evaporated under reduced pressure and the remaining solid was purified by preparative HPLC 
to afford the desired amino acid (46 mg, 88%).  
1H NMR (300 MHz, D2O) δ 6.95 (s, 1H), 4.44 – 4.33 (m, 1H), 4.28 (dd, J = 11.2, 8.7 Hz, 1H), 4.13 
(dt, J = 10.8, 4.9 Hz, 1H), 3.98 (dt, J = 5.3, 3.9 Hz, 2H), 3.91 (t, J = 5.5 Hz, 3H), 3.76 – 3.60 (m, J 
= 5.5 Hz, 5H), 3.53 (dt, J = 16.1, 5.0 Hz, 2H), 2.99 (dd, J = 17.4, 5.7 Hz, 1H), 2.56 (ddt, J = 17.0, 
10.4, 3.0 Hz, 1H), 2.12 (s, 3H). 13C NMR (75 MHz, D2O) δ 175.2, 169.2, 134.8, 129.7, 77.1, 62.5, 
55.7, 55.1, 50.9, 50.8, 48.7, 47.5, 47.4, 28.2, 22.2. HR-ESI-MS calculated for C15H26O6N3S 







carbonyl)-amino)ethoxy)cyclohex-1-ene-1-carboxylate (0.07 g, 
0.17 mmol) was dissolved in DCM (1 mL) followed by addition of 
TFA (0.25 mL), the reaction was stirred for 1 h at room temperature. 
The solvents were removed under reduced pressure and the dry 
residue was dissolved in DMF (1 mL). In a separate flask was 
prepared under inert atmosphere a solution of 2-(1H-benzotriazole-1-yl)-1,1,3,3-
tetramethylaminium tetrafluoroborate (0.13 g, 0.41 mmol), Boc-L-alanine (0.064 g, 0.32 mmol) 
and triethylamine (0.23 mL, 1.7 mL) in DMF (1.5 mL). The reaction was stirred 10 min at room 
temperature followed by addition of the DMF solution containing the amine, the resulting reaction 
was stirred overnight at room temperature. The following day the reaction was quenched by 
addition of a saturated solution of sodium bicarbonate (3 mL) and water (3 mL), the aqueous layer 
was extracted with EtOAc (3x 10 mL) and the combined organic phases were washed with water 
(2x 3 mL), brine (3 mL) and evaporated down. The remaining mixture was purified by flash 
chromatography (DCM/MeOH from 20:1 to 10:1) to yield the amide as a white solid (0.047 g, 
58%). 
1H NMR (400 MHz, Chloroform-d3) δ 6.86 – 6.69 (m, 2H), 5.28 (d, J = 7.4 Hz, 1H), 4.34 – 4.19 
(m, 3H), 4.16 – 4.06 (m, 1H), 3.91 – 3.77 (m, 2H), 3.68 – 3.56 (m, 2H), 3.41 – 3.16 (m, 1H), 2.97 
– 2.83 (m, 1H), 2.41 – 2.23 (m, 1H), 2.10 (s, 3H), 1.88 (s, 2H), 1.45 (s, 9H), 1.43 – 1.35 (m, 3H), 
1.32 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, Chloroform-d3) δ 173.2, 171.8, 165.6, 158.1, 136.0, 
129.4, 80.8, 68.1, 61.4, 61.3, 58.5, 55.2, 50.6, 39.8, 30.6, 28.5, 23.6, 18.5, 14.3. HR-ESI-MS 
calculated for C21H34N6O7Na (M + Na)




Lindlar catalyst (46 mg, 60 w%) was added to a solution of ethyl 
(3R,4R,5S)-4-acetamido-5-azido-3-(2-((S)-2-((tert-butoxycarbon-
yl)amino)propanamido)ethoxy)cyclohex-1-ene-1-carboxylate (77 
mg, 0.16 mmol) in absolute ethanol (2.5 mL), the flask was purged 
with hydrogen twice and the reaction was left stirring at room 
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temperature for 3 h under hydrogen (1 atm) atmosphere. The catalyst was filtered and rinsed several 
times with ethanol. The filtrate was evaporated to dryness under reduced pressure. The remaining 
solid was purified by flash chromatography (DCM/MeOH 10:1) to yield the desired amine (70 mg, 
96%).  
1H NMR (400 MHz, Chloroform-d3) δ 7.37 (broad s, 1H), 7.03 (bread s, 1H), 6.78 (s, 1H), 5.48 
(broad s, 1H), 4.27 – 4.04 (m, 5H), 3.98 (d, J = 9.9 Hz, 2H), 3.76 (dd, J = 7.2, 3.3 Hz, 2H), 3.66 – 
3.42 (m, 2H), 3.23 (s, 1H), 2.90 (d, J = 18.2 Hz, 1H), 2.48 – 2.27 (m, 1H), 2.09 (d, J = 2.6 Hz, 3H), 
1.41 (s, 9H), 1.37 – 1.31 (m, 3H), 1.30 – 1.18 (m, 3H). 13C NMR (101 MHz, Chloroform-d3) δ 
173.2, 172.8, 165.9, 155.8, 136.1, 130.0, 80.1, 78.0, 68.1, 61.3, 55.2, 50.3, 49.9, 39.7, 32.3, 28.5, 
23.8, 19.1, 14.3. HR-ESI-MS calculated for C21H36O7N4Na (M+Na)




 The conditions used are described in the general procedure for the 
saponification of ethyl esters. After removal of the solvent the 
remaining solid was dissolved in TFA (1 mL) and the reaction was 
stirred for 1 h at room temperature. The acid was evaporated under 
reduced pressure and the mixture was purified by preparative 
HPLC to give the desired aminoacid (38 mg, 85%). 
1H NMR (400 MHz, D2O) δ 6.91 (t, J = 2.7 Hz, 1H), 4.33 (dq, J = 7.7, 1.8 Hz, 1H), 4.26 – 4.14 
(m, 1H), 4.06 (dd, J = 8.7, 5.5 Hz, 1H), 3.80 (td, J = 6.6, 3.3 Hz, 1H), 3.74 – 3.55 (m, 2H), 3.55 – 
3.32 (m, 2H), 3.04 – 2.92 (m, 1H), 2.54 (ddt, J = 17.6, 10.2, 3.1 Hz, 1H), 2.10 (s, 3H), 1.53 (d, J = 
7.1 Hz, 3H). 13C NMR (101 MHz, D2O) δ 175.3, 170.8, 168.8, 136.5, 128.7, 76.6, 67.6, 51.2, 49.1, 
48.8, 39.5, 28.0, 22.2, 16.5. HR-ESI-MS calculated for C14H25O5N4 (M+H)








hept-2-ene-3-carboxylate (0.2 g, 0.66 mmol) and propargyl alcohol (0.37 
g, 6.6 mmol) were dissolved in DCM (1.5 mL) and the resulting solution 
was cooled to -40 ºC. Boron trifluoride diethyl etherate 1.65 M in DCM 
(0.6 mL, 0.99 mmol) was slowly added dropwise and the reaction mixture 
was gradually warmed up to room temperature. After 1 h at room 
temperature, the reaction was quenched by addition of water (2 mL), the pH was adjusted to neutral 
by addition of a saturated solution of sodium bicarbonate. The aqueous phase was extracted with 
EtOAc (4x 5 mL), the combined organic layers were washed with brine (3 mL) and evaporated 
down. The residue was purified by flash chromatography (EtOAc) to afford the desired ether (0.14 
g, 58%). 
1H NMR (400 MHz, Chloroform-d3) δ 6.93 (q, J = 2.0 Hz, 1H), 6.15 (d, J = 7.4 Hz, 1H), 5.26 (td, 
J = 3.5, 2.2 Hz, 1H), 4.39 – 4.31 (m, 1H), 4.30 (dd, J = 11.1, 2.3 Hz, 2H), 4.27 – 4.17 (m, 3H), 3.04 
(s, 3H), 2.80 (dt, J = 4.5, 2.2 Hz, 2H), 2.54 (s, 1H), 2.03 (s, 3H), 1.30 (t, J = 7.1 Hz, 3H). 13C NMR 
(101 MHz, Chloroform-d3) δ 171.0, 165.6, 135.4, 128.4, 79.6, 78.2, 75.7, 73.0, 61.4, 57.0, 51.4, 
38.5, 30.3, 23.4, 14.3. HR-ESI-MS calculated for C15H21O7NNa (M+Na)





An oven dried flask was charged with ethyl (3R,4S,5R)-4-
acetamido-5-((methylsulfonyl)oxy)-3-(prop-2-yn-1-yloxy)-
cyclohex-1-ene-1-carboxylate (61 mg, 0.17 mmol) 
tetrakis(acetonitrile)copper(I) hexafluorophosphate (6 mg, 
0.017 mmol), tris (1-benzyl-1H-1,2,3-triazol-4-yl)methyl 
amine (10 mg, 0.017 mmol) and distilled THF (1.5 mL). The 
flask was purged with argon followed by dropwise addition of a solution of 4-(2-
azidoethyl)morpholine (32 mg, 0.20 mmol) in THF (0.5 mL), the reaction mixture was stirred 
overnight at room temperature. The solution was evaporated to dryness and the remaining mixture 
was purified by flash chromatography (DCM/MeOH 20:1) to yield the triazole (67 mg, 77%).  
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1H NMR (600 MHz, Chloroform-d3) δ 7.70 (s, 1H), 7.43 (d, J = 5.7 Hz, 1H), 6.94 (s, 1H), 5.37 (q, 
J = 3.1 Hz, 1H), 4.88 (d, J = 12.9 Hz, 1H), 4.75 (d, J = 13.0 Hz, 1H), 4.46 (t, J = 6.2 Hz, 2H), 4.40 
(d, J = 9.3 Hz, 1H), 4.20 (tt, J = 7.2, 3.4 Hz, 2H), 4.16 – 4.08 (m, 1H), 3.68 (t, J = 4.6 Hz, 3H), 
3.00 (s, 3H), 2.89 – 2.70 (m, 3H), 2.49 (t, J = 4.6 Hz, 4H), 2.27 (s, 1H), 2.01 (s, 3H), 1.29 (t, J = 
7.0 Hz, 3H). 13C NMR (151 MHz, Chloroform-d3) δ 171.5, 165.7, 144.7, 135.7, 128.1, 123.1, 77.8, 
73.6, 66.9 (x2), 62.6, 61.3, 57.9, 53.6 (x2), 52.4, 47.5, 38.1, 30.3, 23.3, 14.3. HR-ESI-MS 
calculated for C21H33O8N5SNa (M+Na)




Sodium azide (82 mg, 1.2 mmol) was added to a solution of 
ethyl (3R,4S,5R)-4-acetamido-5-((methylsulfonyl)oxy)-3-((1-
(2-morpholinoethyl)-1H-1,2,3-triazol-4-yl)methoxy)cyclohex-
1-ene-1-carboxylate (162 mg, 0.32 mmol) in aqueous EtOH 
(1.5 mL, EtOH/water 5:1), the reaction was refluxed for 24 h. 
The ethanol was evaporated under reduced pressure and the 
remaining slurry was dissolved in water (5 mL), the aqueous solution was extracted with EtOAc 
(3x 10 mL) and the combined organic layers were washed with water (3 mL) and brine (3 ml). The 
azide was obtained after evaporation of the solvent, no further purification was needed (55 mg, 
37%).  
1H NMR (400 MHz, Chloroform-d3) δ 7.70 (s, 1H), 6.80 (t, J = 2.4 Hz, 1H), 6.70 (d, J = 8.1 Hz, 
1H), 4.80 (d, J = 12.5 Hz, 1H), 4.68 (d, J = 12.4 Hz, 1H), 4.59 (dt, J = 8.8, 1.9 Hz, 1H), 4.44 (t, J 
= 6.3 Hz, 2H), 4.18 (t, J = 7.1 Hz, 2H), 4.02 – 3.90 (m, 1H), 3.82 – 3.71 (m, 1H), 3.70 – 3.59 (m, 
4H), 2.87 – 2.76 (m, 3H), 2.52 – 2.44 (m, 4H), 2.30 – 2.20 (m, 1H), 1.95 (s, 3H), 1.27 (t, J = 7.1 
Hz, 3H). 13C NMR (101 MHz, Chloroform-d3) δ 171.4, 165.6, 144.6, 136.6, 129.4, 123.6, 75.8, 
66.9 (x2), 62.7, 61.3, 58.0, 57.9, 55.6, 53.5 (x2), 47.4, 30.4, 23.5, 14.3. HR-ESI-MS calculated for 
C20H30O5N8Na (M+Na)






Lindlar catalyst (33 mg, 60 w%) was added to a solution of 
ethyl (3R,4R,5S)-4-acetamido-5-azido-3-((1-(2-morpholino-
ethyl)-1H-1,2,3-triazol-4-yl)methoxy)cyclohex-1-ene-1-
carboxylate (55 mg, 0.12 mmol) in absolute ethanol (1.8 
mL), the flask was purged with hydrogen twice and the 
reaction was left stirring at room temperature for 5 h under 
hydrogen (1 atm) atmosphere. The catalyst was filtered and rinsed several times with ethanol, the 
filtrate was evaporated to dryness under reduced pressure. The resulting amine (44 mg, 85%) was 
used in the following step without further purification.  
1H NMR (400 MHz, Methanol-d4) δ 7.96 (s, 1H), 6.80 (dt, J = 2.6, 1.3 Hz, 1H), 4.73 (d, J = 12.2 
Hz, 1H), 4.64 (d, J = 12.1 Hz, 1H), 4.48 (t, J = 6.3 Hz, 2H), 4.32 – 4.22 (m, 1H), 4.15 (q, J = 7.1 
Hz, 2H), 3.90 (dd, J = 10.7, 8.4 Hz, 1H), 3.63 – 3.54 (m, 4H), 3.31 – 3.20 (m, 1H), 2.87 – 2.73 (m, 
3H), 2.43 (dd, J = 5.5, 3.7 Hz, 4H), 2.28 (ddt, J = 17.8, 9.7, 3.0 Hz, 1H), 1.95 (s, 3H), 1.23 (t, J = 
7.1 Hz, 3H). 13C NMR (101 MHz, Methanol-d4) δ 174.6, 167.0, 145.5, 137.4, 130.3, 125.7, 77.4, 
67.8, 63.6, 62.2, 58.8, 58.3, 54.9, 54.5, 50.5, 31.1, 23.1, 14.5. HR-ESI-MS calculated for 
C20H33O5N6 (M+H)




The conditions used are described in the general procedure for 
the saponification of ethyl esters. Purified by preparative HPLC 
to afford the desired amino acid (24 mg, 57%). 
1H NMR (400 MHz, D2O) δ 8.13 (s, 1H), 6.98 (t, J = 2.5 Hz, 
1H), 4.97 (t, J = 6.1 Hz, 2H), 4.73 (hidden behind the signal of 
D2O, d, J = 12.2 Hz, 1H), 4.64 (hidden behind the signal of D2O 
d, J = 12.1 Hz, 1H), 4.52 – 4.43 (m, 1H), 4.17 (dd, J = 11.4, 8.7 Hz, 1H), 3.99 (broad s, 4H), 3.85 
(t, J = 6.1 Hz, 2H), 3.66 (ddd, J = 11.6, 10.2, 5.7 Hz, 1H), 3.47 (broad s, 4H), 3.06 – 2.91 (m, 1H), 
2.54 (ddt, J = 17.5, 10.2, 3.1 Hz, 1H), 2.04 (s, 3H). 13C NMR (101 MHz, D2O) δ 175.2, 168.8, 
144.3, 136.4, 128.7, 125.6, 76.1, 63.5 (x2), 61.7, 55.4, 52.0 (x2) , 51.3, 48.6, 44.1, 28.1, 22.2. HR-
ESI-MS calculated for C18H28O5N6Na (M+Na)







hept-2-ene-3-carboxylate (0.15 g, 0.49 mmol) and propargyl alcohol (0.33 
mL, 4.9 mmol) were dissolved in DCM (1.25 mL) and the resulting 
solution was cooled to -40 ºC. Boron trifluoride diethyl etherate 1.65 M in 
DCM (0.45 mL, 0.73 mmol) was slowly added dropwise and the reaction 
mixture was gradually warmed up to room temperature. After 1 h at room 
temperature, the reaction was quenched by addition of water (2 mL), the pH was adjusted to neutral 
by addition of a saturated solution of sodium bicarbonate. The aqueous phase was extracted with 
EtOAc (4x 5 mL), the combined organic layers were washed with brine (3 mL) and evaporated 
down. The residue was purified by flash chromatography (EtOAc) to afford the desired ether (0.12 
g, 64%). 
1H NMR (400 MHz, Chloroform-d3) δ 6.95 – 6.90 (m, 1H), 6.14 (d, J = 7.8 Hz, 1H), 5.87 (ddt, J 
= 17.2, 10.4, 5.6 Hz, 1H), 5.32 – 5.18 (m, 3H), 4.29 (ddd, J = 8.8, 7.8, 2.3 Hz, 1H), 4.21 (qd, J = 
7.1, 1.5 Hz, 2H), 4.18 – 4.12 (m, 2H), 4.02 (ddt, J = 12.6, 5.7, 1.4 Hz, 1H), 3.03 (s, 3H), 2.89 – 
2.73 (m, 2H), 2.01 (s, 3H), 1.29 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, Chloroform-d3) δ 170.9, 
165.6, 136.1, 134.2, 128.3, 118.0, 78.3, 73.5, 70.1, 61.4, 51.0, 38.5, 30.2, 23.3, 14.3. HR-ESI-MS 
calculated for C15H23O7NSNa (M+Na)
+ 384.1087,  found 384.1089. 
 
Ethyl (3R,4R,5S)-4-acetamido-3-(allyloxy)-5-azidocyclohex-1-ene-1-carboxylate 
Sodium azide (150 mg, 1.6 mmol) was added to a solution of ethyl 
(3R,4S,5R)-4-acetamido-3-(allyloxy)-5-((methylsulfonyl)oxy)cyclohex-1-
ene-1-carboxylate (150 mg, 0.41 mmol) in aqueous EtOH (1.8 mL, 
EtOH/water 5:1), the reaction was refluxed for 24 h. The ethanol was 
evaporated under reduced pressure and the remaining slurry was dissolved 
in water (5 mL), the aqueous solution was extracted with EtOAc (3x 10 mL) and the combined 
organic layers were washed with water (3 mL) and brine (3 ml). The organic phase was evaporated 
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down and the resulting residue purified by flash chromatography (Hexanes/EtOAc 1:1) to yield the 
desired azide (55 mg, 37%).  
1H NMR (400 MHz, Chloroform-d3) δ 6.84 (s, 1H), 5.96 – 5.81 (m, 1H), 5.75 (d, J = 7.8 Hz, 1H), 
5.29 (d, J = 17.2 Hz, 1H), 5.21 (d, J = 10.3 Hz, 1H), 4.57 – 4.49 (m, 1H), 4.22 (qd, J = 7.2, 1.0 Hz, 
2H), 4.21 – 4.11 (m, 2H), 4.09 – 3.99 (m, 1H), 3.53 (dt, J = 11.1, 8.3 Hz, 1H), 2.88 (dd, J = 18.0, 
5.6 Hz, 1H), 2.27 (ddt, J = 17.3, 10.3, 3.1 Hz, 1H), 2.05 (s, 3H), 1.30 (t, J = 7.2 Hz, 3H). 13C NMR 
(101 MHz, Chloroform-d3) δ 171.1, 165.7, 136.8, 134.3, 129.2, 118.1, 75.1, 70.7, 61.3, 57.5, 56.7, 
30.6, 23.7, 14.3. HR-ESI-MS calculated for C14H20O4N4Na (M+Na)




AD-mix-α (0.35 g, 1.4 g per 1 mmol of alkene) was dissolved in a 
mixture of tert-butanol and water (2.6 mL, 1:1) at room temperature, 
the solution was cooled down to 0 ºC and ethyl (3R,4R,5S)-4-
acetamido-3-(allyloxy)-5-azidocyclohex-1-ene-1-carboxylate (0.078 
g, 0.25 mmol) was added all at once, the reaction mixture was stirred 
for 24 h at 0 ºC. The reaction was quenched by addition of sodium 
sulfite (0.36 g) to the ice-cold solution, the bath was removed and the reaction was stirred for 30 
min at room temperature. The aqueous reaction mixture was extracted with EtOAc (3x 5 mL) and 
the combiner organic layers were washed with brine (3 mL). The organic phase was evaporated 
down under reduced pressure and the resulting mixture purified by flash chromatography 
(DCM/MeOH 20:1) to yield the dehydroxylated product (0.053 g, 61%) as a mixture of 
diastereomers.  
1H NMR (400 MHz, Chloroform-d3) δ 7.26 (d, J = 8.4 Hz, 1H), 6.81 (s, 1H), 4.40 – 4.26 (m, 1H), 
4.20 (q, J = 7.1 Hz, 2H), 4.06 (broad s, 1H), 3.94 – 3.82 (m, 2H), 3.82 – 3.74 (m, 2H), 3.74 – 3.44 
(m, 4H), 2.86 (dd, J = 17.4, 5.4 Hz, 1H), 2.27 (dd, J = 17.6, 9.9 Hz, 1H), 2.06 (s, 3H), 1.29 (t, J = 
7.1 Hz, 3H). Major diastereomer 13C NMR (101 MHz, Chloroform-d3) δ 172.5, 165.7, 136.6, 129.6, 
77.6, 71.0, 70.1, 63.6, 61.5, 58.3, 54.5, 30.6, 23.5, 14.3. Minor diastereomer 13C NMR (101 MHz, 
Chloroform-d3) δ 172.5, 165.7, 136.6, 129.5, 77.7, 71.1, 70.5, 63.5, 61.5, 58.3, 54.6, 30.6, 23.4, 
14.3. HR-ESI-MS calculated for C14H22O6N4Na (M+Na)





Lindlar catalyst (46 mg, 60 w%) was added to a solution of the azide 
(77 mg, 0.23 mmol) in absolute ethanol (3.5 mL), the flask was 
purged with hydrogen twice and the reaction was left stirring at room 
temperature overnight under hydrogen (1 atm) atmosphere. The 
catalyst was filtered and rinsed several times with ethanol, the filtrate 
was evaporated to dryness under reduced pressure. The resulting amine (68 mg, 95%) was used in 
the following step without further purification.  
1H NMR (400 MHz, Methanol-d4) δ 4.08 (q, J = 7.1 Hz, 2H), 3.66 – 3.34 (m, 6H), 3.23 – 3.17 (m, 
1H), 2.71 – 2.62 (m, 1H), 2.47 – 2.33 (m, 2H), 2.16 – 2.07 (m, 1H), 1.97 (s, 3H), 1.45 – 1.28 (m, 
2H), 1.19 (t, J = 7.1 Hz, 3H). Major diastereomer 13C NMR (101 MHz, Methanol-d4) δ 175.3, 
167.5, 80.1, 72.3, 71.9, 64.4, 61.9, 60.0, 53.5, 39.7, 35.8, 34.1, 23.1, 14.5. Minor diastereomer 13C 
NMR (101 MHz, Methanol-d4) δ 174.8, 167.5, 79.4, 72.5, 71.9, 64.3, 62.1, 60.0, 53.5, 39.7, 35.8, 
34.1, 23.1, 14.5. HR-ESI-MS calculated for C14H26O6N2Na (M+Na)




Oseltamivir phosphate (1.5 g, 3.6 mmol) and potassium carbonate (2.5 
g, 18.2 mmol) were dissolved in acetonitrile (60 mL) under inert 
atmosphere, the resulting solution was cooled down to 0 ºC in an ice bath 
followed by dropwise addition of propargyl bromide (80%, 0.47 g, 4.32 
mmol). The reaction mixture was stirred 16 h at room temperature and 
then heated to 50 ºC for 4 h more. The solvent was evaporated under 
reduced pressure and the remaining residue was dissolved in water (50 mL), the aqueous layer was 
extracted with DCM (3x 30 mL), the combined organic layers were washed with brine (10 mL) 
and evaporated to dryness. The resulting product was purified by flash chromatography 
(DCM/MeOH/NH3 80:20:1) to furnish the propargylated product (0.83 g, 65%). 
1H NMR (401 MHz, Chloroform-d3) δ 6.80 (td, J = 2.5, 1.1 Hz, 1H), 5.50 (d, J = 8.2 Hz, 1H), 4.27 
– 4.19 (m, 1H), 4.19 (q, J = 7.1 Hz, 2H), 3.68 (dt, J = 9.9, 8.0 Hz, 1H), 3.58 – 3.38 (m, 2H), 3.40 
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– 3.25 (m, 2H), 2.79 – 2.68 (m, 1H), 2.20 (t, J = 2.4 Hz, 1H), 2.19 – 2.12 (m, 1H), 2.03 (s, 3H), 
1.77 (bs, 1H), 1.56 – 1.46 (m, 4H), 1.29 (t, J = 7.1 Hz, 3H), 0.90 (td, J = 7.4, 3.0 Hz, 6H). 13C NMR 
(101 MHz, Chloroform-d3) δ 170.8, 166.6, 137.3, 129.3, 82.0, 81.8, 74.6, 71.7, 61.0, 56.1, 52.8, 
35.6, 30.2, 26.3, 25.8, 23.9, 14.4, 9.6, 9.5. HR-ESI-MS calculated for C19H31O4N2 (M+H)+ 
351.2278, found 351.2281. 
 
General procedure for CuAAC reaction between azides and propargylated oseltamivir.  
Ethyl (3R,4R,5S)-4-acetamido-3-(pentan-3-yloxy)-5-(prop-2-yn-1-ylamino)cyclohex-1-ene-1-
carboxylate (0.14 mmol) was dissolved in a THF/water mixture (2:1, 3 mL), the corresponding 
azide (0.17 mmol) and (+)-sodium L-ascorbate (0.7 mmol) were added and the reaction was purged 
with argon, copper(II) sulfate pentahydrate (0.28 mmol) was added and the reaction was heated to 
45 ºC for 2 h. The reaction mixture was cooled down to room temperature and a saturated solution 
of NaHCO3 (4 mL) was added, the aqueous layer was extracted with EtOAc (3x 5mL) and the 
combined organic layers were washed with brine (2 mL) and evaporated to dryness under reduced 




The conditions used are described in the general 
procedure for the saponification of ethyl esters. The 
product was purified by preparative HPLC. (33 mg, 
55%). 1H NMR (401 MHz, Methanol-d4) δ 8.16 (s, 1H), 
6.90 (s, 1H), 5.31 (s, 2H), 4.50 (q, J = 14.2 Hz, 2H), 4.27 
– 4.11 (m, 2H), 3.67 – 3.54 (m, 1H), 3.46 (t, J = 5.6 Hz, 
1H), 3.22 – 3.07 (m, 1H), 2.81 (s, 3H), 2.68 – 2.51 (m, 1H), 2.05 (d, J = 1.9 Hz, 3H), 1.66 – 1.43 
(m, 4H), 0.93 (dt, J = 12.4, 7.4 Hz, 6H). 13C NMR (101 MHz, Methanol-d4) δ 175.0, 170.2, 168.5, 
138.9, 138.7, 128.6, 128.1, 83.8, 75.8, 55.7, 53.1, 52.1, 39.9, 27.2, 27.1, 26.6, 26.5, 23.3, 9.8, 9.6. 
HR-ESI-MS calculated for C20H33O5N6 (M+H)






The conditions used are described in the general 
procedure for the saponification of ethyl esters. The 
product was purified by preparative HPLC (13 mg, 
21%).1H NMR (401 MHz, Methanol-d4) δ 8.07 (s 1H), 
6.91 – 6.80 (m, 1H), 5.52 (s, 2H), 4.49 (q, J = 14.3, 2H), 
4.16 (m, 2H), 3.62 – 3.50 (m, 1H), 3.45 (m, 1H), 3.20 – 
3.10 (m, 1H), 3.15 (s, 3H), 3.00 (s, 3H), 2.66 – 2.54 (m, 1H), 2.06 – 1.99 (s, 3H), 1.54 (ddt, J = 9.7, 
5.5, 2.1 Hz, 4H), 0.91 (dt, J = 12.5, 7.2, 6H). 13C NMR (101 MHz, Methanol-d4) δ 175.0, 168.5, 
167.7, 138.8, 138.7, 128.6 (2x), 83.8, 75.8, 55.7, 53.0, 52.1, 39.9, 36.7, 36.1, 27.2, 27.1, 26.6, 23.3, 
9.8, 9.5. HR-ESI-MS calculated for C21H33O5N6 (M-H)




The conditions used are described in the general 
procedure for the saponification of ethyl esters The 
product was purified by preparative HPLC (27 mg, 48 
%).1H NMR (401 MHz, Methanol-d4) δ 8.12 (s, 1H), 
6.89 (d, J = 1.1 Hz, 1H), 4.57 – 4.39 (m, 4H), 4.24 – 4.16 
(m, 1H), 4.12 (dd, J = 10.8, 8.1 Hz, 1H), 3.94 (dd, J = 
5.6, 4.7 Hz, 2H), 3.67 – 3.55 (m, 1H), 3.44 (t, J = 5.6 Hz, 1H), 3.22 – 3.08 (m, 1H), 2.61 (d, J = 
9.7 Hz, 1H), 2.03 (s, 3H), 1.59 – 1.47 (m, 4H), 0.91 (dt, J = 12.3, 7.4 Hz, 6H). 13C NMR (101 MHz, 
Methanol-d4) δ 175.0, 168.5, 138.7 (2x), 128.5, 127.3, 83.7, 75.6, 61.5, 55.5, 54.0, 53.2, 40.0, 27.1, 
27.1, 26.6, 23.2, 9.8, 9.5. HR-ESI-MS calculated for C19H30O5N5 (M-H)







The conditions used are described in the general 
procedure for the saponification of ethyl esters. The 
product was purified by preparative HPLC (29 mg, 45 
%).1H NMR (401 MHz, Methanol-d4) δ 8.08 (s, 1H), 
6.89 (q, J = 1.4 Hz, 1H), 4.53 – 4.39 (m, 4H), 4.20 (dd, 
J = 6.3, 3.5 Hz, 1H), 4.13 (dd, J = 10.7, 8.0 Hz, 1H), 
3.66 – 3.55 (m, 1H), 3.48 – 3.40 (m, 3H), 3.34 (dd, J = 11.1, 2.9 Hz, 2H), 3.11 (dd, J = 17.2, 5.8 
Hz, 1H), 2.59 (ddt, J = 12.3, 9.6, 4.8 Hz, 1H), 2.04 (s, 3H), 1.54 (m, 4H), 0.91 (dt, J = 11.3, 7.4 
Hz, 6H), 0.85 (s, 3H). 13C NMR (101 MHz, Methanol-d4) δ 174.9, 168.5, 138.6, 138.5, 128.5, 
128.2, 83.7, 75.5, 65.8 (2x), 55.7, 54.2, 53.1, 43.0, 40.1, 27.1 (2x), 26.6, 23.2, 17.7, 9.8, 9.5. HR-
ESI-MS calculated for C22H36O6N5 (M-H)




The conditions used are described in the general 
procedure for the saponification of ethyl esters. 
The product was purified by preparative HPLC 
(22 mg, 30 %). 1H NMR (401 MHz, Methanol-d4) 
δ 8.17 (s, 1H), 6.89 (s, 1H), 4.58 (dq, J = 6.8, 3.6 
Hz, 2H), 4.48 (q, J = 14.3 Hz, 2H), 4.23 (m, 1H), 
4.10 (dd, J = 10.8, 8.1 Hz, 1H), 3.67 – 3.56 (m, 1H), 3.45 (p, J = 5.7 Hz, 1H), 3.07 (m, 11H), 2.65 
– 2.52 (m, 1H), 2.04 (s, 3H), 1.53 (m, 4H), 0.91 (dt, J = 11.3, 7.4 Hz, 6H). 13C NMR (101 MHz, 
Methanol-d4) δ 174.9, 168.5, 138.7 (x2), 128.5, 127.2, 83.7, 75.5, 56.4 (2x), 55.5, 53.3, 51.9 (2x), 
51.8 (2x), 40.0, 27.1 (2x), 26.6, 23.3, 9.8, 9.5. HR-ESI-MS calculated for C23H39O6N6S (M+H)
+ 






The conditions used are described in the general 
procedure for the saponification of ethyl esters. The 
product was purified by preparative HPLC (7 mg, 12 %). 
1H NMR (401 MHz, Methanol-d4) δ 8.14 (s, 1H), 6.88 (s, 
1H), 5.27 (s, 2H), 4.57 – 4.39 (m, 2H), 4.24 – 4.05 (m, 
2H), 3.59 (m, 1H), 3.44 (m, 1H), 3.15 (dd, J = 17.4, 5.6 
Hz, 1H), 2.70 – 2.50 (m, 1H), 2.03 (s, 3H), 1.62 – 1.37 (m, 4H), 0.91 (dt, J = 12.8, 7.4 Hz, 6H). 
13C NMR (101 MHz, Methanol-d4) δ 175.0, 170.3, 168.5, 139.0, 138.7, 128.6, 128.1, 83.8, 75.8, 
55.7, 53.1, 52.2, 39.9, 27.2, 27.1, 26.6, 23.3, 9.8, 9.5. HR-ESI-MS calculated for C19H28O6N5 (M-
H)- 422.2045, found 422.2043. 
 
Ethyl (3R,4R,5S)-4-acetamido-5-azido-3-(ethylpropoxy)-1-cyclohexene-1-carboxylate 
Oseltamivir phosphate (1.0 g, 2.4 mmol) was dissolved in a solution of 
potassium carbonate (1.5 g, 10.9 mmol) and copper(II) sulfate pentahydrate 
(0.002 g, 0.024 mmol) in methanol (20 mL). The mixture was stirred for 10 
min followed by addition of imidazole-1-sulfonyl azide hydrochloride (0.6 g, 
2.9 mmol) and further stirring for 2 h. The reaction mixture was quenched by 
addition of H2O and extracted with DCM (3 x 30 mL), the combined organic 
phases were washed with H2O and brine, dried over Na2SO4 and evaporated to dryness under 
reduced pressure. Purification of crude product by flash column chromatography (eluent 
Hexane/EtOAc 1:1) furnished the azide (0.66 g, 80%). 
1H NMR (300 MHz, Chloroform-d3) δ 6.79 (d, J = 2.4 Hz, 1H), 5.73 (bs, 1H), 4.60 (d, J = 8.9 Hz, 
1H), 4.34 (td, J = 10.6, 5.7 Hz, 1H), 4.22 (q, J = 7.1 Hz, 2H), 3.38 – 3.18 (m, 2H), 2.87 (dd, J = 
17.7, 5.8 Hz, 1H), 2.30 – 2.12 (m, 1H), 2.04 (s, 3H), 1.60 – 1.43 (m, 4H), 1.30 (t, J = 7.1 Hz, 3H), 






CuI (0.054 g, 0.29 mmol) was added to a stirred solution of ethyl 
(3R,4R,5S)-4-acetamido-5-azido-3-(3-pentyloxy)cyclohex-1-ene-
carboxylate (0.3 g, 0.89 mmol), propargyl alcohol (0.15 g, 2.6 
mmol) and N,N-diisopropylethylamine (0.46 mL, 2.6 mmol) in 
toluene (6 mL) under inert atmosphere. The reaction mixture was 
refluxed for 5 min and then stirred at room temperature for 2 h more. 
The resulting yellow solution was dried under reduced pressure and purified by flash 
chromatography (DCM/MeOH 90:10) to furnish a solid product that was recrystallized from 
MeOH (0.32 g, 91%).  
1H NMR (300 MHz, Chloroform-d3) δ 7.72 (s, 1H), 6.89 (s, 1H), 6.49 (d, J = 8.0 Hz, 1H), 5.38 (td, 
J = 10.9, 6.4 Hz, 1H), 4.75 (s, 2H), 4.68 (dd, J = 8.8, 2.2 Hz, 1H), 4.22 (q, J = 7.1 Hz, 2H), 4.06 
(dt, J = 11.8, 8.5 Hz, 1H), 3.38 (m, J = 5.7 Hz, 1H), 3.10 – 2.88 (m, 1H), 1.76 (s, 3H), 1.51 (dd, J 
= 11.8, 6.4 Hz, 4H), 1.29 (t, J = 7.1 Hz, 3H), 0.89 (dt, J = 18.8, 7.4 Hz, 6H). 13C NMR (101 MHz, 
Chloroform-d3) δ 171.7, 165.7, 147.5, 138.6, 128.6, 123.6, 83.0, 74.6, 61.3, 57.4, 56.1, 31.3, 29.8, 
26.5, 25.7, 23.2, 14.3, 9.6, 9.4. HR-ESI-MS calculated for C19H31O5N4 (M+H)





The conditions used are described in the general procedure for the 
saponification of ethyl esters. The purification was done by column 
chromatography (DCM/MeOH 80:20) to furnish the free carboxylic 
acid derivative (0.17 g, 85%).  
1H NMR (401 MHz, Methanol-d4) δ 8.42 (s, 1H), 6.98 – 6.85 (m, 
1H), 5.21 – 5.09 (m, 1H), 4.78 (s, 2H), 4.44 (dt, J = 7.5, 2.3 Hz, 1H), 
4.34 (dd, J = 11.5, 8.7 Hz, 1H), 3.45 (p, J = 5.6 Hz, 1H), 3.14 – 3.04 (m, 2H), 1.78 (s, 3H), 1.59 – 
1.43 (m, 4H), 0.90 (dt, J = 30.9, 7.4 Hz, 6H). 13C NMR (101 MHz, Methanol-d4) δ 173.6, 168.5, 
146.8, 139.2, 129.2, 125.8, 83.9, 76.3, 62.4, 55.9, 55.1, 31.4, 27.3, 26.7, 22.6, 9.9, 9.5. HR-ESI-
MS calculated for C17H27O5N4 (M+H)






To a solution of oseltamivir phosphate (0.2 g, 0.49 mmol) and ethyl 2-
bromopropionate (0.11 g, 0.58 mmol) in DMF (3 mL) was added 
NaHCO3 (0.25 g, 2.9 mmol) portionwise. The reaction mixture was 
stirred at 80 ºC overnight. The mixture was then quenched by addition 
of water (5 mL) and extracted with EtOAc (3x 10 mL). The combined 
organic phase was washed with water (2x 5 mL) and brine (3 mL), dried 
over anhydrous MgSO4 and evaporated to dryness. The resulting residue was purified by flash 
chromatography (EtOAc) to yield 70 mg of the A diastereomer and 77 mg of the B diastereomer, 
(73 % yield altogether). 
A diastereomer, less polar (S) 95 
1H NMR (300 MHz, Chloroform-d3) δ 6.82 – 6.70 (m, 1H), 5.66 (d, J = 7.9 Hz, 1H), 4.29 (ddd, J 
= 5.9, 2.9, 1.5 Hz, 1H), 4.17 (tt, J = 8.1, 7.1 Hz, 4H), 3.55 (dt, J = 9.7, 7.8 Hz, 1H), 3.46 (q, J = 7.0 
Hz, 1H), 3.33 (q, J = 5.7 Hz, 1H), 3.15 (ddd, J = 9.8, 8.8, 5.3 Hz, 1H), 2.75 – 2.60 (m, 1H), 2.18 
(ddt, J = 11.7, 5.5, 2.8 Hz, 1H), 2.13 – 2.02 (m, 1H), 1.99 (s, 3H), 1.57 – 1.40 (m, 4H), 1.32 – 1.19 
(m, 9H), 0.88 (t, J = 7.4 Hz, 6H). 13C NMR (75 MHz, Chloroform-d3) δ 176.0, 170.7, 166.5, 137.4, 
129.5, 81.9, 74.3, 60.9 (2x OCH2CH3), 57.0, 55.1, 52.9, 31.5, 26.3, 25.9, 23.8, 19.4, 14.3 (2x 
OCH2CH3), 9.6, 9.5. 
B diastereomer, more polar (R) 96 
1H NMR (300 MHz, Chloroform-d3) δ 6.73 (t, J = 2.5 Hz, 1H), 5.80 (d, J = 6.6 Hz, 1H), 4.15 (dtd, 
J = 8.6, 7.0, 3.3 Hz, 4H), 4.07 – 3.99 (m, 1H), 3.77 (dt, J = 10.7, 8.7 Hz, 1H), 3.49 – 3.38 (m, 1H), 
3.35 – 3.24 (m, 1H), 2.83 – 2.70 (m, 1H), 2.70 – 2.60 (m, 1H), 2.09 (q, J = 5.2, 4.8 Hz, 2H), 2.03 
(s, 3H), 1.56 – 1.38 (m, 4H), 1.25 (td, J = 6.8, 4.3 Hz, 9H), 0.95 – 0.76 (m, 6H). 13C NMR (75 
MHz, Chloroform-d3) δ 176.4, 170.8, 166.4, 137.7, 129.0, 81.8, 75.8, 60.8 (2x OCH2CH3), 55.4, 
53.8, 53.5, 31.4, 26.1, 25.6, 23.7, 19.8, 14.2 (2x OCH2CH3), 9.5, 9.2. 
 HR-ESI-MS calculated for C21H36N2O6Na (M+Na)






4-Nitrobenzoyl chloride (0.086 g, 0.46 mmol) was added to a 
solution of the B diastereomer (0.16 g, 0.39 mmol) and 
trimethylamine (0.1 mL, 0.77 mmol) in DCM (3 mL). The reaction 
mixture was left stirring overnight at room temperature. The 
reaction was quenched by addition of water (1.5 mL) and the 
resulting mixture was extracted with EtOAc (3x 10mL). The 
combined organic layers were washed with water, brine and were 
evaporated to dryness. The residue was purified by flash chromatography (Hex/EtOAc 1:2) which 
was followed with crystallization (EtOH) to furnish the desired compound (79 mg, 36% yield). 
 1H NMR (401 MHz, Chloroform-d3) δ 8.26 (d, J = 8.7 Hz, 2H), 7.48 (d, J = 8.7 Hz, 2H), 7.13 (d, 
J = 6.1 Hz, 1H), 6.75 (t, J = 2.4 Hz, 1H), 5.10 (dd, J = 7.3, 3.5 Hz, 1H), 4.63 (td, J = 10.9, 6.2 Hz, 
1H), 4.35 – 4.16 (m, 4H), 3.79 (q, J = 6.8 Hz, 1H), 3.25 (p, J = 5.7 Hz, 1H), 3.10 (ddd, J = 11.3, 
8.5, 6.1 Hz, 1H), 2.89 – 2.77 (m, 1H), 2.56 – 2.43 (m, 1H), 1.96 (d, J = 6.3 Hz, 3H), 1.67 (d, J = 
6.8 Hz, 3H), 1.55 – 1.40 (m, 4H), 1.39 – 1.27 (m, 6H), 0.95 – 0.80 (m, 6H). 13C NMR (101 MHz, 
Chloroform-d3) δ 171.7, 171.1, 169.8, 166.0, 148.8, 141.2, 138.9, 128.3, 127.9, 126.9, 124.1, 124.0, 
82.1, 71.2, 62.2, 61.3, 56.7, 55.6, 52.6, 28.4, 26.5, 25.7, 24.3, 16.3, 14.4, 14.2, 9.8, 9.3. HR-ESI-
MS calculated for C28H39N3O9Na (M+Na)
+ 584.2579, found 584.2578. 
X-ray analysis of the crystals determinates that the product obtained was the R diastereomer. 
  
(3R,4R,5S)-4-Acetamido-5-{[(S)-1-carboxyethyl]amino}-3-(1-ethylpropoxy)-1-cyclohexene-
1-carboxylic acid  
A solution of aqueous NaOH (1 mL, 0.5 M) was added dropwise to a 
solution of the A diastereomer (S) (0.025 g, 0.06 mmol) in THF (1 mL) 
and the reaction mixture was stirred overnight at room temperature. 
The pH was adjusted to neutral by addition of Amberlite IR 120 
hydrogen form. Amberlite was filtered out and the filtrate was 
concentrated under reduced pressure. The residue was purified by 
preparative HPLC.  
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1H NMR (401 MHz, Methanol-d4) δ 6.90 (d, J = 1.4 Hz, 1H), 4.26 – 4.11 (m, 2H), 3.77 (dd, J = 
13.9, 7.1 Hz, 1H), 3.64 – 3.58 (m, 1H), 3.48 – 3.39 (m, 1H), 2.99 – 2.90 (m, 1H), 2.67 – 2.55 (m, 
1H), 2.04 (s, 3H), 1.64 – 1.42 (m, 7H), 0.99 – 0.84 (m, 6H). 13C NMR (101 MHz, Methanol-d4) δ 
174.7, 173.8, 168.7, 137.7, 129.3, 83.6, 75.2, 57.3, 55.1, 53.2, 27.7, 27.1, 26.6, 23.1, 15.9, 9.9, 9.5. 
HR-ESI-MS calculated for C17H28N2O6Na (M+Na)
+ 379.1840, found 379.1839. 
 
(3R,4R,5S)-4-Acetamido-5-{[(R)-1-carboxyethyl]amino}-3-(1-ethylpropoxy)-1-cyclohexene-
1-carboxylic acid  
A solution of aqueous NaOH (2 mL, 0.5 M) was added dropwise to a 
solution of the diastereomer B (R) (0.05 g, 0.12 mmol) in THF (2 mL) 
and the reaction mixture was stirred overnight at room temperature. The 
pH was adjusted to neutral by addition of Amberlite IR 120 hydrogen 
form. Amberlite was filtered out and the filtrate was concentrated under 
reduced pressure. The residue was purified by preparative HPLC.  
1H NMR (401 MHz, Methanol-d4) δ 6.92 – 6.80 (m, 1H), 4.21 – 4.05 (m, 2H), 3.82 (q, J = 7.2 Hz, 
1H), 3.52 – 3.39 (m, 2H), 3.08 – 2.95 (m, 1H), 2.52 – 2.39 (m, 1H), 2.09 (s, 3H), 1.59 – 1.47 (m, 
7H), 0.91 (dt, J = 11.2, 7.4 Hz, 6H). 13C NMR (101 MHz, Methanol-d4) δ 175.1, 173.6, 168.5, 
138.8, 128.7, 83.9, 76.1, 57.3, 57.2, 53.5, 27.8, 27.2, 26.6, 23.2, 16.9, 9.8, 9.6. HR-ESI-MS 
calculated for C17H28N2O6Na (M+Na)




Dimethyl maleate (0.57 g, 4.0 mmol) was added to a stirred 
solution of oseltamivir free base (0.22 g, 0.73 mmol) in methanol 
(3 mL) under argon atmosphere, the mixture was refluxed 
overnight. The solvent was evaporated under reduced pressure 
and the residue was purified by flash chromatography 
(DCM/MeOH 90:10) to yield the mixture of diastereomers (0.25 
g, 75%).   
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1H NMR (300 MHz, Chloroform-d3) δ 6.68 (s, 1H), 6.03 (d, J = 7.5 Hz, 1H), 4.26 (d, J = 8.3 Hz, 
1H), 4.19 – 4.01 (m, 2H), 3.64 (s, 3H), 3.67 – 3.63 (m, 1H), 3.60 (s, 3H), 3.51 – 3.36 (m, 1H), 3.35 
– 3.20 (m, 1H), 3.08 (dt, J = 10.1, 5.0 Hz, 1H), 2.96 – 2.86 (m, 1H), 2.72 – 2.52 (m, 3H), 2.10 – 
1.95 (m, 1H), 1.92 (s, 3H), 1.42 (ddt, J = 7.4, 5.7, 1.9 Hz, 4H), 1.26 – 1.13 (m, 3H), 0.90 – 0.75 
(m, 6H).13C NMR (75 MHz, Chloroform-d3) of major diastereomer δ 174.2, 171.4, 170.9, 166.3, 
137.7, 129.0, 81.7, 74.4, 60.7, 57.4, 56.1, 53.4, 52.3, 51.8, 37.8, 31.5, 26.2, 25.6, 23.6, 14.2, 9.5, 
9.3. 13C NMR (75 MHz, Chloroform-d3) of minor diastereomer δ 174.8, 171.3, 171.0, 166.5, 137.8, 
129.1, 82.0, 75.9, 60.9, 55.9, 55.2, 53.8, 52.4, 52.0, 38.7, 31.7, 26.2, 25.7, 23.8, 14.3, 9.7, 9.4. HR-
ESI-MS calculated for C22H36N2O8Na (M+Na)
+ 479.2364, found 479.2364. 
 
((1S,5R,6R)-6-Acetamido-3-carboxy-5-(pentan-3-yloxy)cyclohex-3-en-1-yl)aspartic acid 
An aqueous solution of NaOH (0.5 M; 7.2 mL) was added dropwise 
to a stirred solution of ethyl (3R,4R,5S)-4-acetamido-5-[N-[dimethyl 
aspartyl]methyl]-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate  
(0.09 g, 0.19 mmol) in THF (3 mL). The reaction was stirred for 24 
h at room temperature. The pH was adjusted to neutral by addition 
of Amberlite IR 120 hydrogen form. Amberlite was filtered out; the 
filtrate was concentrated under reduced pressure and purified by flash chromatography 
(DCM/MeOH 80:20) to furnish the free carboxylic acid derivative (0.053 g, 70%).  
1H NMR (401 MHz, Methanol-d4) δ 6.87 (t, J = 1.2 Hz, 1H), 4.28 (dd, J = 8.1, 2.0 Hz, 1H), 4.07 
(dd, J = 10.7, 8.1 Hz, 1H), 3.99 (t, J = 5.1 Hz, 1H), 3.67 (td, J = 10.2, 5.6 Hz, 1H), 3.48 – 3.39 (m, 
1H), 3.05 – 2.91 (m, 3H), 2.62 – 2.52 (m, 1H), 2.04 (s, 3H), 1.60 – 1.49 (m, 4H), 0.92 (dt, J = 10.4, 
7.4 Hz, 6H). 13C NMR (101 MHz, Methanol-d4) for the major diastereomer δ 175.4, 175.0, 172.1, 
168.7, 138.4, 129.1, 83.6, 75.3, 58.0, 55.5, 54.1, 33.6, 28.0, 27.2, 26.6, 23.2, 9.9, 9.5. 13C NMR 
(101 MHz, Methanol-d4) for the minor diastereomer δ 175.4, 175.0, 173.9, 168.7, 138.9, 129.0, 
83.9, 76.3, 57.8, 55.5, 53.9, 35.9, 28.0, 27.2, 26.7, 23.2, 9.8, 9.6.  HR-ESI-MS calculated for 
C18H27N2O8 (M-H)






To a solution of and 2-(1H-benzotriazole-1-yl)-
1,1,3,3-tetramethyluronium tetrafluoroborate (0.28 g, 
0.87 mmol) and 2-[2-(2-methoxyethoxy)ethoxy]acetic 
acid (0.13 g, 0.72 mmol) in DMF (3 mL) was added 
triethylamine (0.5 ml, 3.6 mmol) under argon 
atmosphere. The reaction mixture was stirred for 5 
min at room temperature followed by addition of Oseltamivir phosphate (0.15 g, 0.36 mmol) and 
further stirring for 16 h. The reaction mixture was quenched by addition of water (10 mL) and 
NaHCO3 saturated solution (5 mL) until the pH was slightly basic. The aqueous solution was 
extracted with DCM and the combined organic phases were washed with water and brine, dried 
over Na2SO4, and evaporated to dryness under reduced pressure. Purification of crude product by 
flash column chromatography (eluent DCM/MeOH 90:10) furnished the amide (0.16 g, 93%).  
1H NMR (401 MHz, Chloroform-d3) δ 7.33 (d, J = 8.6 Hz, 1H), 6.82 – 6.74 (m, 1H), 6.06 (d, J = 
8.8 Hz, 1H), 4.19 (qd, J = 7.1, 1.0 Hz, 3H), 4.13 – 4.06 (m, 1H), 4.04 – 3.99 (m, 1H), 3.69 – 3.61 
(m, 8H), 3.59 – 3.52 (m, 2H), 3.37 - 3.31 (m, 1H), 3.35 (s, 3H), 2.85 – 2.69 (m, 1H), 2.37 (dd, J = 
17.7, 9.8 Hz, 1H), 1.92 (s, 3H), 1.56 – 1.43 (m, 4H), 1.27 (t, J = 7.1 Hz, 3H), 0.87 (dt, J = 10.4, 7.4 
Hz, 6H). 13C NMR (101 MHz, Chloroform-d3) δ 170.8, 170.7, 166.1, 137.9, 129.3, 82.4, 75.7, 72.0, 
71.1, 70.7, 70.4, 70.4, 61.0, 59.1, 54.5, 47.5, 30.6, 26.3, 25.8, 23.4, 14.3, 9.7, 9.4. HR-ESI-MS 
calculated for C23H40O8N2 (M+H)




The conditions used are described in the general 
procedure for the saponification of ethyl esters. The 
product was purified by column chromatography 
(DCM/MeOH 80:20) to furnish the free carboxylic 
acid derivative (0.069 g, 70% yield). 
1H NMR (401 MHz, Chloroform-d3) δ 7.73 (d, J = 9.2 
Hz, 1H), 6.92 (dt, J = 9.1, 4.6 Hz, 1H), 6.85 (d, J = 2.5 Hz, 1H), 5.74 (bs, 1H), 4.24 – 4.16 (m, 1H), 
4.15 – 4.10 (m, 1H), 4.07 – 4.00 (m, 1H), 3.71 – 3.61 (m, 8H), 3.59 – 3.53 (m, 2H), 3.40 – 3.31 
(m, 1H), 3.36 (s, 3H), 2.71 (dd, J = 18.0, 5.2 Hz, 1H), 2.47 – 2.32 (m, 1H), 1.95 (d, J = 1.7 Hz, 
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3H), 1.59 – 1.40 (m, 4H), 0.87 (m, 6H). 13C NMR (101 MHz, Chloroform-d3) δ 177.1, 176.7, 174.0, 
144.6, 134.5, 87.9, 81.2, 77.3, 76.5, 76.1, 75.9, 64.5, 60.1, 56.0, 53.2, 35.9, 31.8, 31.1, 28.6, 15.2, 
14.7. HR-ESI-MS calculated for C21H36O8N2 (M+Na)




Mercury(II) chloride (0.11 g, 0.40 mmol) was added portionwise to a 
solution of oseltamivir base  (0.10 g, 0.32 mmol), N,N′−di-(tert-
butoxycarbonyl)thiourea (0.11 g, 0.40 mmol) and triethylamine (0.11 
mL, 0.80 mmol) in DMF (15 mL) at 0 °C. The reaction mixture was 
stirred for 24 h at room temperature. The mixture was diluted with 
EtOAc (10 mL), filtered through a pad of Celite and concentrated 
under reduced pressure. The residue was diluted with water (30 mL) and extracted with EtOAc 
(3x10 mL). The combined organic phase was washed with water, brine, dried over Na2SO4, filtered 
and evaporated. The residue was purified by flash column chromatography (eluent 
Hexanes/EtOAc, 2:1) to afford the Boc-protected guanidine derivative (0.16 g, 89%).  
TLC (Hexanes/EtOAc 1:1) Rf = 0.4. 
1H NMR (300 MHz, Chloroform-d3) δ 11.33 (s, 1H), 8.57 (d, 
J = 8.1 Hz, 1H), 6.76 (s, 1H), 6.16 (d, J = 8.9 Hz, 1H), 4.43 – 4.23 (m, 1H), 4.20 – 4.01 (m, 3H), 
3.96 (d, J = 7.7 Hz, 1H), 3.36 – 3.21 (m, 1H), 2.72 (dd, J = 17.6, 5.3 Hz, 1H), 2.42 – 2.23 (m, 1H), 
1.85 (s, 3H), 1.55 – 1.49 (m, J = 8.4, 4.7 Hz, 22H), 1.22 (dd, J = 12.6, 5.5 Hz, 3H), 0.82 (dt, J = 
10.3, 7.4 Hz, 6H). 13C NMR (101 MHz, Chloroform-d3) δ 170.3, 166.0, 163.3, 157.0, 152.7, 138.1, 
128.7, 83.6, 82.8, 79.6, 76.3, 61.1, 54.5, 48.2, 30.6, 28.4, 28.2, 26.2, 25.9, 23.4, 14.3, 9.7, 9.4. HR-
ESI-MS calculated for C27H47O8N4 (M+H)
+ 555.3388, found 555.3389. 
 
 (3R,4R,5S)-4-Acetamido-5-[N2,N3-bis(tert-butoxycarbonyl)guanidino]-3-(1-ethylpropoxy)-
1-cyclohexene-1-carboxylic acid  
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The conditions used are described in the general procedure for the 
saponification of ethyl esters. The residue was purified by flash 
column chromatography (Toluene/EtOAc/AcOH 1:1:0.5%) to afford 
the free acid (0.07 g, 48%). 
 TLC (Toluene/EtOAc/AcOH 1:1:0.5%) Rf = 0.2.
 1H NMR (300 
MHz, Chloroform-d3) δ 8.64 (d, J = 8.1 Hz, 1H), 6.82 (s, 1H), 6.23 (d, J = 8.9 Hz, 1H), 4.39 (dd, J 
= 8.3, 6.0 Hz, 1H), 4.26 – 4.16 (m, 2H), 4.16 – 4.08 (m, 1H), 4.06 – 3.98 (m, 1H), 3.41 – 3.29 (m, 
1H), 2.78 (dd, J = 17.6, 5.3 Hz, 1H), 2.47 – 2.32 (m, 1H), 1.91 (s, 3H), 1.61 – 1.41 (m, 22H), 1.27 
(dt, J = 10.9, 7.1 Hz, 4H), 0.89 (dt, J = 10.3, 7.4 Hz, 6H). 13C NMR (75 MHz, Methanol-d4) δ 
173.6, 169.3, 164.4, 157.7, 153.7, 138.7, 130.4, 84.6, 84.0, 80.5, 76.6, 54.6, 50.0, 31.4, 28.5, 28.2, 
27.3, 26.9, 22.7, 9.9, 9.7. HR-ESI-MS calculated for C25H43O8N4 (M+H)
+ 527.3075, found 
527.3076. 
 
 (3R,4R,5S)-4-Acetamido-5-guanidino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylic acid  
(3R,4R,5S)-4-Acetamido-5-[N2,N3-bis(tert-butoxycarbonyl)guanidino]-
3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylic acid (0.07 g, 0.13 
mmol) was stirred with trifluoroacetic acid (50% in water, 5 mL) at room 
temperature for 1 h. The solution was evaporated under reduced pressure 
and purified by preparative HPLC to furnish the guanidine derivative 
(0.02 g, 43%). 
 1H NMR (400 MHz, Methanol-d4) δ 7.28 (d, J = 9.0 Hz, 1H), 6.79 (s, 1H), 4.15 (dd, J = 5.3, 2.1 
Hz, 1H), 3.93 – 3.73 (m, 2H), 3.42 – 3.31 (m, 1H), 2.77 (dd, J = 17.6, 5.0 Hz, 1H), 2.37 – 2.20 (m, 
1H), 1.94 (s, 3H), 1.48 (tdd, J = 12.9, 6.2, 4.5 Hz, 4H), 0.86 (dt, J = 12.8, 7.4 Hz, 6H). 13C NMR 
(101 MHz, Methanol-d4) δ 174.2, 169.0, 158.6, 138.8, 129.8, 83.8, 76.1, 55.8, 51.7, 31.3, 27.2, 
26.8, 22.8, 9.8, 9.7. HR-ESI-MS calculated for C15H27O4N4 (M+H)






To a solution of oseltamivir free base (0.38 g, 1.21 mmol) in DCM (3 mL) 
was added triethylamine (0.61 g, 6.08 mmol) followed by addition of di-
tert-butyl dicarbonate (0.53 g, 2.42 mmol) and then the reaction mixture 
was stirred for 4 h at room temperature. The mixture was diluted with 
water (10 mL) and then extracted with DCM (3x10 mL). The combined 
organic phase was washed with brine, dried over MgSO4 and concentrated 
under reduced pressure. The residue was purified by flash column chromatography (eluent DCM 
to DCM/MeOH, 20:1) to afford the protected amine (0.49 g, 98% yield) as a white solid. 
1H NMR (300 MHz, Chloroform-d3) δ 6.78 (s, 1H), 5.80 (d, J = 8.2 Hz, 1H), 5.11 (d, J = 9.0 Hz, 
1H), 4.20 (q, J = 7.1 Hz, 2H), 4.13 – 4.00 (m, 1H), 3.97 (s, 1H), 3.79 (dd, J = 9.7, 5.1 Hz, 1H), 3.52 
– 3.28 (m, 1H), 2.74 (dd, J = 18.1, 4.9 Hz, 1H), 2.29 (dd, J = 17.7, 9.6 Hz, 1H), 1.98 (s, 3H), 1.51 
(dd, J = 5.5, 4.1 Hz, 4H), 1.42 (s, 9H), 1.28 (t, J = 7.1 Hz, 3H), 0.88 (dd, J = 13.6, 7.3 Hz, 6H). 13C 
NMR (75 MHz, Chloroform-d3) δ 170.9, 166.1, 156.4, 137.7, 129.5, 82.3, 79.8, 76.0, 61.1, 54.5, 
49.2, 31.1, 28.5, 26.3, 25.8, 23.5, 14.3, 9.6, 9.4. HR-ESI-MS calculated for C21H37O6N2 (M+H)
+ 
413.2646, found 413.2648. 
 
(3R,4R,5S)-4-Acetamido-5-[(tert-butoxycarbonyl)-amino]-3-(1-ethylpropoxy)-1-
cyclohexene-1-carboxylic acid  
 The conditions used are described in the general procedure for the 
saponification of ethyl esters. Purified by flash column chromatography 
(eluent DCM/MeOH gradient 10:1 to 10:3) to furnish the free acid (1.28 
g, 95% yield) as a white solid.  
1H NMR (300 MHz, Chloroform-d3) δ 6.81 (s, 1H), 6.69 (s, 1H), 5.72 (d, 
J = 9.3 Hz, 1H), 4.02 (d, J = 6.8 Hz, 2H), 3.75 (dd, J = 13.1, 8.4 Hz, 1H), 
3.39 – 3.26 (m, 1H), 2.70 (dd, J = 17.5, 5.0 Hz, 1H), 2.25 (dd, J = 17.7, 11.1 Hz, 1H), 1.99 (s, 3H), 
1.49 (dd, J = 14.0, 6.7 Hz, 4H), 1.41 (s, 9H), 0.86 (dd, J = 16.5, 7.4 Hz, 6H). 13C NMR (75 MHz, 
Chloroform-d3) δ 171.5, 169.1, 156.9, 139.2, 129.2, 82.3, 79.8, 76.2, 55.2, 49.6, 31.0, 28.5, 26.3, 
25.7, 23.4, 9.8, 9.2. HR-ESI-MS calculated for C19H33O6N2 (M+H)








phosphate (0.26 g, 0.70 mmol) was added to a solution of (3R,4R,5S)-
4-acetamido-5-[(tert-butoxycarbonyl)-amino]-3-(1-ethylpropoxy)-1-
cy-clohexene-1-carboxylic acid  (0.21 g, 0.54 mmol), triethylamine 
(0.22 mL, 1.61 mmol) and 4-(dimethylamino)pyridine (0.007 g, 0.054 
mmol) in dry THF (4 mL). The reaction was stirred in the dark for 40 
min at room temperature. The solvent was removed by evaporation under reduced pressure. The 
remaining green oil was dissolved in DCM (2 mL) and bromotrichloromethane (2 mL). The formed 
solution was irradiated (refluxed) with a flood lamp for 90 min. The mixture was concentrated and 
purified by flash column chromatography (eluent Toluene/EtOAc gradient 2:1 to 1:1) to afford the 
vinyl bromide (0.18 g, 78% yield).  
TLC (Toluene/EtOAc 1:1) Rf = 0.45. 
1H NMR (300 MHz, Chloroform-d3) δ 6.07 (s, 1H), 5.52 (d, 
J = 9.4 Hz, 1H), 5.35 (d, J = 9.0 Hz, 1H), 4.09 (dd, J = 9.1, 6.8 Hz, 1H), 3.88 (dd, J = 7.9, 5.5 Hz, 
1H), 3.83 (s, 1H), 3.39 – 3.25 (m, 1H), 2.68 (m, J = 26.0, 18.0, 6.8 Hz, 2H), 1.99 (s, 3H), 1.59 (s, 
1H), 1.49 (dd, J = 7.3, 6.0 Hz, 3H), 1.42 (s, 9H), 0.88 (t, J = 7.4 Hz, 6H). 13C NMR (75 MHz, 
Chloroform-d3) δ 171.5, 156.9, 139.2, 129.2, 82.3, 79.8, 76.2, 55.2, 50.9, 49.6, 28.5, 26.3, 25.7, 
23.4, 9.7, 9.2. HR-ESI-MS calculated for C18H31BrO4N2Na (M+Na)




To a solution of (3R,4R,5S)-4-acetamido-5-[(tert-butoxycarbonyl)-
amino]-3-(1-ethylpropoxy)-1-bromocyclohexene (0.18 g, 0.39 mmol) in 
toluene (10 mL) was added tetrakis(triphenylphosphine)palladium (0.07 
g, 0.06 mmol), triethylamine (0.21 mL, 1.54 mmol) and dimethyl 
phosphite (0.14 mL, 1.54 mmol). The reaction mixture was stirred at 80 
°C for 90 min. The reaction was quenched with a saturated solution of 
NH4Cl (6 mL)  and later was diluted with DCM (30 mL). The organic 
phase was washed with a saturated solution of NH4Cl (6 mL) and brine (2x5 mL), dried over 
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MgSO4 and concentrated. The residue was purified by flash column chromatography (eluent 
EtOAc gradient to EtOAc/MeOH 6:1) to afford the phosphonate (0.16 g, 86% yield).  
TLC (EtOAc/MeOH 6:1) Rf = 0.42. 
1H NMR (300 MHz, Chloroform-d3) δ 6.59 (d, J = 21.8 Hz, 
1H), 6.02 (d, J = 8.8 Hz, 1H), 5.17 (d, J = 9.0 Hz, 1H), 4.11 – 3.99 (m, 1H), 3.94 (s, 1H), 3.77 (d, 
J = 11.9 Hz, 1H), 3.72 (d, J = 2.4 Hz, 3H), 3.69 (d, J = 2.4 Hz, 3H), 3.39 – 3.27 (m, 1H), 2.67 – 
2.49 (m, 1H), 2.28 – 2.11 (m, 1H), 1.97 (s, 3H), 1.56 – 1.44 (m, 4H), 1.40 (s, 9H), 0.86 (td, J = 7.4, 
5.1 Hz, 6H). 13C NMR (75 MHz, Chloroform-d3) δ 171.2, 156.3, 141.9 (d, J = 6.8 Hz), 129.3 (d, J 
= 180.4 Hz), 81.8, 79.8, 76.0 (d, J = 20.2Hz), 54.1, 52.8 (d), 52.7 (d), 49.8 (d), 30.7 (d), 28.2, 25.9, 
25.6, 23.1, 9.7, 9.3. HR-ESI-MS calculated for C20H37O7NaN2P (M+Na)





An aqueous solution of NaOH (0.5M; 2.8 mL) was added to a stirred 
solution of the dimethyl (3R,4R,5S)-4-acetamido-5-[(tert-
butoxycarbonyl)-amino]-3-(1-ethylpropoxy)-1-cyclohexene-1-phospho-
nate (0.31 g, 0.698 mmol) in 1,4-dioxane (2.8 mL). The reaction mixture 
was stirred for 18 h at room temperature. The pH was adjusted to neutral 
by addition of Amberlite IR 120 hydrogen form. Amberlite was filtered 
out, rinsed with methanol several times and the filtrate was concentrated 
under reduced pressure. The residue was purified by flash column chromatography (eluent 
EtOAc/MeOH gradient 6:1 to 1:2) to furnish phosphonic acid (0.27 g, 91% yield) as a white solid.  
TLC (DCM/MeOH 2:1), Rf = 0.2. 
1H NMR (600 MHz, D2O) δ 6.32 (d, J = 19.7 Hz, 1H), 4.25 (d, 
J = 8.6 Hz, 1H), 3.83 (t, J = 10.0 Hz, 1H), 3.75 (s, 1H), 3.52 (d, J = 10.7 Hz, 3H), 2.45 – 2.43 (m, 
2H), 2.24 (s, 3H), 1.57 (dd, J = 13.6, 6.7 Hz, 4H), 1.51 – 1.34 (m, 9H), 0.88 (dt, J = 34.7, 7.3 Hz, 
6H).13C NMR (151 MHz, D2O) δ 174.2, 157.6, 137.0, 131.6, 130.5, 84.2, 80.9, 76.9, 76.7, 55.6, 
51.6, 51.6, 49.3, 49.2, 31.1, 27.6, 25.6, 25.3, 22.2, 8.6, 8.5. 31P NMR (121 MHz, D2O) δ 15.27. 
HR-ESI-MS calculated for C19H36O7N2P (M+H)
+ 435.2255, found 435.2256. 
 




ethylpropoxy)-1-cyclohexene-1-phosphonate (0.05 g, 1.14 mmol) was stirred 
with trifluoroacetic acid (50% in water, 4 mL) at room temperature for 1 h. 
The solution was evaporated under reduced pressure and later residue was 
purified by preparative HPLC to furnish the title compound (0.02 g, 43% 
yield). 
 1H NMR (600 MHz, D2O) δ 6.38 (d, J = 19.4 Hz, 1H), 4.28 (d, J = 7.5 Hz, 
1H), 4.14 – 4.01 (m, 1H), 3.65 – 3.55 (m, 2H), 3.53 (d, J = 10.8 Hz, 3H), 2.82 – 2.72 (m, 1H), 2.49 
– 2.40 (m, 1H), 2.09 (s, 3H), 1.60 – 1.45 (m, 4H), 0.90 (t, J = 7.2 Hz, 3H), 0.85 (t, J = 7.2 Hz, 3H). 
13C NMR (151 MHz, D2O) δ 175.8, 137.9 (d, J = 6.8 Hz), 129.7 (d, J = 174.4 Hz), 84.9, 76.5 (d, J 
= 19.4 Hz), 53.5, 52.5 (d, J = 5.1 Hz), 50.3 (d, J = 14.1 Hz), 29.8 (d, J = 11.0 Hz), 26.1, 25.8, 22.9, 
9.2, 9.1. HR-ESI-MS calculated for C14H28O5N2P (M+H)
+ 335.1730, found 335.1732. 
 
 (3R,4R,5S)-4-Acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-phosphonate  
Trimethylsilyl bromide (0.41 mL, 3.18 mmol) and 2,6-lutidine (0.44 mL, 
3.81 mmol) were added to a solution of methyl (3R,4R,5S)-4-acetamido-5-
amino-3-(1-ethylpropoxy)-1-cyclohexene-1-phosphonate (0.14 g, 0.318 
mmol) in DCM (10 mL) and the reaction was allowed to stir for 9 h at room 
temperature. The solvent was evaporated and TFA (50% in water, 10 mL) 
was added. Then the reaction was allowed to stir for 1 h and the solvent was 
evaporated under reduced pressure. The residue was purified by preparative 
HPLC.  
HR-ESI-MS calculated for C13H25O5N2NaP (M+Na)







3-(1-ethylpropoxy)-1-cyclohexene-1-phosphonate (0.12 g, 0.259 
mmol) was treated with neat TFA (1 mL) for 1 h and then the acid 
was removed by evaporation under reduced pressure. The residue 
was dissolved in acetonitrile (1.5 mL) and  triethylamine (0.18 mL, 
1.29 mmol) was added dropwise followed by addition of N,N’-di-
Boc-1H-pyrazole-1-carboxamidine (0.08 g, 0.26 mmol). The reaction mixture was stirred for 18 h 
at room temperature and then was evaporated to dryness. The residue was purified by flash column 
chromatography (eluent EtOAc gradient to EtOAc/MeOH 6:1) to afford the guanidine phosphonate 
(0.07 g, 47% yield).  
1H NMR (300 MHz, Chloroform-d3) δ 11.39 (s, 1H), 8.60 (d, J = 7.3 Hz, 1H), 6.64 (d, J = 22.5 Hz, 
1H), 6.35 (d, J = 9.2 Hz, 1H), 4.41 (d, J = 8.2 Hz, 1H), 4.23 – 4.04 (m, 1H), 3.99 (s, 1H), 3.73 (s, 
3H), 3.70 (s, 3H), 3.39 – 3.27 (m, 1H), 2.72 – 2.58 (m, 1H), 2.36 – 2.22 (m, 1H), 1.92 (s, 3H), 1.58 
– 1.41 (m, 22H), 0.88 (dd, J = 16.2, 7.4 Hz, 6H). 13C NMR (75 MHz, Chloroform-d3) δ 170.6, 
163.2, 157.0, 152.7, 143.2, 143.1, 132.2, 132.1, 126.6, 124.1, 83.7, 82.8, 79.8, 76.4, 76.1, 54.3, 
52.8, 52.7, 52.6, 52.6, 48.4, 48.2, 30.9, 30.8, 28.3, 28.1, 26.0, 25.7, 23.3, 9.6, 9.3. HR-ESI-MS 
calculated for C26H48O9N4P (M+H)
+ 591.3153, found 591.3153. 
 
(3R,4R,5S)-4-Acetamido-5-guanidino-3-(1-ethylpropoxy)-1-cyclohexene-1-phosphonate  
Neat bromotrimethylsilane (1.49 g, 9.68 mmol) was added to a solution 
of dimethyl (3R,4R,5S)-4-acetamido-5-[N2,N3-bis(tert-
butoxycarbonyl)-guanidino]-3-(1-ethylpropoxy)-1-cyclohexene-1-
phosphonate (0.07 g, 0.121 mmol) in DCM (5 mL) at 0 °C and the 
reaction was allowed to stir for 24 h at room temperature. The solvent 
was evaporated under reduced pressure; the remaining residue was 
quenched with water (4 mL) and then the mixture was stirred for 2 h. The solution was evaporated 
to dryness and later was purified by preparative HPLC to afford the free guanidine (0.09 g, 21% 
yield).  
1H NMR (400 MHz, D2O) δ 6.31 (d, J = 19.8 Hz, 1H), 4.26 (d, J = 8.5 Hz, 1H), 4.01 – 3.88 (m, 
1H), 3.80 (td, J = 10.4, 5.2 Hz, 1H), 3.60 – 3.47 (m, 1H), 2.85 – 2.66 (m, 1H), 2.46 – 2.31 (m, 1H), 
2.04 (s, 3H), 1.65 – 1.50 (m, 3H), 1.45 (dt, J = 14.4, 7.2 Hz, 1H), 0.87 (dt, J = 19.5, 7.4 Hz, 6H). 
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13C NMR (151 MHz, H2O +D2O + tert-butyl alcohol) δ 175.3, 157.6, 157.5, 135.3, 135.3, 134.0, 
132.8, 85.0, 77.0, 76.9, 70.5 (C), 55.9, 55.9, 51.8, 51.7, 31.5, 31.4, 30.2 (CH3), 26.3, 26.0, 22.7, 
22.6, 9.3, 9.2. 31P NMR (162 MHz, D2O) δ 11.13. HR-ESI-MS calculated for C14H28O5N4P (M+H)
+ 





ethoxy)ethane (0.1 g, 0.30 mmol) was added 
dropwise to a solution of the free base of 
oseltamivir (0.11 g, 0.33 mmol) and 
triethylamine (0.12 mL, 0.91 mmol) in 
acetonitrile (3 mL), the reaction was then 
stirred for 24 h at room temperature. The solvent was evaporated under reduced pressure and the 
remaining oil was dissolved in water (5 mL), the aqueous solution was then extracted with DCM 
(3x 10 mL) and the combined organic layers were washed with brine (5 mL), dried over anhydrous 
MgSO4 and evaporated down. The remaining mixture was purified by flash chromatography 
(DCM/MeOH 9:1) to yield the alkylated oseltamivir (0.093 g, 60%). 
1H NMR (300 MHz, Chloroform-d3) δ 6.77 (d, J = 2.3 Hz, 1H), 6.09 (d, J = 8.2 Hz, 1H), 4.30 (d, 
J = 8.5 Hz, 1H), 4.19 (q, J = 7.2 Hz, 2H), 3.75 – 3.48 (m, 12H), 3.45 – 3.30 (m, 3H), 3.31 – 3.19 
(m, 1H), 2.92 (ddd, J = 12.2, 6.2, 3.9 Hz, 1H), 2.76 (ddd, J = 17.0, 10.5, 3.9 Hz, 4H), 2.22 (dt, J = 
10.4, 3.4 Hz, 1H), 2.03 (s, 3H), 1.57 – 1.39 (m, 4H), 1.28 (t, J = 7.1 Hz, 3H), 0.88 (td, J = 7.4, 5.3 
Hz, 6H). 13C NMR (75 MHz, Chloroform-d3) δ 171.3, 166.4, 137.9, 129.0, 81.9, 75.0, 70.6, 70.6, 
70.5, 70.1, 70.0, 70.0, 60.9, 56.0, 54.1, 50.7, 45.7, 30.3, 26.2, 25.7, 23.7, 14.3, 9.6, 9.3. HR-ESI-
MS calculated for C24H44O7N5 (M+H)






The conditions used are described in the general 
procedure for the saponification of ethyl esters. 
The resulting product was purified by flash 
chromatography (DCM/MeOH 80:20) to 
furnish the free carboxylic acid derivative 
(0.055 g, 83% yield).  
1H NMR (401 MHz, Methanol-d4) δ 6.85 (t, J = 2.0 Hz, 1H), 4.31 – 4.19 (m, 1H), 4.11 (dd, J = 
10.9, 8.0 Hz, 1H), 3.77 (ddd, J = 7.9, 6.2, 3.7 Hz, 2H), 3.72 – 3.59 (m, 12H), 3.46 (d, J = 5.6 Hz, 
1H), 3.41 – 3.37 (m, 2H), 3.37 – 3.32 (m, 1H), 2.98 (dd, J = 17.4, 5.6 Hz, 1H), 2.55 (ddt, J = 17.4, 
9.7, 2.8 Hz, 1H), 2.05 (s, 3H), 1.54 (tq, J = 9.9, 4.4, 3.4 Hz, 4H), 0.91 (dt, J = 10.9, 7.4 Hz, 6H). 
13C NMR (101 MHz, Methanol-d4) δ 174.7, 169.0, 138.0, 129.3, 83.7, 75.9, 71.6, 71.5, 71.4, 71.40, 
71.1, 66.7, 56.1, 52.8, 51.7, 45.3, 27.3, 27.1, 26.6, 23.3, 9.8, 9.5. HR-ESI-MS calculated for 
C22H40O7N5 (M+H)




To a solution of methyl (3R,4R,5S)-4-acetamido-5-[(tert-
butoxycarbonyl)-amino]-3-(1-ethylpropoxy)-1-cyclohexene-
1-phosphonate (0.05 g, 0.11 mmol) and triethylamine (0.12 
ml, 0.88 mmol) in DMF (2 mL) under argon was added 1-
azido-6-bromohexane (0.052 g, 0.25 mmol), the reaction 
mixture was stirred at 40 ºC for 48 h. The DMF was 
evaporated under reduced pressure and the residue was 
purified by flash chromatography (EtOAc) to yield the alkylated phosphonate (0.015 g, 25%).  
1H NMR (300 MHz, Chloroform-d3) δ 6.60 (dd, J = 21.6, 2.2 Hz, 1H), 5.77 (dd, J = 9.2, 5.4 Hz, 
1H), 5.06 (d, J = 9.1 Hz, 1H), 4.10 – 3.95 (m, 3H), 3.92 (m, 1H), 3.79 (dd, J = 9.8, 5.2 Hz, 1H), 
3.70 (dd, J = 11.0, 2.3 Hz, 3H), 3.33 (t, J = 5.6 Hz, 1H), 3.27 (td, J = 6.9, 1.1 Hz, 2H), 2.69 – 2.51 
(m, 1H), 2.21 (m, 1H), 1.98 (s, 3H), 1.68 -1.61 (m, 4H), 1.56 – 1.31 (m, 17H), 0.96 – 0.74 (m, 6H). 
13C NMR (75 MHz, Chloroform-d3) δ 170.9, 156.3, 142.2, 126.7 (d, J = 188.9 Hz), 82.2, 79.7, 
76.3, 76.2, 66.5 – 65.01 (m), 54.5, 52.5 (d, J = 5.9 Hz), 51.3, 49.2, 31.3, 30.3 (d, J = 6.2 Hz), 28.7, 
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28.3, 28.3, 26.3, 26.1, 25.5, 25.1, 23.3, 9.6, 9.1. HR-ESI-MS calculated for C25H47O7N5P (M+H)
+ 






(100 mg, 0.23 mmol) was dissolved in DMF (1.5 mL) 
followed by addition of DIPEA (0.16 mL, 0.92 mmol), 1-
azido-6-bromohexane (120 mg, 0.57 mmol) and sodium 
iodide (5 mg, 0.034 mmol). The reaction was then purged 
with argon and heated to 60 oC for 48 h. The solvent was 
evaporated under reduced pressure and the crude mixture purified by flash chromatography (from 
EtOAc to EtOAc/MeOH 80:20) to yield the alkylated phosphonic acid (72 mg, 56%). 
1H NMR (401 MHz, Methanol-d4) δ 6.36 (d, J = 19.0 Hz, 1H), 4.15 – 4.00 (m, 1H), 3.88 – 3.78 
(m, 1H), 3.77 (t, J = 6.4 Hz, 1H), 3.70 (dd, J = 10.0, 4.4 Hz, 1H), 3.55 – 3.44 (m, 1H), 3.41 (t, J = 
5.4 Hz, 1H), 3.28 (d, J = 6.8 Hz, 2H), 2.62 (d, J = 17.1 Hz, 1H), 2.22 (t, J = 14.2 Hz, 1H), 1.97 (s, 
3H), 1.61 (m, 3H), 1.50 (ddd, J = 16.4, 7.6, 6.1 Hz, 4H), 1.43 (s, 12H), 1.34 (d, J = 6.6 Hz, 2H), 
0.89 (dt, J = 15.1, 7.4 Hz, 6H). 13C NMR (101 MHz, Methanol-d4) δ 172.4, 156.6, 136.0, 132.6 (d, 
J = 211.8 Hz), 82.1, 78.8, 76.5, 64.2, 55.2, 54.5, 51.0, 30.4, 28.5 (x3), 27.4, 26.2, 26.0, 25.4, 25.2, 
21.7, 18.0, 8.6, 8.3. 31P NMR (162 MHz, Methanol-d4) δ 13.12. HR-ESI-MS calculated for 
C24H43O7N5P (M-H)
- = 544.2906, found 544.2906. 
 
Method 2. 1-(6-Azidohexyl)-1-methyl-(3R,4R,5S)-4-acetylamino-5-[(tert-butoxycarbonyl)-
amino]-3-(1-ethylpropoxy)-1-cyclohexene-1-phosphonate (40 mg, 0.071 mmol) was dissolved in 
diethyl ether (0.5 mL) under argon atmosphere. Potassium trimethylsilanolate (11 mg, 0.086 mmol) 
was added and the resulting solution was left stirring overnight at room temperature. The solvent 
was removed under reduced pressure and the resulting oil triturated in ice-cold diethyl ether. The 







The resulting mixture was dissolved in trifluoro acetic acid (3 
mL) and stirred for 2 h at room temperature. The solution was 
dried under reduced pressure and the resulting residue was 
purified by preparative HPLC to afford the deprotected 
phosphonic acid.  
1H NMR (500 MHz, Methanol-d4) δ 6.42 (dd, J = 19.4, 1.0 Hz, 
1H), 4.14 – 4.06 (m, 1H), 3.95 (dd, J = 11.2, 8.3 Hz, 1H), 3.83 (q, J = 6.5 Hz, 2H), 3.50 – 3.36 (m, 
2H), 3.31 – 3.23 (m, 2H), 2.82 – 2.69 (m, 1H), 2.39 (ddd, J = 17.0, 10.1, 2.9 Hz, 1H), 2.03 (s, 3H), 
1.69 – 1.56 (m, 4H), 1.55 – 1.46 (m, 4H), 1.45 – 1.37 (m, 4H), 0.91 (dt, J = 15.0, 7.4 Hz, 6H). 13C 
NMR (126 MHz, Methanol-d4) δ 174.7, 137.1, 131.6 (d, J = 175.9 Hz), 83.4, 76.3 (d, J = 18.9 Hz), 
65.7 (d, J = 5.4 Hz), 54.6, 52.4, 51.4, 31.8 (d, J = 6.8 Hz), 30.4 (d, J = 10.4 Hz), 29.9, 27.5, 27.3, 
26.6, 26.5, 23.1, 9.9, 9.6. HR-ESI-MS calculated for C19H35O5N5P (M+H)







1-cyclohexene-1-phosphonic acid (22 mg, 0.04 mmol) was dissolved in MeOH/water (1 mL, 3:1) 
followed by addition of Lindlar catalyst (22 mg, 100 w%), the flask was sealed and purged with 
hydrogen, the reaction mixture was left stirring for 5 h at room temperature under 1 atm of 
hydrogen. The catalyst was filtered out and rinsed with MeOH several times, the filtrate was 
evaporated to dryness under reduced pressure. The resulting oil was dissolved in DMF (1 mL) 
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under inert atmosphere, followed by addition of triethylamine (17 µl, 0.12 mmol) and a solution of 
azido-PEG6-NHS ester (16 mg, 0.05 mmol) in DMF (0.3 mL), the reaction mixture was stirred 
16h at room temperature. The reaction mixture was dried under reduced pressure, the remaining 
oil was dissolved in TFA (1 mL, 100%) and stirred for 1 h at room temperature. The reaction was 
evaporated to dryness and the resulting mixture was purified by semi-preparative HPLC to yield 
the desired probe. (13 mg, 42%) 
1H NMR (401 MHz, Methanol-d4) δ 6.51 (d, J = 20.2 Hz, 1H), 4.17 (d, J = 8.7 Hz, 1H), 4.01 – 
3.86 (m, 2H), 3.72 (t, J = 6.0 Hz, 2H), 3.70 – 3.53 (m, 24H), 3.43 (t, J = 5.7 Hz, 1H), 3.38 (t, J = 
5.0 Hz, 2H), 3.19 (t, J = 7.1 Hz, 2H), 2.91 (dd, J = 12.4, 6.3 Hz, 1H), 2.84 – 2.73 (m, 1H), 2.45 (td, 
J = 5.9, 0.9 Hz, 2H), 2.04 (s, 3H), 1.66 (p, J = 6.6 Hz, 2H), 1.59 – 1.47 (m, 6H), 1.47 – 1.31 (m, 
4H), 0.91 (dt, J = 11.8, 7.4 Hz, 6H). 13C NMR (126 MHz, Methanol-d4) δ 173.3, 172.5, 136.5 (d, J 
= 6.3 Hz), 129.7 (d, J = 176.7 Hz), 82.0, 74.9 (d, J = 19.2 Hz), 70.2 (x2), 70.1, 70.1, 70.1, 70.1 
(x2), 70.1 70.0 (x2), 69.9, 69.7, 66.9, 64.5 (d, J = 5.5 Hz), 53.2, 50.4, 49.9, 38.7, 36.2, 30.3 (d, J = 
6.8 Hz), 29.0 (d, J = 10.7 Hz), 28.8, 25.9 (d, J = 12.6 Hz), 25.2 (d, J = 17.6 Hz), 22.8, 21.8, 8.5, 
8.2. 31P NMR (202 MHz, Methanol-d4) δ 12.22. HR-ESI-MS calculated for C34H66O12N6P (M+H)
+ 
= 781.4471, found 781.4473. 
 
5-Fluoro-1H-pyrrolo[2,3-b]pyridine 
In an oven dried flask was dissolved 2-amino-3-bromo-5-fluoropyridine (0.2 g, 
1.04 mmol), tetrabutylammonium bromide (0.033 g, 0.10 mmol) and DABCO 
(0.17 g, 1.56 mmol) in a mixture of DMSO (0.4 mL) and EtOAc (1.2 mL). The 
reaction mixture was purged with argon over a 30 min period followed by addition 
of tBuXPhos Pd G3 (0.04 g, 0.05 mmol), the flask was sealed and purged again with argon for 10 
min. Acetaldehyde was added (0.11 mL, 2.08 mmol) and the mixture was stirred for 1 h at room 
temperature and subsequently heated to 75 ºC overnight. The reaction was quenched by addition 
of water (10 mL) and extracted with EtOAc (3x 20 mL), the combined organic layers were washed 
with water (5 mL), brine (5 mL) and evaporated to dryness under reduced pressure. The remaining 




1H NMR (401 MHz, Chloroform-d3) δ 10.54 (bs, 1H), 8.21 (t, J = 2.3 Hz, 1H), 7.66 (dd, J = 8.9, 
2.7 Hz, 1H), 7.42 (dd, J = 3.4, 2.5 Hz, 1H), 6.50 (dd, J = 3.5, 2.0 Hz, 1H). 13C NMR (101 MHz, 
Chloroform-d3) δ 155.8 (d, J = 240.9 Hz), 145.6, 131.3 (d, J = 29.9 Hz), 127.4, 120.6 (d, J = 7.2 
Hz), 114.7 (d, J = 20.7 Hz), 101.q (d, J = 4.3 Hz).  
 
 5-Fluoro-1-tosyl-1H-pyrrolo[2,3-b]pyridine 
Method 1. Sodium hydride (0.07 g, 1.76 mmol) was added portionwise to an ice-
cold solution of the azaindole (0.2 g, 1.47 mmol) in dry THF (5 mL), the reaction 
was stirred for 10 min at 0 ºC followed by dropwise addition of a solution of p-
toluenesulfonyl chloride (0.31 g, 1.61 mmol) in THF (2 mL). The resulting 
solution was left stirring for 1 h at room temperature and then quenched by addition of NaHCO3 
saturated solution (5 mL), the aqueous layer was extracted with EtOAc (3x 10 mL), the combined 
organic layers were washed with brine (5 mL), dried over anhydrous MgSO4 and evaporated to 
dryness under reduced pressure. The resulting solid was used in the next step without further 
purification (0.37 g, 88%). 
1H NMR (400 MHz, Chloroform-d3) δ 8.28 (ddd, J = 2.3, 1.5, 0.7 Hz, 1H), 8.04 (d, J = 8.4 Hz, 
2H), 7.78 (dd, J = 4.0, 0.5 Hz, 1H), 7.52 (dd, J = 8.3, 2.7 Hz, 1H), 7.28 (dd, J = 8.7, 0.7 Hz, 2H), 
6.56 (d, J = 4.0 Hz, 1H), 2.38 (s, 3H). 13C NMR (101 MHz, Chloroform-d3) δ 157.1 (d, J = 247.4 
Hz), 145.5, 135.3, 133.5 (d, J = 29.2 Hz), 130.3, 129.8 (x2), 128.7, 128.2 (x2), 127.2, 115.5 (d, J 
= 21.1 Hz), 105.1 (d, J = 3.7 Hz), 21.8. 
 
5-Fluoro-3-((trimethylsilyl)ethynyl)pyridin-2-amine 
A THF solution of 2-amino-3-bromo-5-fluoropyridine (0.5 g, 2.6 mmol) 
copper(I) iodide (0.074 g, 0.39 mmol) and triethylamine (8.8 mL) in THF 
(9.3 mL) was purged with argon over 30 min period followed by addition 
of [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex 
with dichloromethane (0.134 g, 0.112 mmol). The mixture was purged for 10 min 
and  ethynyltrimethylsilane (0.54 mL, 3.9 mmol) was added. The reaction mixture was heated to 
55 ºC overnight. The chilled solution was poured into water (10 mL) and extracted with EtOAc (3x 
10 mL), the combiner organic layers were washed with water (5 mL), brine (5 mL) and evaporated 
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down. The remaining residue was purified by column chromatography (DCM/MeOH 20:1) to 
afford the desired product (0.45 g, 83%). 
1H NMR (401 MHz, Chloroform-d3) δ 7.90 (s, 1H), 7.30 (dd, J = 8.2, 2.8 Hz, 1H), 5.12 (bs, 2H), 
0.27 (s, 9H). 13C NMR (101 MHz, Chloroform-d3) δ 156.2, 152.76 (d, J = 242.8 Hz), 135.5 (d, J = 
25.2 Hz), 127.2 (d, J = 21.3 Hz), 102.5 (x2), 99.2 (d, J = 2.1 Hz), -0.1 (x3). 
 
Method 2. A solution of 5-fluoro-3-((triemethylsilyl)ethynyl)pyridin-2-amine (0.4 g, 1.92 mmol) 
in NMP (1 mL) was added to a solution of potassium tert-butoxide (0.26 g, 2.3 mmol) in NMP (4 
mL). The reaction mixture was heated to 70 ºC for 2 h. When the LC-MS showed total consumption 
of the starting material the reaction flask was removed from and oil bath. The reaction was chilled 
to 0 ºC and a solution of p-toluenesulfonyl chloride (0.4 g, 2.11 mmol) in NMP (1 mL) was added 
dropwise, the reaction was left stirring at room temperature for 1 h. The mixture was quenched by 
addition of water (5 mL) and the aqueous layer was extracted with DCM (3x 10 mL), the combined 
organic layers were washed with water (5 mL), brine (5 mL) and concentrated under reduced 
pressure. The remaining residue was purified by flash chromatography (Hexanes/EtOAc 1:1) to 
yield the desired azaindole (0.17 g, 31 %). 
 
3-Bromo-5-fluoro-1-tosyl-1H-pyrrolo[2,3-b]pyridine 
A solution of 5-fluoro-1-tosyl-1H-pyrrolo[2,3-b]pyridine (0.46 g, 1.47 mmol) in 
DCM (4 mL) was added dropwise to an ice-cold suspension of N-
bromosuccinimide (0.3 g, 1.69 mmol) in DCM (2 mL) and the reaction was 
allowed to stir overnight at room temperature. The solution was diluted with 
DCM (15 mL) and quenched by addition of NaHCO3 saturated solution (15 mL). The aqueous 
layer was extracted with DCM (3x 20mL) and the combined organic layers were washed with brine 
(10 mL), concentrated under reduced pressure and purified by flash chromatography 
(hexanes/EtOAc 1:1) to furnish the brominated azaindole (0.37 g, 68%). 
1H NMR (401 MHz, Chloroform-d3) δ 8.33 (dd, J = 2.8, 1.4 Hz, 1H), 8.12 – 8.02 (m, 2H), 7.85 (s, 
1H), 7.50 (dd, J = 7.8, 2.7 Hz, 1H), 7.37 – 7.28 (m, 2H), 2.40 (s, 3H). 13C NMR (101 MHz, 
Chloroform-d3) δ 157.4 (d, J = 249.7 Hz), 145.9, 142.3, 134.9 (d, J = 29.4 Hz), 134.8, 129.9 (2x), 
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128.3 (2x), 127.2, 123.2 (d, J = 7.2 Hz), 114.6 (d, J = 22.1 Hz), 94.7 (d, J = 3.6 Hz), 21.8. HR-ESI-
MS calculated for C14H10O2N2SBrF (M) 367.9630, found 367.9632. 
 
5-Fluoro-1-tosyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrrolo[2,3-b]pyridine 
A solution of 3-bromo-5-fluoro-1-tosyl-1H-pyrrolo[2,3-b]pyridine (0.35 g, 
0.95 mmol) in 1,4-dioxane (2.5 mL) was purged with argon for 15 min 
followed by addition of bis(pinacolato)diboron (0.27 g, 1.04 mmol), potassium 
acetate (0.25 g, 2.59 mmol), palladium(II) acetate (0.021 g, 0.09 mmol) and 
triphenylphosphine (0.076 g, 0.29 mmol). The reaction mixture was purged 
with argon for 10 min, sealed and heated to reflux for 15h. The reaction was 
diluted in EtOAc (60 mL) and the organic layer was washed with water (5 mL) and brine (3 mL). 
The solvent was evaporated under reduced pressure and the remaining residue was purified by 
chromatography (hexanes/EtOAc 10:1 to 8:1). The oil obtained after chromatography was 
triturated with hexanes to produce the boronic ester as a white solid that was filtered and dried 
(0.30 g, 76%). 
1H NMR (401 MHz, Chloroform-d3) δ 8.28 (dd, J = 2.8, 1.4 Hz, 1H), 8.20 (s, 1H), 8.09 (d, J = 8.3 
Hz, 2H), 7.90 (dd, J = 8.6, 2.8 Hz, 1H), 7.32 – 7.26 (m, 2H), 2.39 (s, 3H), 1.37 (s, 12H). 13C NMR 
(101 MHz, Chloroform-d3) δ 157.3 (d, J = 247.3 Hz), 145.5, 144.3, 136.9, 135.0, 133.3 (d, J = 29.4 
Hz), 129.7 (2x), 128.2 (2x), 128.0, 126.9 (d, J = 7.3 Hz), 117.3 (d, J = 20.9 Hz), 83.9 (2x), 24.9 
(4x), 21.7. HR-ESI-MS calculated for C20H23O4N2SBF (M+H)
+ 417.1450, found 417.1452. 
 
Potassium (5-fluoro-1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-yl)trifluoroborate 
Potassium hydrogenfluoride (0.1 g, 1.3 mmol) was added to a suspension of 
the boronic ester (0.09 g, 0.21 mmol) in a mixture of acetone (2.5 mL) and 
water (1 mL). The resulting solution was stirred for 5 h at room temperature. 
The solvent was evaporated under reduced pressure, the remaining solid was 
triturated with refluxing acetone and the solvent was decanted and saved, the 
trituration was repeated two times more and the combined aliquots of solvent were concentrated to 
approximately 1 mL. Et2O (0.3 mL) was added dropwise and the solution was left overnight at 4 
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ºC without stirring. The formed crystals were filtered and dried under reduced pressure to yield the 
trifluoroborate salt (0.082 g, 97%). 
1H NMR (401 MHz, Methanol-d4) δ 8.09 (dd, J = 2.9, 1.6 Hz, 1H), 7.97 – 7.87 (m, 2H), 7.75 (dd, 
J = 9.0, 2.8 Hz, 1H), 7.56 (d, J = 1.3 Hz, 1H), 7.36 – 7.25 (m, 2H), 2.36 (s, 3H). 19F NMR (377 
MHz, Methanol-d4) δ -138.33 (dd, J = 8.7, 2.7 Hz), -140.78. HR-ESI-MS calculated for 
C14H10O2N2SBF4 (M)
- 357.0498, found 357.0493. 
 
Meso-endo-tetrahydro-4,7-ethanoisobenzofuran-1,3-dione 
Cyclohexa-1,3-diene (1.01 mL, 10.6 mmol) was added dropwise to an ice-cold 
solution of maleic anhydride (1.0 g, 9.7 mmols) in DCM (12 mL). The mixture 
was left stirring overnight in the dark at room temperature. The solvent was 
evaporated down under reduced pressure and the remaining white solid was 
dissolved in anhydrous MeOH (10 mL) and refluxed for 5 min. The solution was 
cooled down to room temperature and the white crystals were filtrated and dried under reduced 
pressure to furnish 1.46 g (85 %) of the cycloaddition product. 
1H NMR (401 MHz, chloroform-d3) δ 6.30 (dd, J = 4.5, 3.1 Hz, 2H), 3.22 (dp, J = 4.7, 1.5 Hz, 2H), 
3.12 (dd, J = 2.0, 1.4 Hz, 2H), 1.63 – 1.55 (m, 2H), 1.44 – 1.33 (m, 2H). 13C NMR (101 MHz, 
chloroform-d3) δ 172.9, 133.1, 44.9, 31.7, 23.1. HR-ESI-MS calculated for C10H10O3 (M) 
178.0630, found 178.0628. 
 
Di-endo-3-carbamoylbicyclo[2.2.2]oct-5-ene-2-carboxylic acid 
Meso-endo-tetrahydro-4,7-ethanoisobenzofuran-1,3-dione (1.0 g, 5.71 mmol) 
was slowly added portion-wise to a solution of ammonium hydroxide solution 
(28%, 5 mL) in THF (5 mL) at 0 ºC. The resulting slurry was left stirring at room 
temperature for 5 h. The formed solid was filtered, rinsed with cold THF and dried 
under reduced pressure to yield the corresponding amide as a racemate (1.03 g, 
94 %).  
1H NMR (401 MHz, D2O) δ 6.46 (ddd, J = 8.0, 6.5, 1.3 Hz, 2H), 6.28 (ddd, J = 8.0, 6.4, 1.2 Hz, 
2H), 3.07 – 2.88 (m, 2H), 2.76 (dddd, J = 11.9, 5.0, 3.5, 1.7 Hz, 2H), 1.65 – 1.46 (m, 2H), 1.34 – 
1.07 (m, 2H). 13C NMR (101 MHz, D2O) δ 181.5, 180.3, 134.8, 131.3, 52.1, 49.8, 33.2, 32.6, 24.5, 
24.4. HR-ESI-MS calculated for C10H13NO3Na (M+Na)





The racemic di-endo-3-carbamoylbicyclo[2.2.2]oct-5-ene-2-carboxylic acid (2.6 
g, 13.3 mmol) was dissolved in a mixture of EtOAc (17 mL), acetonitrile (17 mL) 
and water (8.5 mL) and was cooled down to 0 ºC on an ice bath. 
(Diacetoxyiodo)benzene (5.6 g, 17.3 mmol) was added portionwise under 
vigorous stirring and the reaction mixture was stirred overnight at room 
temperature. The reaction mixture was acidified by addition of concentrated HCl and extracted 
with Et2O (3x 15 mL), the combined ethereal layers were washed with water (5 mL) and brine (5 
mL) and evaporated under reduced pressure to furnish the corresponding racemic ammonium salt 
(2.4 g, 90%). The product was used in the next step without further purification. 
1H NMR (401 MHz, Methanol-d4) δ 6.53 (ddd, J = 8.0, 6.6, 1.2 Hz, 1H), 6.37 – 6.21 (m, 1H), 3.73 
(dd, J = 9.2, 2.6 Hz, 1H), 3.08 (d, J = 9.6 Hz, 2H), 2.96 – 2.80 (m, 1H), 1.77 – 1.55 (m, 2H), 1.49 
– 1.25 (m, 2H). 13C NMR (101 MHz, Methanol-d4) δ 174.5, 137.0, 130.4, 52.6, 46.2, 35.4, 35.0, 
25.2, 23.0. HR-ESI-MS calculated for C9H12O2 (M-H)
- 166.0874, found 166.0874. 
 
Ethyl di-endo-3-aminobicyclo[2.2.2]oct-5-ene-2-carboxylate 
Thionyl chloride (0.72 mL, 9.7 mmol) was added dropwise to absolute EtOH (11 
mL) at 0 ºC, followed by addition of di-endo-3-aminobicyclo[2.2.2]oct-5-ene-2-
carboxylic acid (0.78 g, 3.9 mmol). The reaction mixture was stirred overnight at 
room temperature and subsequently refluxed for 5h. The solvent was evaporated 
under reduced pressure, the remaining slurry was dissolved in water (5 mL) and 
the pH was adjusted to basic by addition of NaHCO3 saturated solution. The aqueous layer was 
extracted with DCM (3x 15 mL), the combined organic layers were washed with brine (5 mL) and 
evaporated to dryness. The residue was purified by chromatography (DCM/MeOH/NH3 90:10:1) 
to furnish the racemic aminoester (0.56 g, 73%).  
1H NMR (401 MHz, Chloroform-d3) δ 6.56 – 6.42 (m, 1H), 6.19 – 6.06 (m, 1H), 4.10 (dt, J = 7.1, 
3.5 Hz, 2H), 3.41 – 3.26 (m, 1H), 2.81 (d, J = 8.9 Hz, 1H), 2.74 (ddd, J = 6.8, 3.0, 1.6 Hz, 1H), 
2.64 (d, J = 5.7 Hz, 1H), 1.36 (bs, 2H), 1.62 – 1.37 (m, 2H), 1.33 – 1.10 (m, 5H). 13C NMR (101 
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MHz, Chloroform-d3) δ 173.1, 135.7, 129.8, 60.3, 53.9, 52.3, 38.3, 32.4, 25.2, 22.5, 14.5. HR-ESI-
MS calculated for C11H18O2N (M + H)
+ 196.1332, found 196.1332.  
 
Ethyl (1S,2R,3S,4R)-3-aminobicyclo[2.2.2]oct-5-ene-2-carboxylate (-)-DBTA 
To a refluxing solution of the racemic ethyl di-endo-3-aminobicyclo[2.2.2]oct-5-
ene-2-carboxylate (0.63 g, 3.23 mmol) in EtOH (5.8 mL) was added portionwise 
(-)-dibenzoyl-L-tartaric acid monohydrate (0.6 g, 1.61 mmol). The mixture was 
vigorously stirred at reflux until complete dissolution of all solids, the solution 
was cooled to room temperature over a 30 min period. The slurry was filtered and rinsed with Et2O, 
the white solid was recrystallized from ethanol to afford the pure diastereomeric salt (0.43 g, 25%).  
1H NMR (401 MHz, Methanol-d4) δ 8.20 – 8.06 (m, 4H), 7.67 – 7.54 (m, 2H), 7.49 (dd, J = 8.4, 
7.0 Hz, 4H), 6.45 (ddd, J = 8.1, 6.5, 1.3 Hz, 1H), 6.24 (t, J = 7.3 Hz, 1H), 5.91 (s, 2H), 4.26 – 4.00 
(m, 2H), 3.69 (dd, J = 9.4, 2.7 Hz, 1H), 3.07 (dd, J = 9.3, 1.9 Hz, 1H), 2.99 (ddd, J = 6.6, 3.2, 1.5 
Hz, 1H), 2.90 – 2.76 (m, 1H), 1.70 – 1.54 (m, 2H), 1.27 (t, J = 7.2 Hz, 5H). 13C NMR (101 MHz, 
Methanol-d4) δ 172.9, 171.5, 167.3, 136.7, 134.4, 131.2, 131.0, 130.6, 129.5, 75.0, 62.4, 52.6, 46.5, 
35.3, 35.0, 25.2, 22.9, 14.3. [α]D = -81.4 (c = 0.5, EtOH). 
 
Ethyl (1S,2S,3S,4R)-3-aminobicyclo[2.2.2]oct-5-ene-2-carboxylate hydrochloride 
The diastereomeric salt of ethyl (1S,2R,3S,4R)-3-aminobicyclo[2.2.2]oct-5-ene-
2-carboxylate (-)-DBTA (1.13 g, 2.04 mmol) was dissolved in water (15 mL) and 
the solution was basified by addition of aqueous NaHCO3 saturated solution (7.5 
mL). The aqueous layer was extracted with DCM (3x 20mL) and the combined 
organic layers were washed with brine (5 mL), dried over anhydrous Na2SO4, filtered and 
evaporated to dryness under reduced pressure. The free base was dissolved in absolute ethanol (12 
mL) and freshly prepared sodium ethoxide (0.29 g, 4.08 mmol) was added. The reaction mixture 
was refluxed for 2h. The reaction was evaporated down, the residue was dissolved in DCM (90 
mL) and the organic layer was washed with water (2x 20 mL), dried over anhydrous Na2SO4 and 
evaporated to dryness. The remaining oil was dissolved in a hydrogen chloride solution (2.45 M in 
dioxane, 5 mL) and evaporated under reduced pressure to furnish the corresponding product as 
hydrochlorid (0.15 g, 32%). 
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1H NMR (401 MHz, Methanol-d4) δ 6.63 (ddd, J = 8.1, 6.7, 1.3 Hz, 1H), 6.36 – 6.17 (m, 1H), 4.25 
(qd, J = 7.1, 4.1 Hz, 2H), 3.90 (t, J = 3.4 Hz, 1H), 3.04 (ddd, J = 6.7, 2.8, 1.1 Hz, 1H), 2.91 – 2.79 
(m, 1H), 2.38 – 2.26 (m, 1H), 1.73 – 1.57 (m, 1H), 1.52 – 1.35 (m, 2H), 1.36 – 1.18 (m, 3H), 1.18 
(ddd, J = 3.9, 2.0, 1.0 Hz, 1H). 13C NMR (101 MHz, Methanol-d4) δ 173.0, 137.7, 130.7, 62.6, 
53.1, 50.1, 34.5, 34.2, 23.3, 20.2, 14.5. [α]D = + 38.4 (c = 0.5, EtOH). 
 
Ethyl (2S,3S)-3-aminobicyclo[2.2.2]octane-2-carboxylate hydrochloride 
Palladium on carbon 10% w/w (0.09 g, 0.38 mmol) was added to a solution of 
ethyl (1S,2S,3S,4R)-3-aminobicyclo[2.2.2]oct-5-ene-2-carboxylate hydrochloride 
(0.44 g, 1.9 mmol) in ethanol (13 mL) under argon atmosphere. The vessel was 
purged with hydrogen twice and then it was left stirring overnight at room 
temperature under hydrogen atmosphere (1 atm). The catalyst was filtered out and rinsed with 
EtOH, the filtrate was evaporated to dryness and the resulting oil was dissolved in a hydrogen 
chloride solution (2.45 M in dioxane, 5 mL) and evaporated again to yield the reduced aminoester 
as a white solid (0.43 g, 95%).  
1H NMR (401 MHz, Chloroform-d3) δ 8.49 (bs, 2H), 4.22 (q, J = 7.1 Hz, 2H), 3.94 – 3.81 (m, 1H), 
3.50 – 3.34 (m, 1H), 2.74 (dd, J = 6.0, 2.3 Hz, 1H), 2.18 – 1.97 (m, 2H), 1.88 (m, 1H), 1.66 – 1.39 
(m, 6H), 1.30 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, Chloroform-d3) δ 172.5, 90.4, 61.3, 59.4, 
51.4, 47.8, 27.8, 25.0, 24.0, 20.7, 18.8, 14.3. [α]D = - 12.2 (c = 1, MeOH). HR-ESI-MS calculated 
for C11H19O2N (M)
+ 197.1416, found 197.1418. 
 
 
Tetraethylene glycol ditosylate 
To a solution of tetraethylene glycol (8.8 mL, 51.4 mmol) 
and p-toluenesulfonyl chloride (19.6 g, 102.8 mmol) in 
DCM (50 mL) at 0 ºC was portionwise added powdered 
KOH (23.8 g, 411.2 mmol) keeping the temperature always below 4 ºC. The resulting slurry was 
stirred a further 3h at 0 ºC. The reaction mixture was diluted with DCM (50 mL) and quenched by 
addition of ice-cold water (100 mL). The organic layer was separated and saved, the aqueous layer 
was extracted with DCM (2x 50 mL) and the combined organic layers were washed with water (30 
mL), dried over anhydrous MgSO4, filtered and evaporated to dryness under reduced pressure to 
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yield the bis-tosylated tetraethylene glycol (23.8 g, 98%). The product was used without further 
purification. 
1H NMR (300 MHz, Chloroform-d3) δ 7.82 – 7.75 (m, 4H), 7.38 – 7.28 (m, 4H), 4.20 – 4.10 (m, 
4H), 3.80 – 3.59 (m, 4H), 3.55 (d, J = 1.1 Hz, 8H), 2.44 (s, 6H). 
 
1,11-Diazido-3,6,9-trioxaundecane 
Sodium azide (0.38 g, 6.0 mmol) was added to a solution of 
tetraethylene glycol ditosylate (1.0 g, 2.0 mmol) in DMF (5 
mL) and the mixture was heated to 60 ºC overnight. The 
reaction was quenched by addition of water (10 mL) and the aqueous layer was extracted with 
EtOAc (3x 20 mL). The combined organic phases were washed with water (2x 5mL) and brine (5 
mL) and then evaporated to dryness. The remaining oil was purified by flash chromatography 
(hexanes/EtOAc 1:1) to yield the bis-azido linker (0.4 g, 82%).  
1H NMR (300 MHz, Chloroform-d3) δ 3.74 – 3.61 (m, 12H), 3.38 (t, J = 5.1 Hz, 4H). 
 
2-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)ethylamine 
A solution of triphenylphosphine (0.64 g, 2.45 mmol) in 
Et2O (5 mL) was added dropwise over a period of 10 min 
to a solution of  1,11-diazido-3,6,9-trioxaundecane (0.70 g, 
2.89 mmol) in aqueous HCl (5%, 7 mL). The biphasic mixture was stirred overnight at room 
temperature. The two phases were then separated and the organic layer was discarded, the aqueous 
layer was further washed with DCM (3x 2 mL). The aqueous phase was cooled to 0 ºC and the pH 
was adjusted to basic by addition of KOH pellets. The basic aqueous layer was extracted with DCM 
(5x 10 mL) and the combined organic layers were washed with brine (2 mL), dried over anhydrous 
Na2SO4, filtered and evaporated under reduced pressure to yield the desired product as an oil (0.43 
g, 81%).  
1H NMR (401 MHz, Chloroform-d3) δ 3.72 – 3.57 (m, 10H), 3.52 (t, J = 5.2 Hz, 2H), 3.39 (d, J = 
5.0 Hz, 2H), 2.87 (t, J = 5.2 Hz, 2H), 1.72 (bs, 2H). 13C NMR (101 MHz, Chloroform-d3) δ 73.5, 





A solution of di-tert-butyl dicarbonate (2 g, 9.16 mmol) 
in THF was added to an ice-cold solution of 2-(2-(2-(2-
azidoethoxy)ethoxy)ethoxy)ethylamine (1.0 g, 4.58 
mmol) and triethylamine (1.9 mL, 13.7 mmol) in THF (30 mL), the solution was warmed to room 
temperature and stirred for 5 h. The solvent was evaporated under reduced pressure and the 
remaining oil was dissolved in EtOAc (100 mL), the organic phase was washed with a diluted 
aqueous solution of NH4Cl (2x 10 mL) and a saturated aqueous solution of NaHCO3 (5 mL). The 
organic layer was evaporated to dryness under reduced pressure and the remaining oil was purified 
by chromatography (EtOAc) to yield the boc-protected amine (1.3 g, 89%). 
1H NMR (401 MHz, Chloroform-d3) δ 5.04 (bs, 1H), 3.77 – 3.60 (m, 10H), 3.56 (t, J = 5.2 Hz, 
2H), 3.47 – 3.37 (m, 2H), 3.33 (q, J = 5.4 Hz, 2H), 1.46 (s, 9H). 13C NMR (101 MHz, Chloroform-




ethyl)-carbamate (0.7 g, 2.2 mmol) was dissolved in 
THF (10 mL) and triphenylphosphine (0.86 g, 3.3 
mmol) was added portionwise, the reaction mixture was left stirring overnight at room temperature. 
Subsequently, water (3 mL) was added and the reaction mixture was heated to 60 ºC for 2 h. The 
solvent was evaporated and the remaining residue was purified by flash chromatography 
(DCM/MeOH 5:1) to yield the reduced linker (0.57 g, 90%).  
1H NMR (401 MHz, Chloroform-d3) δ 5.30 (bs, 1H), 3.71 – 3.60 (m, 8H), 3.59 – 3.49 (m, 4H), 






A solution of the linker (0.14, 0.47 mmol) in 
DCM (1 mL) was added dropwise to a 
solution of 2,4-dichloropyrimidine-5-
carbonyl chloride (0.1 g, 0.47 mmol) in DCM 
(2 mL) at -78 ºC, followed by dropwise addition of DIPEA (0.16 mL, 0.95 mmol). The reaction 
mixture was slowly warmed up to room temperature over a 40 min period. The solvent was then 
evaporated down, and the remaining residue was purified by column chromatography 
(DCM/MeOH 100:5) to furnish the desired compound (0.12 g, 56%). 
1H NMR (401 MHz, Chloroform-d3) δ 8.85 (s, 1H), 7.42 (s, 1H), 5.04 (s, 1H), 3.71 – 3.61 (m, 8H), 
3.60 – 3.54 (m, 4H), 3.48 (t, J = 5.2 Hz, 2H), 3.26 – 3.17 (m, 2H), 1.39 (s, 9H). 13C NMR (101 
MHz, Chloroform-d3) δ 162.7, 161.7, 161.2, 161.1, 156.1, 127.6, 79.3, 70.4, 70.3, 70.2, 70.0, 69.2 
(2x), 40.3, 40.1, 28.4 (3x). HR-ESI-MS calculated for C18H29O6N4Cl2 (M + H)





To an ice-cool solution of the tert-butyl (1-
(2,4-dichloropyrimidin-5-yl)-1-oxo-5,8,11-
trioxa-2-azatridecan-13-yl)carbamate (52 
mg, 0.12 mmol) in isopropyl alcohol (1.5 
mL) was added dropwise a solution of ethyl 
(2S,3S)-3-aminobicyclo[2.2.2]octane-2-
carboxylate hydrochloride (23 mg, 0.12 mmol) in isopropyl alcohol (0.5 mL) followed by addition 
of DIPEA (31 mg, 0.26 mmol) and the reaction mixture was left stirring at room temperature 
overnight. The solvent was removed under reduced pressure and the residue was purified by 
column chromatography (DCM/i-PrOH 20:1) to yield the substituted pyrimidine (63 mg, 83%). 
1H NMR (401 MHz, Chloroform-d3) δ 9.23 (d, J = 6.4 Hz, 1H), 8.39 (s, 1H), 7.35 (bs, 1H), 5.35 – 
5.19 (bs, 1H), 4.55 – 4.45 (m, 1H), 4.22 (q, J = 7.2 Hz, 2H), 3.72 – 3.57 (m, 12H), 3.54 (t, J = 5.2 
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Hz, 2H), 3.29 (d, J = 6.4 Hz, 2H), 2.42 – 2.33 (m, 1H), 2.31 (s, 1H), 1.97 (d, J = 2.8 Hz, 1H), 1.87 
– 1.81 (m, 1H), 1.83 – 1.72 (m, 2H), 1.71 – 1.52 (m, 5H), 1.43 (s, 9H), 1.27 (t, J = 7.1 Hz, 3H). 13C 
NMR (101 MHz, Chloroform-d3) δ 174.3, 166.3, 162.3, 161.4, 156.1, 155.5, 106.8, 79.2, 70.4, 
70.4, 70.3, 70.2, 70.0, 69.5, 60.6, 60.4, 51.4, 50.7, 40.3, 39.6, 28.5, 28.4 (3x), 25.9, 24.0, 20.8, 19.6, 
14.2. HR-ESI-MS calculated for C29H47O8N5Cl (M + H)









xylate (28 mg, 0.044 mmol) was dissolved 
in a mixture of THF/water (0.2 mL, 25:1) 
and the flask was purged with argon for 15 
min. 5-Fluoro-1-tosyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrrolo[2,3-b]pyridine (20 
mg, 0.049 mmol), K2CO3 (24 mg, 0.18 mmol) and SPhos Pd G3 (4 mg, 0.004 mmol) were added 
and the reaction mixture was purged with argon for 10 min more, the reaction mixture was then 
heated to 70 ºC overnight. The solvent was evaporated under reduced pressure and the black residue 
was purified by column chromatography (DCM/MeOH 20:1) to furnish the coupled product (26 
mg, 67%). 
1H NMR (401 MHz, Chloroform-d3) δ 9.10 (d, J = 7.4 Hz, 1H), 8.69 (s, 1H), 8.61 (dd, J = 9.0, 2.8 
Hz, 1H), 8.54 (s, 1H), 8.30 (dd, J = 2.8, 1.1 Hz, 1H), 8.12 (d, J = 8.4 Hz, 2H), 7.28 (d, J = 8.2 Hz, 
2H), 7.05 (bs, 1H), 5.16 (bs, 1H), 4.85 (d, J = 6.8 Hz, 1H), 4.16 – 4.05 (m, 2H), 3.74 – 3.58 (m, 
12H), 3.55 (t, J = 5.1 Hz, 2H), 3.29 (t, J = 5.5 Hz, 2H), 2.44 (dt, J = 5.7, 1.8 Hz, 1H), 2.37 (s, 3H), 
2.07 – 2.05 (m, 1H), 1.96 (q, J = 2.9 Hz, 1H), 1.93 – 1.59 (m, 6H), 1.60 – 1.44 (m, 2H), 1.39 (s, 
9H), 1.15 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, Chloroform-d3) δ 174.4, 167.0, 162.5, 160.3, 
157.5 (d, J = 247.6 Hz), 156.1, 154.1, 145.6, 143.9, 134.9, 133.8, 133.7, 131.4 (d, J = 6.6 Hz), 
129.7, 129.7, 128.4, 128.3, 122.2 (d, J = 8.4 Hz), 118.2, 105.7, 79.2, 70.5, 70.3, 70.3, 70.2, 70.1, 
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69.6, 60.6, 51.4, 51.3, 49.8, 40.3, 39.5, 28.8, 28.6, 28.4, 28.3, 25.9, 24.1, 21.6, 21.0, 19.6, 14.3. 19F 
NMR (377 MHz, Chloroform-d3) δ -133.55. HR-ESI-MS calculated for C43H57O10N7FS (M + H)
+ 




An aqueous soliton of LiOH 2M (0.15 mL) 





octane-2-carboxylate (26 mg, 0.029 mmol) 
in THF (1mL) and the reaction was stirred at 45 ºC for 4 days. When the LC-MS analysis showed 
total consumption of the starting material the reaction mixture was evaporated to dryness under 
reduced pressure. The resulting product was dissolved in a TFA/DCM (1 mL, 1:1) mixture and the 
reaction was stirred at room temperature for 40 min. The solvent was evaporated under reduced 
pressure and the remaining solid was purified by preparative HPLC to afford the desired product 
(12 mg, 69%). 
1H NMR (401 MHz, Methanol-d4) δ 8.66 (dd, J = 2.9 Hz, J = 1.0 Hz 1H), 8.64 (s, 1H), 8.59 (s, 
1H), 8.31 (dd, J = 2.8, 1.6 Hz, 1H), 5.16 (dt, J = 5.9, 1.9 Hz, 1H), 3.73 – 3.64 (m, 12H), 3.64 – 3.55 
(m, 2H), 3.12 (t, J = 4.1, 2H), 2.65 – 2.56 (m, 1H), 2.18 (q, J = 2.8 Hz, 1H), 2.03 (m, 1H), 1.91 (m, 
1H), 1.86 – 1.67 (m, 5H), 1.66 – 1.53 (m, 2H). 13C NMR (101 MHz, Methanol-d4) δ 175.5, 165.4, 
160.2, 156.9 (d, J = 244.2 Hz), 156., 145.8, 145.0, 133.9, 133.1 (d, J = 30.0 Hz), 130.2, 118.6 (d, 
J = 8.9 Hz), 116.1 (d, J = 22.4 Hz), 104.5, 70.1 (2x), 69.8, 69.8, 68.9, 66.4, 51.1, 50.2, 47.9, 39.2, 
28.9, 28.5, 25.3, 23.7, 20.5, 19.0. 19F NMR (377 MHz, Methanol-d4) δ -137.44. HR-ESI-MS 
calculated for C29H39O6N7F (M + H)








To an ice-cool solution of (2S,3S)-3-((5-((2-(2-(2-(2-aminoethoxy)ethoxy)-ethoxy)-
ethyl)carbamoyl)-2-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl)amino)bicycle-[2.2.2 
]octane-2-carboxylic acid (3 mg, 0.005 mmol) in a mixture of AcCN/DMF (2:1, 1.5 mL) was added 
triethylamine (1.5 mg, 0.015 mmol)  followed by a dropwise addition of a solution of biotin-PEG6-
NHS ester (4 mg, 0.0055 mmol) in AcCN (0.5 mL) over a 10 min period, the reaction was stirred 
for 24 h at room temperature. The solvents were removed under reduced pressure and the remaining 
oil was purified by preparative HPLC to afford the desired probe (2.5 mg, 43 %). 
1H NMR (500 MHz, Methanol-d4) δ 8.69 – 8.64 (m, 1H), 8.66 (s, 1H), 8.63 (s, 1H), 8.35 (dd, J = 
2.8, 1.4 Hz, 1H), 5.25 – 5.18 (m, 1H), 4.49 (ddd, J = 7.9, 5.0, 1.0 Hz, 1H), 4.29 (dd, J = 7.9, 4.4 
Hz, 1H), 3.69 – 3.55 (m, 34H), 3.55 – 3.49 (m, 4H), 3.34 (q, J = 5.8 Hz, 4H), 3.19 (ddd, J = 8.8, 
5.8, 4.4 Hz, 1H), 2.91 (dd, J = 12.7, 5.0 Hz, 1H), 2.69 (d, J = 12.7 Hz, 1H), 2.64 (dt, J = 5.9, 1.9 
Hz, 1H), 2.44 (t, J = 6.1 Hz, 2H), 2.20 (t, J = 7.4 Hz, 2H), 2.19 (s, 1H), 2.03 (m, 1H), 1.91 (m, 1H), 
1.88 – 1.53 (m, 11H), 1.43 (m, 2H). 13C NMR (126 MHz, Methanol-d4) δ 175.3, 174.7, 172.7, 
164.8, 164.7, 160.2, 157.0 (d, J = 244.6 Hz), 155.7, 148.6, 145.8, 134.2, 133.5 (d, J = 30.0 Hz), 
131.7, 118.6, 116.1 (d, J = 22.7 Hz), 104.6, 70.2, 70.2, 70.1 (x2), 70.13(x4), 70.1, 70.0, 69.9, 69.9, 
69.8, 69.8, 69.2, 69.0, 68.9, 66.8, 62.0, 60.2, 55.6, 51.3, 50.0, 39.6, 39.5, 39.0, 38.9, 36.1, 35.3, 
29.0, 28.4, 28.3, 28.1, 25.4, 25.2, 23.7, 20.4, 19.0. 19F NMR (470 MHz, Methanol-d4) δ -136.95. 
HR-ESI-MS calculated for C54H82O15N10FS (M + H)








To an ice-cool solution of (2S,3S)-3-((5-((2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)-
ethyl)carbamoyl)-2-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl)amino)bicycle-
[2.2.2]-octane-2-carboxylic acid (6 mg, 0.01 mmol) in a mixture of AcCN/DMF (2:1, 2 mL) was 
added triethylamine (3 mg, 0.03 mmol) followed by a dropwise addition of a solution of azido-
PEG6-NHS ester (5 mg, 0.011 mmol) in AcCN (0.5 mL) over a 10 min period, the reaction was 
stirred for 24 h at room temperature. The solvents were removed under reduced pressure and the 
remaining oil was purified by preparative HPLC to afford the desired probe. (4.8 mg, 51 %). 
1H NMR (500 MHz, Methanol-d4) δ 8.68 – 8.64 (m, 1H), 8.65 (s,1H), 8.59 (s, 1H), 8.32 (s, 1H), 
5.16 (d, J = 4.7 Hz, 1H), 3.72 – 3.55 (m, 36H), 3.53 (t, J = 5.6 Hz, 2H), 3.37 – 3.33 (m, 4H), 2.64 
– 2.57 (m, 1H), 2.43 (t, J = 6.1 Hz, 2H), 2.17 (q, J = 2.8 Hz, 1H), 2.02 (q, J = 2.9 Hz, 1H), 1.96 – 
1.88 (m, 1H), 1.87 – 1.54 (m, 7H). 13C NMR (126 MHz, Methanol-d4) δ 176.9, 174.1, 166.7, 161.6, 
158.3 (d, J = 243.8 Hz), 158.2 (detected by HMBC), 148.7 (detected by HMBC), 147.2, 135.2, 
134.5 (d, J = 29.3 Hz), 131.7 (detected by HMBC), 120.1 (d, J = 8.2 Hz), 117.5, 106.0. 71.64, 71.6 
(x2), 71.5 (x8), 71.4, 71.3, 71.3, 71.1, 70.4, 70.3, 68.2, 52.4, 51.7, 51.6, 40.8, 40.4, 37.5, 30.3, 29.9, 
26.7, 25.1, 21.9, 20.4. 19F NMR (470 MHz, Methanol-d4) δ -137.40. HR-ESI-MS calculated for 
C44H66O13N10F (M + H)





Ethyl isonipecotate (1.5 g, 9.5 mmol) was dissolved in DCM (7.5 mL) and the solution 
was cooled on an ice bath, triethylamine (2.0 mL, 14.3 mmol) was added follower by 
a solution of di-tert-butyl dicarbonate (2.7 g, 12.4 mmol) in DCM (7.5 mL) and the 
reaction mixture was stirred for 16 h at room temperature. The reaction was quenched 
by addition of water (20 mL), the phases were separated and the organic layer was 
washed with a saturated solution of NH4Cl (2x 10 mL) and brine (5 mL), the organic 
phase was dried over MgSO4, filtered and evaporated to dryness. The product was used in the next 
step without further purification (2.38 g, 97%). 
1H NMR (400 MHz, Chloroform-d3) δ 4.08 (q, J = 7.1 Hz, 2H), 4.01 – 3.88 (m, 2H), 2.86 – 2.72 
(m, 2H), 2.43 – 2.29 (m, 1H), 1.81 (dd, J = 13.5, 3.8 Hz, 2H), 1.56 (dtd, J = 13.4, 11.3, 4.3 Hz, 
2H), 1.47 (s, 3H), 1.40 (s, 6H), 1.20 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, Chloroform-d3) δ 
174.5, 154.6, 79.4, 60.4, 43.1 (br), 41.1 (2x), 28.4 (3x), 28.0, 27.4, 14.2. HR-ESI-MS calculated 
for C13H23NO4Na (M + Na)
+ 280.1519, found 280.1520. 
 
1-(tert-Butyl) 4-ethyl 4-(4-chlorobenzyl)piperidine-1,4-dicarboxylate 
 Ethyl 1-tert-butyloxycarbonyl-4-piperidinecarboxylate (2.9 g, 11.2 mmol) 
was dissolved in freshly distilled THF (29 mL) and the solution was cooled 
to -78 ºC under inert atmosphere. A solution of sodium 
bis(trimethylsilyl)amide 0.6 M in toluene (28 mL, 16.8 mmol) was added 
dropwise and the mixture was stirred for 15 min at -78 ºC.  A 4-chlorobenzyl 
chloride (1.9 g, 12.3 mmol) solution in distilled THF (17 mL) was added and 
the reaction mixture was stirred for a further 3 h at -78 ºC followed by 1.5 h at room temperature. 
The reaction was then quenched by addition of water (55 mL) and the aqueous phase was extracted 
with EtOAc (3x 40 mL), the combined organic layers were washed with water (10 mL) and brine 
(7 mL) and evaporated to dryness under reduced pressure. The remaining crude mixture was 
purified by flash chromatography (hexanes/EtOAc 10:1) to furnish the desired alkylated product 
(3.4 g, 80%). 
1H NMR (400 MHz, Chloroform-d3) δ 7.25 – 7.19 (m, 2H), 6.99 – 6.92 (m, 2H), 4.10 (q, J = 7.2 
Hz, 2H), 3.92 (bs, 2H), 2.83 (bs, 2H), 2.78 (s, 2H), 2.09 – 1.96 (m, 2H), 1.62 (s, 2H), 1.44 (s, 9H), 
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1.19 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, Chloroform-d3) δ 174.6, 154.8, 134.8, 132.7, 131.2 
(2x), 128.2 (2x), 79.5, 60.6, 47.2 (2x), 45.9, 41.0 (br), 33.2 (2x), 28.4 (3x), 14.2. 
 
1-(tert-Butoxycarbonyl)-4-(4-chlorobenzyl)piperidine-4-carboxylic acid 
1-(tert-butyl) 4-ethyl 4-(4-chlorobenzyl)piperidine-1,4-dicarboxylate (2.6 g, 
6.7 mmol) was dissolved in a mixture of 1,4-dioxane (36 mL) and MeOH (66 
mL) at room temperature, KOH in pellets (3.8 g, 67 mmol) was added and 
the mixture was heated to reflux for 48 h. The solvents were evaporated under 
reduced pressure and the remaining residue was dissolved in water (50 mL), 
the aqueous solution was acidified by addition of aqueous HCl 5% and then 
it was extracted with EtOAc (3x 40 mL), the combiner organic layers were washed with brine (15 
mL), dried over MgSO4 and evaporated to dryness under reduced pressure to furnish the free acid 
(2.3 g, 98%). The product was used in the next step without further purification.  
1H NMR (400 MHz, Chloroform-d3) δ 7.26 – 7.18 (m, 2H), 7.11 – 6.98 (m, 2H), 3.95 (bs, 2H), 
2.88 (bs, 2H), 2.84 (s, 2H), 2.05 (d, J = 13.5 Hz, 2H), 1.45 (m, 11H). 13C NMR (101 MHz, 
Chloroform-d3) δ 180.2, 155.0, 134.5, 133.1, 131.3 (2x), 128.5 (2x), 79.9, 47.3 (2x), 45.7, 41.0 
(br), 33.1 (2x), 28.6 (3x). HR-ESI-MS calculated for C18H24NO4Na (M + Na)





(1.1 g, 3.06 mmol) was dissolved in distilled THF (14 mL) under inert 
atmosphere, N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride (0.81 g, 4.3 mmol) was added all at once and the reaction 
mixture was stirred for 15 min at room temperature. N,O-
Dimethylhydroxylamine hydrochloride (0.44 g, 4.6 mmol) was 
subsequently added and the reaction mixture was stirred for 48h at room temperature. The reaction 
was then quenched by addition of a saturated solution of sodium bicarbonate (10 mL) and the 
aqueous layer was extracted with DCM (3x 20 mL), the combined organic layers were washed with 
brine (10 mL) and evaporated to dryness. The resulting product was purified by column 
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chromatography (Hexanes/EtOAc form 2:1 to 1:1) to furnish the desired Weinreb amide (0.8 g, 
66%). 
1H NMR (400 MHz, Chloroform-d3) δ 7.23 – 7.13 (m, 2H), 7.01 – 6.89 (m, 2H), 3.86 (bs, 2H), 
3.68 (s, 3H), 3.15 (s, 3H), 2.97 (bs, 4H), 2.18 (d, J = 13.4 Hz, 2H), 1.48 – 1.26 (m, 11H). 13C NMR 
(101 MHz, Chloroform-d3) δ 175.0, 155.0, 135.5, 132.6, 131.3 (2x), 128.3 (2x), 79.4, 60.6, 47.9, 
42.8 (2x), 41.0 (bs), 34.1 (2x), 33.8, 28.5 (3x).  
 
tert-Butyl 4-acetyl-4-(4-chlorobenzyl)piperidine-1-carboxylate 
To a solution of tert-butyl 4-(4-chlorobenzyl)-4-(methoxy(methyl)-
carbamoyl)piperidine-1-carboxylate (0.64 g, 1.62 mmol) in distilled THF (7.5 
mL) under argon atmosphere was added dropwise a solution of 
methylmagnesium chloride 3.0 M in THF (6.4 mL, 19.1 mmol) and the reaction 
was heated to reflux for 40 min. The reaction was quenched by dropwise 
addition of NaHCO3 saturated solution (25 mL) and the aqueous layer was 
extracted with EtOAc (3x 20 mL), the combined organic phases were washed with water (10 mL) 
and brine (5 mL) and then evaporated under reduced pressure. The resulting mixture was purified 
by flash chromatography (hexanes/EtOAc 1:1) to afford the desired ketone (0.53, 94%). 
1H NMR (400 MHz, Chloroform-d3) δ 7.24 – 7.16 (m, 2H), 6.97 – 6.87 (m, 2H), 3.81 (bs, 2H), 
2.96 – 2.79 (m, 2H), 2.75 (s, 2H), 2.08 (s, 3H), 2.03 – 1.91 (m, 2H), 1.45 – 1.40 (m, 11H). 13C 
NMR (101 MHz, Chloroform-d3) δ 211.4, 154.8, 134.4, 132.9, 131.2 (2x), 128.5 (2x), 79.7, 52.0, 
44.3 (2x), 41.0 (bs), 32.4 (2x), 28.4 (3x), 26.7. HR-ESI-MS calculated for C19H26NO3Na (M + Na)
+ 






A solution of sodium bis(trimethylsilyl)amide 0.6 M in toluene (0.9 
mL, 0.55 mmol) was added dropwise to a solution of tert-butyl 4-
acetyl-4-(4-chlorobenzyl)piperidine-1-carboxylate (0.13 g, 0.37 
mmol) in distilled THF (1.5 mL) at -78 ºC under argon atmosphere. 
The reaction was left stirring on the bath for 20 min followed by 
addition of di-tert-butyl oxalate (0.09 g, 0.44 mmol), the dry-ice 
bath was removed and the reaction was stirred overnight at room temperature. The reaction mixture 
was quenched by addition of water (2 mL) and the THF was removed under reduced pressure, the 
remaining aqueous solution was acidified by addition of an aqueous citric acid solution (5%, 10 
mL) and the aqueous layer was extracted with DCM (3x 15 mL). The combined organic layer was 
washed with brine (5mL) and evaporated to dryness, the resulting mixture was purified by flash 
chromatography (from DCM to DCM/MeOH 100:2) to yield the β-diketo ester (0.14 g, 78%). 
1H NMR (400 MHz, Chloroform-d3) δ 14.81 (bs, 1H), 7.26 7.08 (m, 2H), 6.90 (dd, J = 8.4, 2.1 Hz, 
2H), 6.34 (s, 1H), 3.94 – 3.71 (m, 2H), 2.88 –2.81 (m, 2H), 2.81 (s, 2H), 2.05 (d, J = 13.8 Hz, 2H), 
1.71 –1.37 (m, 2H), 1.56 (s, 9H), 1.43 (s, 9H). 13C NMR (101 MHz, Chloroform-d3) δ 205.5, 169.2, 
161.1, 154.9, 134.1, 133.1, 131.4 (2x), 128.5 (2x), 99.0, 84.2, 79.8, 49.3, 45.5 (2x), 40.5 (bs), 32.6 
(2x), 28.5 (3x), 27.9 (3x). HR-ESI-MS calculated for C25H35NO6Cl (M + H)




Dimethyl 4-hydroxyisophthalate (1.5 g, 7.6 mmol) was dissolved in pyridine (21 
mL) under argon atmosphere and the reaction mixture was heated to reflux for 20 
h. Pyridine was evaporated under reduced pressure and the remaining mixture was 
dissolved in an aqueous solution of HCl 1M (8.2 mL), the formed precipitate was 
filtered and washed with ice-cold water, the solid was dried under reduced pressure 
overnight (1.3 g, 93 %). The free acid was used in the next step without further 
purification. 
1H NMR (400 MHz, DMSO-d6) δ 8.38 (d, J = 2.3 Hz, 1H), 8.03 (dd, J = 8.7, 2.3 Hz, 1H), 7.05 (d, 
J = 8.7 Hz, 1H), 3.82 (s, 3H). 13C NMR (101 MHz, DMSO-d6) δ 171.1, 165.4, 164.8, 135.9, 132.2, 




3-(tert-Butyl) 1-methyl 4-hydroxyisophthalate 
2-Hydroxy-5-(methoxycarbonyl)benzoic acid (1.45 g, 7.39 mmol) was 
dissolved in dry DCM (72 mL) followed by addition of anhydrous MgSO4 (7.7 
g, 62.0 mmol) to the solution. tert-Butanol (7.6 mL) was added followed by 
dropwise addition of concentrated sulfuric acid (0.85 mL, 15.3 mmol), the 
reaction was stirred for 48 h. The MgSO4 was filtered out and the filtrate was 
mixed with NaHCO3 saturated solution to adjust the pH to neutral, the phases were separated and 
the organic layer was dried over MgSO4 and evaporated to dryness to afford the tert-butyl ester 
(0.95 g, 53%). The product was used in the next step without further purification.  
1H NMR (400 MHz, Chloroform-d3) δ 11.53 (s, 1H), 8.46 (d, J = 2.2 Hz, 1H), 8.07 (dd, J = 8.7, 
2.2 Hz, 1H), 6.97 (d, J = 8.8 Hz, 1H), 3.90 (s, 3H), 1.63 (s, 9H). 13C NMR (101 MHz, Chloroform-
d3) δ 169.5, 166.4, 165.5, 136.2, 132.7, 121.2, 117.8, 113.7, 83.9, 52.2, 28.3 (3x). 
 
11-Azido-3,6,9-trioxa-undecanyl p-toluenesulfonate 
Sodium azide (0.64 g, 10.0 mmol) was added to solution of 
tetraethylene glycol di(p-toluenesulfonate)  (5 g, 10.0 
mmol) in DMF (17 mL) under inert atmosphere and the reaction was heated to 60 ºC for 24h. Water 
(50 mL) was added to the reaction and the aqueous solution was extracted with EtOAc (40 mL), 
the combiner organic phase was washed with water (2x 20 mL) and brine (10 mL) a then evaporated 
down under reduced pressure. The resulting oil was purified by flash chromatography (Hex/EtOAc 
1:1) to furnish the mono-azide (1.5 g, 40%). 
1H NMR (401 MHz, Chloroform-d3) δ 7.85 – 7.73 (m, 2H), 7.35 (d, J = 8.0 Hz, 2H), 4.17 (t, J = 
4.5 Hz, 2H), 3.71 – 3.64 (m, 12H), 3.39 (t, J = 5.1 Hz, 2H), 2.46 (s, 3H). 
 
3-(tert-Butyl) 1-methyl 4-(2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethoxy)isophthalate 
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The linker 11-azido-3,6,9-trioxa-undecanyl p-
toluenesulfonate (0.93 g, 2.5 mmol) was added to a 
solution of 3-(tert-butyl) 1-methyl 4-
hydroxyisophthalate (0.57 g, 2.2 mmol) and K2CO3 
(0.62 g, 5.0 mmol) in DMF (10 mL), the reaction 
was heated to 60 ºC for 24 h. The reaction mixture 
was concentrated under reduced pressure and the remaining oil was dissolved in water (20 mL), 
the aqueous solution was extracted with EtOAc (3x 30mL) and the combined organic layers were 
washed with water (2x 15 mL) and brine (10 mL), evaporated to dryness and purified by flash 
chromatography (hexanes/EtOAc 1:1) to yield the alkylated phenol (0.96, 94%).  
1H NMR (300 MHz, Chloroform-d3) δ 8.32 (d, J = 2.3 Hz, 1H), 8.06 (dd, J = 8.8, 2.3 Hz, 1H), 6.96 
(d, J = 8.8 Hz, 1H), 4.23 (dd, J = 5.6, 4.4 Hz, 2H), 3.93 – 3.84 (m, 2H), 3.88 (s, 3H), 3.77 – 3.69 
(m, 2H), 3.68 – 3.61 (m, 8H), 3.36 (dd, J = 5.6, 4.6 Hz, 2H), 1.57 (s, 9H). 13C NMR (75 MHz, 
Chloroform-d3) δ 166.3, 165.2, 161.3, 134.2, 132.9, 129.9, 128.1, 122.4, 112.7, 81.7, 71.1, 70.9, 
70.8, 70.2, 69.5, 68.7, 52.2, 50.8, 28.3 (3x). HR-ESI-MS calculated for C21H31N3O8Na (M + Na)
+ 
476.2003, found 476.2003. 
 
4-(2-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)ethoxy)-3-(tert-butoxycarbonyl)benzoic acid 
The conditions used are described in the general 
procedure for the saponification of ethyl esters. The 
free acid was used in the following step without 
further purification (0.9 g, 97%).  
1H NMR (300 MHz, Chloroform-d3) δ 8.38 (d, J = 
2.3 Hz, 1H), 8.11 (dd, J = 8.8, 2.3 Hz, 1H), 6.98 (d, 
J = 8.9 Hz, 1H), 4.24 (t, J = 4.9 Hz, 2H), 3.90 (dd, J = 5.6, 4.2 Hz, 2H), 3.73 (dt, J = 5.2, 2.0 Hz, 
2H), 3.69 – 3.58 (m, 8H), 3.35 (t, J = 5.0 Hz, 2H), 1.57 (s, 9H). 13C NMR (75 MHz, Chloroform-
d3) δ 170.7, 164.9, 161.9, 134.8, 133.6, 123.0, 121.5, 112.7, 81.7, 71.0, 70.8, 70.7, 70.7, 70.1, 69.4, 
68.7, 50.7, 28.3. HR-ESI-MS calculated for C20H29N3O8Na (M + Na)







-3-(tert-butoxycarbonyl)benzoic acid (0.15 g, 0.34 
mmol) was dissolved in distilled THF (3 mL) under 
argon atmosphere followed by addition of 
triethylamine (0.1 mL, 0.68 mmol) and 2-(1H-
benzotriazole-1-yl)-1,1,3,3-tetramethylaminium 
tetrafluoroborate (0.14 g, 0.44 mmol), the reaction 
was stirred for 10 min and subsequently N-hydroxysuccinimide (0.05 g, 0.44 mmol) was added 
and the mixture was stirred for 24 h at room temperature. The solvent was evaporated under 
reduced pressure and the remaining mixture was purified by flash chromatography (from 
hexanes/EtOAc 1:1 to EtOAc) to yield the NHS-ester (0.16 g, 87%). 
1H NMR (300 MHz, Chloroform-d3) δ 8.44 (d, J = 2.3 Hz, 1H), 8.16 (dd, J = 8.8, 2.4 Hz, 1H), 7.04 
(d, J = 8.9 Hz, 1H), 4.27 (t, J = 4.9 Hz, 2H), 3.92 (t, J = 4.9 Hz, 2H), 3.77 – 3.70 (m, 2H), 3.70 – 
3.59 (m, 8H), 3.37 (t, J = 5.1 Hz, 2H), 2.89 (s, 4H), 1.57 (s, 9H). 13C NMR (75 MHz, Chloroform- 
d3) δ 169.4 (2x), 164.3, 162.9, 161.1, 135.3, 134.2, 123.4, 116.9, 113.1, 82.1, 71.1, 70.8, 70.8, 70.8, 
70.1, 69.4, 68.9, 50.8, 28.3 (3x), 25.8 (2x). HR-ESI-MS calculated for C24H32N4O10Na (M + Na)
+ 
559.2011, found 559.2011. 
 
Biotin N-hydroxysuccinimide ester 
Biotin (0.15 g, 0.61 mmol) was dissolved in warm DMF (3.5 
mL) under inert atmosphere and N,N′-dicyclohexylcarbodiimide 
(0.14 g, 0.67 mmol) was added. The reaction was allowed to stir 
for 15 min at room temperature. N-Hydroxysuccinimide (0.09 g, 
0.76 mmol) was subsequently added and the reaction mixture 
was further stirred for 24 h at room temperature. The resulting suspension was filtered, the filtrate 
was evaporated to dryness under reduced pressure and the remaining oil was triturated in Et2O. 
The formed precipitate was filtrate and dried under high vacuum to yield the NHS-ester (0.19 g, 





Biotin N-hydroxysuccinimide ester (0.09 g, 0.26 mmol) was 
dissolved in warm DMF (2.5 mL) under inert atmosphere 
followed by addition of 1-amino-3-butyne (0.02 g, 0.29 
mmol), the reaction was left stirring overnight at room 
temperature. The following day the solvent was evaporated 
under reduced pressure and the remaining mixture was purified by flash chromatography 
(DCM/MeOH 10:1) to yield the desired amide (0.045 g, 58%). 
 1H NMR (300 MHz, Chloroform-d3 + a drop of methanol-d4) δ 4.29 (dd, J = 7.9, 4.8 Hz, 1H), 4.09 
(dd, J = 7.8, 4.4 Hz, 1H), 3.12 (dd, J = 7.5, 4.9 Hz, 2H), 2.99 – 2.86 (m, 1H), 2.70 (dd, J = 12.9, 
4.9 Hz, 1H), 2.51 (d, J = 12.3 Hz, 1H), 2.17 (td, J = 6.8, 2.6 Hz, 2H), 1.99 (t, J = 7.3 Hz, 2H), 1.85 






carboxylate (synthon A, 35 mg, 0.073 mmol) was dissolved in a solution of TFA in DCM (1:1, 
1mL) at 0 ºC. The reaction was stirred for 1h and then the solvent was removed under reduced 
pressure. The dried residue was dissolved again in DCM (1.5 mL) and triethylamine (0.5 mL) was 
added followed by a solution of 3-(tert-butyl) 1-(2,5-dioxopyrrolidin-1-yl) 4-(2-(2-(2-(2-
azidoethoxy)ethoxy)ethoxy)ethoxy)isophthalate (synthon B, 39 mg, 0.073 mmol) in DCM (0.5 
mL), the reaction was stirred overnight period at room temperature. The solvent was evaporated, 
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and the remaining residue was purified by flash chromatography (DCM/MeOH 20:1) afford the 
connected product (18 mg, 30%). 
1H NMR (400 MHz, Chloroform-d3) δ 14.74 (s, 1H), 7.72 (d, J = 2.3 Hz, 1H), 7.44 (dd, J = 8.6, 
2.3 Hz, 1H), 7.20 (d, J = 8.3 Hz, 2H), 6.95 (d, J = 8.6 Hz, 1H), 6.89 (d, J = 8.4 Hz, 2H), 6.36 (s, 
1H), 4.38 (m, 2H), 4.20 (t, J = 5.0 Hz, 2H), 3.89 (t, J = 5.0 Hz, 2H), 3.73 (dt, J = 4.8, 3.2 Hz, 2H), 
3.66 (q, J = 3.3 Hz, 8H), 3.37 (t, J = 5.1 Hz, 2H), 3.03 (d, J = 3.4 Hz, 2H), 2.84 (s, 2H), 2.23 – 2.01 
(m, 2H), 1.56 (d, J = 2.3 Hz, 18H), 1.47 – 1.33 (m, 2H). 13C NMR (101 MHz, Chloroform-d3) δ 
205.2, 169.6, 169.1, 165.2, 161.0, 159.1, 133.8, 133.2, 132.0, 131.3 (2x), 130.7, 128.6 (2x), 127.6, 
122.8, 113.3, 98.9, 84.3, 81.7, 71.1, 70.9, 70.8, 70.8, 70.2, 69.6, 68.8, 50.8, 49.7, 45.7 (2x), 40.0, 










4-oxobut-2-enoyl)-4-(4-chlorobenzyl)piperidine-1-carbonyl)benzoate (23 mg, 0.028 mmol) was 
dissolved in a mixture of ethanol, water and THF (EtOH/water/THF 2:2:1, 2.5 mL) and the 
resulting solution was purged with argon for 10 min. Copper (II) sulfate pentahydrate (14 mg, 0.057 
mg) was added followed by N-(but-3-ynyl)biotinamide (12 mg, 0.042 mmol) and (+)-sodium L-
ascorbate (56 mg, 0.28 mmol). The reaction was stirred for 1 h at room temperature under inert 
atmosphere. The reaction mixture was then filtered and evaporated to dryness under reduced 
pressure. The crude mixture was then dissolved in a TFA (33% in DCM, 1.5 mL) and the reaction 
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was stirred for one more hour at room temperature. The solvents were removed under reduced 
pressure and the remaining mixture was purified by preparative HPLC.  
1H NMR (600 MHz, Methanol-d4) δ 7.87 (d, J = 2.3 Hz, 1H), 7.83 (d, J = 2.4 Hz, 1H), 7.58 (dd, J 
= 8.6, 2.4 Hz, 1H), 7.28 – 7.20 (m, 4H), 7.06 – 7.00 (m, 2H), 4.56 – 4.49 (m, 2H), 4.49 – 4.43 (m, 
1H), 4.35 – 4.24 (m, 4H), 3.88 (dt, J = 24.6, 4.5 Hz, 4H), 3.72 (dt, J = 7.8, 3.1 Hz, 2H), 3.63 – 3.53 
(m, 6H), 3.45 (t, J = 7.0 Hz, 2H), 3.19 (dt, J = 3.3, 1.7 Hz, 1H), 3.09 – 3.04 (m, 1H), 2.96 (s, 2H), 
2.93 – 2.90 (m, 1H), 2.87 (t, J = 7.0 Hz, 2H), 2.69 (d, J = 12.7 Hz, 1H), 2.22 – 2.13 (m, 2H), 2.21 
(bs, 2H), 1.74 – 1.45 (m, 8H), 1.39 (t, J = 7.6 Hz, 2H). 13C NMR (151 MHz, Methanol-d4) δ 207.2, 
176.1, 175.8, 171.3, 168.5, 167.9, 164.9, 160.7, 146.1, 135.9, 133.9, 133.9, 133.1, 132.7 (x2), 
132.0, 129.2 (x2), 129.1, 124.6, 121.9, 114.9, 71.9, 71.6, 71.5, 71.5, 70.4, 70.4, 70.3, 63.3, 61.6, 
57.0, 55.3, 51.3, 51.1, 49.6, 45.7, 41.0, 40.1, 40.0, 36.8, 36.5, 30.8, 29.8, 29.4, 26.5. HR-ESI-MS 
calculated for C46H59ClN7O13S (M+H)





4-(2-(2-(2-(2-Azidoethoxy)ethoxy)ethoxy)ethoxy)-3-(tert-butoxycarbonyl)benzoic acid (77 mg, 
0.17 mmol) and Lindlar catalyst (23 mg, 30 w%) were suspended in MeOH (2 mL), the flask was 
purged with argon and then purged with hydrogen gas and the reaction mixture was stirred for 90 
min at room temperature under hydrogen atmosphere (1 atm). Once the TLC showed complete 
reduction of the starting material the catalyst was filtered out and the filtrate was evaporated to 
dryness. The resulting crude mixture was dissolved in DMF (2 mL) followed by addition of 
triethylamine (50 μl, 0.36 mmol) and (+)-biotin N-hydroxysuccinimide ester (60 mg, 0.17 mmol). 
The reaction mixture was stirred for 48 h at room temperature followed by removal of the solvent 
under reduced pressure. The remaining mixture was diluted in DCM (25 mL) and the organic phase 
was washed with an aqueous solution of citric acid (5%, 3 mL) and brine (3 mL). The organic layer 
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was evaporated down and purified by flash chromatography (DCM/MeOH from 9:1 to 8:2) to yield 
the biotinylated product (43 mg, 39%). 
1H NMR (400 MHz, Methanol-d4) δ 8.24 (d, J = 2.3 Hz, 1H), 8.11 (dd, J = 8.8, 2.3 Hz, 1H), 7.18 
(d, J = 8.8 Hz, 1H), 4.48 (ddd, J = 7.9, 5.8, 5.0, 1H), 4.36 – 4.24 (m, 3H), 3.94 – 3.87 (m, 2H), 3.76 
– 3.70 (m, 2H), 3.70 – 3.56 (m, 6H), 3.52 (t, J = 5.5 Hz, 2H), 3.34 (d, J = 5.5 Hz, 1H), 3.26 – 3.12 
(m, 1H), 2.92 (ddd, J = 12.6, 7.5, 5.0 Hz, 1H), 2.75 – 2.65 (m, 1H), 2.31 (t, J = 7.4 Hz, 1H), 2.19 
(t, J = 7.4 Hz, 1H), 1.79 – 1.61 (m, 4H), 1.60 (s, 9H), 1.52 – 1.35 (m, 3H). 13C NMR (101 MHz, 
Methanol-d4) δ 176.1, 167.1, 166.1, 162.5, 135.6, 133.5, 129.8, 127.0, 123.9, 114.0, 83.0, 71.9, 
71.6, 71.6, 71.2, 70.6, 70.6, 70.0, 63.3, 61.6, 57.0, 41.0, 40.3, 36.7, 29.7, 29.5, 28.5, 26.8. HR-ESI-
MS calculated for C30H46N3O10S (M+H)






le-4-yl)-3,6,9-trioxa-12-azaheptadecyl)oxy)benzoic acid (70 mg, 0.11 mmol) was dissolved in 
DMF (2 mL) under inert atmosphere followed by addition of O-(benzotriazol-1-yl)-N,N,N',N'-
tetramethyluronium tetrafluoroborate (45 mg, 0.14 mmol) and triethylamine (30 μl, 0.22 mmol), 
the reaction was stirred for 10 min at room temperature and N-hydroxysuccinimide  (16 mg, 0.14 
mmol) was subsequently added. After stirring for 16 h at room temperature the solvent was 
evaporated under reduced pressure and the resulting mixture was purified by flash chromatography 
(DCM/MeOH 9:1) to afford the activated ester (56 mg, 70%).  
1H NMR (400 MHz, Chloroform-d3) δ 8.40 (d, J = 2.4 Hz, 1H), 8.16 (dd, J = 8.8, 2.3 Hz, 1H), 7.07 
(d, J = 8.9 Hz, 1H), 6.66 (t, J = 5.6 Hz, 1H), 6.25 (s, 1H), 5.64 (s, 1H), 4.47 (dd, J = 7.9, 4.8 Hz, 
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1H), 4.27 (t, J = 4.7 Hz, 3H), 3.94 – 3.84 (m, 2H), 3.72 (dd, J = 6.1, 3.2 Hz, 2H), 3.67 – 3.55 (m, 
6H), 3.52 (t, J = 5.2 Hz, 2H), 3.42 – 3.30 (m, 2H), 3.09 (td, J = 7.3, 4.4 Hz, 1H), 2.89 (s, 4H), 2.84 
(d, J = 4.8 Hz, 1H), 2.72 (d, J = 12.9 Hz, 1H), 2.17 (t, J = 7.4 Hz, 2H), 1.74 – 1.57 (m, 4H), 1.55 
(s, 9H), 1.38 (d, J = 7.6 Hz, 2H). 13C NMR (101 MHz, Chloroform-d3) δ 173.6, 169.5 (x2), 164.5, 
164.2, 162.8, 161.0, 135.4, 134.0, 123.3, 116.8, 113.2, 82.2, 71.0, 70.5, 70.5, 70.1, 69.9, 69.4, 68.9, 
61.9, 60.4, 55.6, 40.6, 39.2, 35.9, 28.3 (x3), 28.2, 28.1, 25.8 (x2), 25.6. HR-ESI-MS calculated for 
C34H48N4O12SNa (M+Na)







carboxylate (40 mg, 0.083 mmol) was dissolved in DCM (1 mL) and the resulting solution was 
cooled down on an ice bath, TFA (100%, 0.5 mL) was added and the reaction was stirred for 30 
min at room temperature. Once the TLC showed total consumption of the starting material the 
solvents were evaporated under reduced pressure and the resulting oil was further dried under high 
vacuum for 2 h. The dried mixture was then dissolved in DCM (1 mL) followed by addition of 
triethylamine (0.3 mL) and 3-(tert-butyl) 1-(2,5-dioxopyrrolidin-1-yl) 4-((13-oxo-17-
((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-3,6,9-trioxa-12-azaheptadecyl)-
oxy)-isophthalate (56 mg, 0.076 mmol). After being stirred for 24 h at room temperature, the 
reaction mixture was evaporated down and dried under high vacuum. The resulting oil was 
dissolved in a mixture of DCM/TFA (2:1, 1.5 mL) and was stirred for 2 h at room temperature. 
After complete removal of the solvent under reduced pressure the mixture was purified by 
preparative HPLC to yield the final probe (18 mg, 27%). 
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 1H NMR (600 MHz, Methanol-d4) δ 7.87 (d, J = 2.3 Hz, 1H), 7.59 (dd, J = 8.6, 2.3 Hz, 1H), 7.24 
(m, 4H), 7.03 (d, J = 8.3 Hz, 2H), 4.48 (dd, J = 7.9, 4.9 Hz, 1H), 4.35 – 4.30 (m, 2H), 4.31 – 4.25 
(m, 1H), 3.95 – 3.88 (m, 2H), 3.79 – 3.72 (m, 2H), 3.69 – 3.61 (m, 6H), 3.60 (dd, J = 5.6, 2.9 Hz, 
2H), 3.52 (t, J = 5.5 Hz, 2H), 3.34 (t, J = 5.5 Hz, 2H), 3.19 (ddd, J = 9.2, 6.0, 4.6 Hz, 1H), 3.07 (bs, 
2H), 2.96 (s, 2H), 2.91 (dd, J = 12.7, 5.0 Hz, 1H), 2.69 (d, J = 12.7 Hz, 1H), 2.21 (bs, 2H), 2.22 – 
2.17 (m, 2H), 1.78 – 1.54 (m, 6H), 1.46 – 1.38 (m, 2H). 13C NMR (151 MHz, Methanol-d4) δ 207.2, 
176.1, 171.3, 168.6, 167.8, 166.1, 164.7, 160.7, 135.9, 133.9, 133.9, 133.1, 132.7, 132.0, 129.2, 
129.1, 121.9, 114.9, 71.9, 71.6, 71.6, 71.3, 70.6, 70.4, 70.4, 63.4, 61.6, 57.0, 51.1, 49.6, 46.6, 45.7, 
41.0 (x2), 40.4, 36.7 (x2), 29.7, 29.5, 26.8. HR-ESI-MS calculated for C42H52ClN4O13S (M-H)
- 






(0.64 g, 1.46 mmol) and Lindlar catalyst (0.19 
g, 30 w%) were suspended in MeOH (15 mL), 
the flask was first purged with argon and then 
hydrogen gas was bubbled through the solution for 1 h at room temperature. The catalyst was 
filtered out and the filtrate was evaporated to dryness under reduced pressure. The resulting crude 
product was dissolved in DCM (15 mL), the reaction was cooled down in an ice bath followed by 
addition of triethylamine (0.4 mL, 2.92 mmol) and di-tert-butyl dicarbonate (0.38 g, 1.75 mmol). 
After stirring the reaction for 24 h at room temperature the mixture was diluted in DCM (20 mL) 
and the organic phase was washed with a saturated solution of ammonium chloride (2x 5 mL) and 
brine (5 mL), the organic layer was then evaporated to dryness and purified by flash 
chromatography (DCM/MeOH 20:1) to yield the Boc-protected amine (0.48 g, 64%). 
1H NMR (300 MHz, Chloroform-d3) δ 8.36 (d, J = 2.3 Hz, 1H), 8.09 (dd, J = 8.8, 2.3 Hz, 1H), 6.96 
(d, J = 8.9 Hz, 1H), 5.11 (s, 1H), 4.24 (dd, J = 5.7, 4.2 Hz, 2H), 3.90 (dd, J = 5.5, 4.3 Hz, 2H), 3.74 
(dt, J = 4.5, 3.1 Hz, 2H), 3.68 – 3.55 (m, 6H), 3.52 (t, J = 5.2 Hz, 2H), 3.36 – 3.19 (m, 2H), 1.57 
(s, 9H), 1.42 (s, 9H). 13C NMR (75 MHz, Chloroform-d3) δ 170.1, 165.0, 161.7, 149.5, 134.8, 
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133.5, 122.9, 122.0, 112.6, 81.7, 79.3, 71.0, 70.7, 70.6, 70.3 (x2), 69.5, 68.7, 40.5, 28.5 (x3), 28.3 
(x3). HR-ESI-MS calculated for C25H40NO10 (M + H)






16-yl)oxy)benzoic acid (0.48 g, 0.94 mmol) 
was dissolved in THF (17 mL) under inert 
atmosphere followed by addition of O-
(benzotriazol-1-yl)-N,N,N',N'-tetramethyl-
uronium tetrafluoroborate (0.39 g, 1.22 
mmol) and triethylamine (0.26 ml, 0.22 mmol), the reaction was stirred for 10 min at room 
temperature and N-hydroxysuccinimide  (16 mg, 1.88 mmol) was subsequently added. After 
stirring for 16 h at room temperature the solvent was evaporated under reduced pressure and the 
resulting mixture was purified by flash chromatography (DCM/MeOH 20:1) to afford the activated 
ester (0.47 g, 81%).  
1H NMR (300 MHz, Chloroform-d3) δ 8.40 (d, J = 2.3 Hz, 1H), 8.13 (dd, J = 8.8, 2.2 Hz, 1H), 7.02 
(d, J = 8.9 Hz, 1H), 5.01 (bs, 1H), 4.24 (t, J = 5.0 Hz, 2H), 3.88 (q, J = 5.1 Hz, 2H), 3.71 (dd, J = 
6.1, 3.5 Hz, 2H), 3.60 (dd, J = 14.6, 3.6 Hz, 6H), 3.49 (t, J = 5.3 Hz, 2H), 3.26 (q, J = 5.5 Hz, 2H), 
2.86 (s, 4H), 1.54 (s, 9H), 1.39 (s, 9H). 13C NMR (75 MHz, Chloroform-d3) δ 169.4 (x2), 164.3, 
162.8, 161.0, 156.0, 135.2, 134.0, 123.4, 116.8, 113.0, 81.9, 79.1, 71.0, 70.6, 70.6, 70.2, 70.2, 69.3, 
68.8, 40.4, 28.45 (x3), 28.2 (x3), 25.7 (x2). HR-ESI-MS calculated for C29H42N2O12Na (M+Na)
+ 









carboxylate (65 mg, 0.136 mmol) was dissolved in DCM (1 mL) and the resulting solution was 
cooled down on an ice bath, TFA (100%, 0.2 mL) was added and the reaction was stirred for 15 
min at room temperature. Once the TLC showed total consumption of the starting material the 
solvents were evaporated under reduced pressure and the resulting oil was further dried under high 
vacuum for 2 h. The dried mixture was then dissolved in DCM (1.5 mL) followed by addition of 
triethylamine (0.3 mL) and 3-(tert-butyl) 1-(2,5-dioxopyrrolidin-1-yl) 4-((2,2-dimethyl-4-oxo-
3,8,11,14-tetraoxa-5-azahexadecan-16-yl)oxy)isophthalate (82 mg, 0.136 mmol), the reaction 
mixture was left stirring at room temperature overnight period. Later, the solvents were removed 
under reduced pressure and the remaining residue was purified by flash chromatography 
(DCM/MeOH 20:1) to yield the desired amide (80 mg, 68%). 
1H NMR (400 MHz, Chloroform-d3) δ 14.76 (s, 1H), 7.73 (d, J = 2.3 Hz, 1H), 7.44 (dd, J = 8.6, 
2.3 Hz, 1H), 7.20 (d, J = 8.4 Hz, 2H), 6.95 (d, J = 8.6 Hz, 1H), 6.93 – 6.86 (m, 2H), 6.37 (s, 1H), 
5.02 (s, 1H), 4.20 (t, J = 5.0 Hz, 2H), 3.90 (t, J = 5.0 Hz, 2H), 3.78 – 3.69 (m, 2H), 3.69 – 3.57 (m, 
8H), 3.53 (t, J = 5.1 Hz, 2H), 3.34 – 3.25 (m, 2H), 3.05 (bs, 2H), 2.84 (s, 2H), 2.25 – 2.02 (bs, 2H), 
1.72 (bs, 2H), 1.56 (s, 9H), 1.56 (s, 9H), 1.43 (s, 9H). 13C NMR (101 MHz, Chloroform-d3) δ 205.2, 
169.6, 169.1, 165.1, 161.0, 159.1, 134.6, 133.8, 133.4, 133.2, 132.0, 131.3 (x2), 130.7, 128.6 (x2), 
127.6, 122.8, 113.3, 99.0, 84.3, 81.7, 71.1, 70.8, 70.7, 70.3, 70.3, 69.6, 68.8, 49.7 (x2), 45.7, 40.5, 










mg, 0.023 mmol) was dissolved in DCM (1 mL) and the solution was cooled down on an ice bath. 
Neat TFA (0.2 mL) was added dropwise and the reaction was stirred for 15 min. Once the TLC 
showed complete consumption of the starting material, the solvent was evaporated under reduced 
pressure and the remaining oil was further dried for 3 h under high vacuum. The dried product was 
dissolved in DCM (1 mL) followed by addition of triethylamine (0.3 mL) and biotin-PEG6-NHS 
ester (16 mg, 0.023 mmol). After stirring the reaction for 24 h at room temperature, the solvent was 
removed under reduced pressure and the remaining mixture dried under high vacuum for 2 h more. 
The crude mixture was dissolved in DCM (1 mL) again and TFA (0.5 mL) was added and the 
reaction was stirred for 1 h at room temperature. After removing the solvents under reduced 
pressure, the mixture was purified by preparative HPLC to yield the desired probe (4 mg, 15%). 
1H NMR (600 MHz, Methanol-d4) δ 7.87 (d, J = 2.3 Hz, 1H), 7.59 (dd, J = 8.6, 2.3 Hz, 1H), 7.29 
– 7.20 (m, 4H), 7.07 – 6.99 (m, 2H), 4.49 (ddd, J = 7.9, 5.0, 1.0 Hz, 1H), 4.39 – 4.25 (m, 4H), 3.94 
– 3.88 (m, 2H), 3.79 – 3.73 (m, 2H), 3.71 (t, J = 6.2 Hz, 3H), 3.69 – 3.55 (m, 26H), 3.53 (td, J = 
5.5, 4.1 Hz, 4H), 3.35 (td, J = 5.5, 2.5 Hz, 4H), 3.20 (ddd, J = 8.9, 6.0, 4.6 Hz, 1H), 3.06 (bs, 2H), 
2.96 (s, 2H), 2.92 (dd, J = 12.7, 5.0 Hz, 1H), 2.70 (d, J = 12.7 Hz, 1H), 2.44 (t, J = 6.2 Hz, 2H), 
2.27 – 2.12 (m, 4H), 1.78 – 1.55 (m, 6H), 1.49 – 1.38 (m, 2H). 13C NMR (151 MHz, Methanol-d4) 
δ 207.3, 176.1, 174.0, 171.2, 168.6, 167.7, 166.1, 164.7, 160.7, 135.9, 133.9, 133.9, 133.1, 132.7 
(x2), 132.0, 129.2 (x2), 129.2, 129.0, 121.9, 114.9, 71.9, 71.6, 71.6 (x7), 71.5, 71.5, 71.4, 71.3, 
71.3, 70.6, 70.5, 70.4, 70.3, 68.3, 63.4, 61.6, 57.0, 51.1, 46.6, 45.7, 41.1, 40.4, 40.4, 37.6, 36.7, 
34.0, 33.4, 29.8, 29.5, 26.9. HR-ESI-MS calculated for C57H82ClN5O20S (M+H)
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